Alzheimer's disease

Lancet, The 388, 505-517

DOI: 10.1016/s0140-6736(15)01124-1

Citation Report

#	Article	IF	CITATIONS
1	Therapies for Prevention and Treatment of Alzheimer's Disease. BioMed Research International, 2016, 2016, 1-17.	0.9	172
2	Effects of Folic Acid on Secretases Involved in A \hat{I}^2 Deposition in APP/PS1 Mice. Nutrients, 2016, 8, 556.	1.7	19
3	Bile Acids in Neurodegenerative Disorders. Frontiers in Aging Neuroscience, 2016, 8, 263.	1.7	84
4	Reelin and Neuropsychiatric Disorders. Frontiers in Cellular Neuroscience, 2016, 10, 229.	1.8	143
5	CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. Frontiers in Neuroscience, 2016, 10, 243.	1.4	92
7	Putative Role of Red Wine Polyphenols against Brain Pathology in Alzheimer's and Parkinson's Disease. Frontiers in Nutrition, 2016, 3, 31.	1.6	101
8	Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery. Annals of the New York Academy of Sciences, 2016, 1366, 61-75.	1.8	14
9	Identification of learning-induced changes in protein networks in the hippocampi of a mouse model of Alzheimer's disease. Translational Psychiatry, 2016, 6, e849-e849.	2.4	14
10	Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration. Journal of Alzheimer's Disease, 2016, 55, 73-75.	1.2	6
11	Purported Interactions of Amyloid-β andÂGlucocorticoids in Cytotoxicity andÂGenotoxicity: Implications inÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 1085-1094.	1.2	2
12	Anti-Viral Properties of Amyloid-Î ² Peptides. Journal of Alzheimer's Disease, 2016, 54, 859-878.	1.2	70
13	Disrupted Brain Network in Progressive Mild Cognitive Impairment Measured by Eigenvector Centrality Mapping is Linked to Cognition and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2016, 54, 1483-1493.	1.2	21
14	Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. Current Opinion in Neurology, 2016, 29, 749-755.	1.8	10
15	Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 51.	3.0	19
16	Molecular medicine – To be or not to be. Biophysical Chemistry, 2016, 214-215, 33-46.	1.5	4
17	Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?. Lancet Neurology, The, 2016, 15, 650-651.	4.9	10
18	Disease-associated glycans on cell surface proteins. Molecular Aspects of Medicine, 2016, 51, 56-70.	2.7	64
19	Identification of the Sites of 4-Hydroxy-2-Nonenal and Neprilysin Adduction Using a Linear Trap Quadrapole Velos Pro-Orbitrap Elite Mass Spectrometer. European Journal of Mass Spectrometry, 2016, 22, 133-139.	0.5	5

#	Article	IF	Citations
20	Biomarker-guided classification scheme of neurodegenerative diseases. Journal of Sport and Health Science, 2016, 5, 383-387.	3.3	22
21	TREM1 facilitates microglial phagocytosis of amyloid beta. Acta Neuropathologica, 2016, 132, 667-683.	3.9	79
22	^{99m} Tc-Labeled 2-Arylbenzothiazoles: Aβ Imaging Probes with Favorable Brain Pharmacokinetics for Single-Photon Emission Computed Tomography. Bioconjugate Chemistry, 2016, 27, 2493-2504.	1.8	24
23	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
24	Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. CNS Drugs, 2016, 30, 1111-1120.	2.7	139
25	Longitudinal imaging of the ageing mouse. Mechanisms of Ageing and Development, 2016, 160, 93-116.	2.2	47
26	Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research and Therapy, 2016, 8, 39.	3.0	323
27	SIRT1 as a therapeutic target for Alzheimer's disease. Reviews in the Neurosciences, 2016, 27, 813-825.	1.4	41
28	Mammalian prions and their wider relevance in neurodegenerative diseases. Nature, 2016, 539, 217-226.	13.7	193
29	Expression of B4GALNT1, an essential glycosyltransferase for the synthesis of complex gangliosides, suppresses BACE1 degradation and modulates APP processing. Scientific Reports, 2016, 6, 34505.	1.6	20
30	Clinical heterogeneity in familial Alzheimer's disease. Lancet Neurology, The, 2016, 15, 1296-1298.	4.9	21
31	Searching for the mechanisms of consciousness in epilepsy. Lancet Neurology, The, 2016, 15, 1298-1299.	4.9	0
32	Mitochondrial Abnormalities and Synaptic Loss Underlie Memory Deficits Seen in Mouse Models of Obesity and Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 915-932.	1.2	55
33	Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 34.	3.0	15
34	Gramine Derivatives Targeting Ca ²⁺ Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2016, 59, 6265-6280.	2.9	25
35	Alzheimer's Disease is an Important Risk Factor of Fractures: a Meta-analysis of Cohort Studies. Molecular Neurobiology, 2017, 54, 3230-3235.	1.9	18
36	Characterization of human induced pluripotent stem cell (iPSC) line from a 72 year old male patient with later onset Alzheimer's disease. Stem Cell Research, 2017, 19, 34-36.	0.3	6
37	Ketogenic diets and Alzheimer's disease. Food Science and Human Wellness, 2017, 6, 1-9.	2.2	39

#	ARTICLE	IF	CITATIONS
38	Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study. Aging Male, 2017, 20, 33-38.	0.9	32
39	Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. Medicinal Research Reviews, 2017, 37, 1186-1225.	5.0	248
40	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	1.2	57
41	How to handle adsorption of cerebrospinal fluid amyloid \hat{l}^2 (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A \hat{l}^2 42 /A \hat{l}^2 40 ratio., 2017, 13, 885-892.		52
42	Alzheimer's disease as an inflammatory disease. Biomolecular Concepts, 2017, 8, 37-43.	1.0	173
43	Diagnostic pathology of Alzheimer's disease from routine microscopy to immunohistochemistry and experimental correlations. Annals of Diagnostic Pathology, 2017, 28, 24-29.	0.6	8
45	Dementia in Women. Psychiatric Clinics of North America, 2017, 40, 299-307.	0.7	4
46	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. Expert Review of Proteomics, 2017, 14, 285-299.	1.3	78
47	Tetraspanin 6: a pivotal protein of the multiple vesicular body determining exosome release and lysosomal degradation of amyloid precursor protein fragments. Molecular Neurodegeneration, 2017, 12, 25.	4.4	70
48	Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease. Bioorganic Chemistry, 2017, 71, 305-314.	2.0	62
49	Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury. Molecular Neurodegeneration, 2017, 12, 21.	4.4	23
50	Correlation of rs9331888 polymorphism with Alzheimer's disease among Caucasian and Chinese populations: a meta-analysis and systematic review. Metabolic Brain Disease, 2017, 32, 981-989.	1.4	6
51	PET Imaging Agents for Alzheimer's Disease. Topics in Medicinal Chemistry, 2017, , 181-197.	0.4	0
52	Tongxinluo improves cognition by decreasing \hat{l}^2 -amyloid in spontaneous hypertensive rats. Brain Research, 2017, 1663, 151-160.	1.1	5
53	Alzheimer's Disease: An Overview of Recent Developments and a Look to the Future. Focus (American) Tj ETC	Qq <u>8,9</u> 0 rg	;BT ₉ /Overlock
54	Epidemiological Approaches to Understanding the Link Between Type 2 Diabetes and Dementia. Journal of Alzheimer's Disease, 2017, 59, 393-403.	1.2	36
55	Alzheimer's Disease II. Topics in Medicinal Chemistry, 2017, , .	0.4	2
56	Neural changes in Alzheimer's disease from circuit to molecule: Perspective of optogenetics. Neuroscience and Biobehavioral Reviews, 2017, 79, 110-118.	2.9	12

#	ARTICLE	IF	CITATIONS
57	Fucoxanthin Inhibits \hat{l}^2 -Amyloid Assembly and Attenuates \hat{l}^2 -Amyloid Oligomer-Induced Cognitive Impairments. Journal of Agricultural and Food Chemistry, 2017, 65, 4092-4102.	2.4	98
58	Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia. Dementia and Geriatric Cognitive Disorders Extra, 2017, 7, 143-159.	0.6	50
59	N -glycan and Alzheimer's disease. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2447-2454.	1.1	94
60	Effect of longâ€term storage in biobanks on cerebrospinal fluid biomarker Aβ _{1â€42} , Tâ€tau, and Pâ€tau values. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 45-50.	1.2	21
61	Cerebrospinal fluid neurofilament light chain as a biomarker of neurodegeneration in the Tg4510 and MitoPark mouse models. Neuroscience, 2017, 354, 101-109.	1.1	9
62	Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. CNS Drugs, 2017, 31, 495-509.	2.7	60
63	Tricyclic Polyprenylated Acylphloroglucinols from St John's Wort, <i>Hypericum perforatum</i> Journal of Natural Products, 2017, 80, 1493-1504.	1.5	54
64	Alterations of Golgi organization in Alzheimer's disease: A cause or a consequence?. Tissue and Cell, 2017, 49, 133-140.	1.0	27
65	The blood brain barrier in Alzheimer's disease. Vascular Pharmacology, 2017, 89, 12-18.	1.0	84
66	Clinical Amyloid Imaging. Seminars in Nuclear Medicine, 2017, 47, 31-43.	2.5	56
67	Spreading of Pathology in Alzheimer's Disease. Neurotoxicity Research, 2017, 32, 707-722.	1.3	13
68	Structural and functional analyses of pyroglutamate-amyloid- \hat{l}^2 -specific antibodies as a basis for Alzheimer immunotherapy. Journal of Biological Chemistry, 2017, 292, 12713-12724.	1.6	24
69	State of Play in Alzheimer's Disease Genetics. Journal of Alzheimer's Disease, 2017, 58, 631-659.	1.2	34
70	Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer AÎ ² Peptides. Circulation Research, 2017, 121, 258-269.	2.0	159
71	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. Scientific Reports, 2017, 7, 2477.	1.6	28
72	miR-34a knockout attenuates cognitive deficits in APP/PS1 mice through inhibition of the amyloidogenic processing of APP. Life Sciences, 2017, 182, 104-111.	2.0	61
73	The relevance of nutrition for the concept of cognitive frailty. Current Opinion in Clinical Nutrition and Metabolic Care, 2017, 20, 61-68.	1.3	39
74	rs3851179 Polymorphism at 5′ to the PICALM Gene is Associated with Alzheimer and Parkinson Diseases in Brazilian Population. NeuroMolecular Medicine, 2017, 19, 293-299.	1.8	18

#	Article	IF	CITATIONS
75	Rab21, a Novel PS1 Interactor, Regulates \hat{I}^3 -Secretase Activity via PS1 Subcellular Distribution. Molecular Neurobiology, 2018, 55, 3841-3855.	1.9	12
76	Serum Protein-Based Profiles as Novel Biomarkers for the Diagnosis of Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 3999-4008.	1.9	12
77	Neurocognitive Effect of Nootropic Drug <i>Brahmi</i> (Bacopa monnieri) in Alzheimer's Disease. Annals of Neurosciences, 2017, 24, 111-122.	0.9	113
78	Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. Nature Communications, 2017, 8, 14727.	5.8	308
79	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. Brain, 2017, 140, 1466-1485.	3.7	132
80	Alzheimer's Disease and Exercise: A Literature Review. Current Sports Medicine Reports, 2017, 16, 19-22.	0.5	142
81	Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 166-176.	1.8	19
82	The cholinergic anti-inflammatory pathway: An innovative treatment strategy for neurological diseases. Neuroscience and Biobehavioral Reviews, 2017, 77, 358-368.	2.9	52
83	Neural activity, memory, and dementias: serotonergic markers. Behavioural Pharmacology, 2017, 28, 132-141.	0.8	13
84	Diagnosis in vascular dementia, applying â€~Cochrane diagnosis rules' to â€~dementia diagnostic tools'. Clinical Science, 2017, 131, 729-732.	1.8	7
85	Molecular Interaction of Antiâ€Diabetic Drugs With Acetylcholinesterase and Sodium Glucose Coâ€Transporter 2. Journal of Cellular Biochemistry, 2017, 118, 3855-3865.	1.2	25
86	The bridging integrator 1 Gene rs7561528 polymorphism contributes to Alzheimer's disease susceptibility in East Asian and Caucasian populations. Clinica Chimica Acta, 2017, 469, 13-21.	0.5	8
87	A disease with a sweet tooth: exploring the Warburg effect in Alzheimer's disease. Biogerontology, 2017, 18, 301-319.	2.0	56
88	Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: An integrative review. Progress in Neurobiology, 2017, 156, 1-68.	2.8	112
89	Crossâ€seeding between Aβ40 and Aβ42 in Alzheimer's disease. FEBS Letters, 2017, 591, 177-185.	1.3	42
90	Alzheimer's disease: experimental models and reality. Acta Neuropathologica, 2017, 133, 155-175.	3.9	513
91	Brain tau deposition linked to systemic causes of death in normal elderly. Neurobiology of Aging, 2017, 50, 163-166.	1.5	2
92	Redox-sensitive GFP to monitor oxidative stress in neurodegenerative diseases. Reviews in the Neurosciences, 2017, 28, 133-144.	1.4	7

#	ARTICLE	IF	CITATIONS
93	Photobiomodulation and the brain: a new paradigm. Journal of Optics (United Kingdom), 2017, 19, 013003.	1.0	141
94	Using transcranial direct current stimulation to treat symptoms in mild cognitive impairment and Alzheimer's disease. Neurodegenerative Disease Management, 2017, 7, 317-329.	1.2	30
95	Prion-like Protein Seeding and the Pathobiology of Alzheimer's Disease. , 2017, , 57-82.		0
96	Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2017, 60, 939-947.	1.2	6
97	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	4.9	175
98	Omega-3 polyunsaturated fatty acids and brain health: Preclinical evidence for the prevention of neurodegenerative diseases. Trends in Food Science and Technology, 2017, 69, 203-213.	7.8	50
99	Alzheimer's disease prevention: from risk factors to early intervention. Alzheimer's Research and Therapy, 2017, 9, 71.	3.0	424
100	A Meta-Analysis on the Relationship of the PON Genes and Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 303-310.	1.2	22
101	Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. Experimental Gerontology, 2017, 100, 45-53.	1.2	37
102	A mimotope of Aβ oligomers may also behave as a βâ€sheet inhibitor. FEBS Letters, 2017, 591, 3615-3624.	1.3	7
103	Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. Acta Neurologica Belgica, 2017, 117, 811-819.	0.5	15
104	Identifying rescuers of misfolding. Nature Biomedical Engineering, 2017, 1, 782-783.	11.6	1
105	Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. Journal of Alzheimer's Disease, 2017, 60, 401-425.	1,2	158
106	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481.	4.5	77
107	MicroRNAs in Neurodegenerative Diseases. International Review of Cell and Molecular Biology, 2017, 334, 309-343.	1.6	151
108	Potential neurotoxicity of prenatal exposure to sevoflurane on offspring: Metabolomics investigation on neurodevelopment and underlying mechanism. International Journal of Developmental Neuroscience, 2017, 62, 46-53.	0.7	10
109	Lessons from Anti-Amyloid- \hat{l}^2 Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. Neurodegenerative Diseases, 2017, 17, 242-250.	0.8	34
110	Salidroside protects PC12 cells from Aβ1–40-induced cytotoxicity by regulating the nicotinamide phosphoribosyltransferase signaling pathway. Molecular Medicine Reports, 2017, 16, 2700-2706.	1.1	13

#	ARTICLE	IF	Citations
111	Bloodâ€based metabolic signatures in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 196-207.	1.2	56
112	Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer's Disea Related Pathology and Cognitive Decline. Scientific Reports, 2017, 7, 8009.	se 1.6	47
113	A Mouse Model of Alzheimer's Disease with Transplanted Stem-Cell-Derived Human Neurons. Neuroscience Bulletin, 2017, 33, 766-768.	1.5	2
114	Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer's disease. Journal of Neural Transmission, 2017, 124, 1621-1625.	1.4	27
115	Vaccination strategies in tauopathies and synucleinopathies. Journal of Neurochemistry, 2017, 143, 467-488.	2.1	30
116	Production of Monoclonal Antibodies to Pathologic \hat{l}^2 -sheet Oligomeric Conformers in Neurodegenerative Diseases. Scientific Reports, 2017, 7, 9881.	1.6	13
117	Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves 18FDG retention in 5XFAD mouse model of Alzheimer's disease. Brain Research, 2017, 1671, 102-110.	1.1	27
118	The anteroposterior and primary-to-posterior limbic ratios as MRI-derived volumetric markers of Alzheimer's disease. Journal of the Neurological Sciences, 2017, 378, 110-119.	0.3	2
119	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. NeuroImage: Clinical, 2017, 15, 673-681.	1.4	33
120	A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process. Journal of Molecular Graphics and Modelling, 2017, 76, 274-288.	1.3	5
121	Activation of brain glucose metabolism ameliorating cognitive impairment in APP/PS1 transgenic mice by electroacupuncture. Free Radical Biology and Medicine, 2017, 112, 174-190.	1.3	56
122	The diagnostic value of FDG and amyloid PET in Alzheimer's disease—A systematic review. European Journal of Radiology, 2017, 94, 16-24.	1.2	113
123	Estandarización del test de reacción cognitiva. Comprobación de su utilidad en el diagnóstico del deterioro cognitivo mÃnimo. Neurologia Argentina, 2017, 9, 163-172.	0.1	0
124	Inactivation of Nitric Oxide Synthesis Exacerbates the Development of Alzheimer Disease Pathology in APPPS1 Mice (Amyloid Precursor Protein/Presenilin-1). Hypertension, 2017, 70, 613-623.	1.3	27
125	Melatonin as a mitochondrial protector in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2017, 74, 3999-4014.	2.4	57
126	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathologyâ€based cohort. European Journal of Neurology, 2017, 24, 1326.	1.7	71
127	<scp>APP</scp> mouse models for Alzheimer's disease preclinical studies. EMBO Journal, 2017, 36, 2473-2487.	3.5	530
128	A preliminary examination of gut microbiota, sleep, and cognitive flexibility in healthy older adults. Sleep Medicine, 2017, 38, 104-107.	0.8	116

#	Article	IF	CITATIONS
129	Differential Pattern of Phospholipid Profile in the Temporal Cortex from E280A-Familiar and Sporadic Alzheimer's Disease Brains. Journal of Alzheimer's Disease, 2017, 61, 209-219.	1.2	27
131	Alzheimer's Dementia: An Overview. Journal of the Indian Institute of Science, 2017, 97, 591-602.	0.9	3
132	Why do so many clinical trials of therapies for Alzheimer's disease fail?. Lancet, The, 2017, 390, 2327-2329.	6.3	193
133	Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis. Neuroepidemiology, 2017, 49, 165-173.	1.1	13
134	Vitamins Associated with Brain Aging, Mild Cognitive Impairment, and Alzheimer Disease: Biomarkers, Epidemiological and Experimental Evidence, Plausible Mechanisms, and Knowledge Gaps. Advances in Nutrition, 2017, 8, 958-970.	2.9	56
135	The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 903-912.	1.2	23
136	Amylin Receptor: A Potential Therapeutic Target for Alzheimer's Disease. Trends in Molecular Medicine, 2017, 23, 709-720.	3.5	21
137	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
138	Chinese herbal medicine for Alzheimer's disease: Clinical evidence and possible mechanism of neurogenesis. Biochemical Pharmacology, 2017, 141, 143-155.	2.0	103
139	New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents. European Journal of Medicinal Chemistry, 2017, 138, 761-773.	2.6	57
140	Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample. Molecular Neurodegeneration, 2017, 12, 26.	4.4	17
141	Microglia limit the expansion of β-amyloid plaques in a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2017, 12, 47.	4.4	88
142	Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 18.	3.0	19
143	A vaccine with $A\hat{l}^2$ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer $\hat{a} \in \mathbb{Z}$ disease. Alzheimer's Research and Therapy, 2017, 9, 41.	3.0	9
144	Differential Aging Trajectories of Modulation of Activation to Cognitive Challenge in APOE $\hat{\mu}$ 4 Groups: Reduced Modulation Predicts Poorer Cognitive Performance. Journal of Neuroscience, 2017, 37, 6894-6901.	1.7	13
145	Characterization of circRNA-Associated-ceRNA Networks in a Senescence-Accelerated Mouse Prone 8 Brain. Molecular Therapy, 2017, 25, 2053-2061.	3.7	109
146	Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease. Journal of Neuroscience Research, 2017, 95, 1360-1372.	1.3	120
147	Positive cooperative regulation of double binding sites for human acetylcholinesterase. Chemical Biology and Drug Design, 2017, 89, 694-704.	1.5	9

#	Article	IF	CITATIONS
148	Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 125, 784-792.	2.6	55
149	Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury?. Brain, Behavior, and Immunity, 2017, 60, 369-382.	2.0	66
150	A Mitocentric View of Alzheimer's Disease. Molecular Neurobiology, 2017, 54, 6046-6060.	1.9	45
151	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. European Radiology, 2017, 27, 1169-1175.	2.3	97
152	The Yin and Yang of nucleic acid-based therapy in the brain. Progress in Neurobiology, 2017, 155, 194-211.	2.8	22
153	Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease. British Journal of Dermatology, 2017, 177, 273-275.	1.4	21
154	Pumping the Brakes: Neurotrophic Factors for the Prevention of Cognitive Impairment and Dementia after Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 971-986.	1.7	15
156	Tauopathies: Mechanisms and Therapeutic Strategies. Journal of Alzheimer's Disease, 2017, 61, 487-508.	1.2	19
157	An Intracellular Amyloid-β/AβPP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 1079-1096.	1.2	15
158	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. Journal of Visualized Experiments, 2017, , .	0.2	1
159	Stress-Induced NLRP3 Inflammasome in Human Diseases. Advances in Protein Chemistry and Structural Biology, 2017, 108, 127-162.	1.0	18
160	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain, 2017, 140, 2286-2294.	3.7	149
161	EEG fluctuations of wake and sleep in mild cognitive impairment., 2017, 2017, 3612-3615.		2
162	Transcranial Direct Current Stimulation as an Alternative Treatment in Patients with Alzheimer's Disease. Brain & Neurorehabilitation, 2017, 10, .	0.4	2
163	Similarity and Differences in Inflammation-Related Characteristics of the Peripheral Immune System of Patients with Parkinsonâ∈™s and Alzheimerâ∈™s Diseases. International Journal of Molecular Sciences, 2017, 18, 2633.	1.8	39
164	The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1909-1928.	1.0	43
165	Approaches for extending human healthspan: from antioxidants to healthspan pharmacology. Essays in Biochemistry, 2017, 61, 389-399.	2.1	13
166	Interleukin 1 Receptor and Alzheimer's Disease-Related Neuroinflammation. , 0, , .		1

#	Article	IF	CITATIONS
167	A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer's Disease and MCI Patients: Implications for Regenerative Medicine Approaches. International Journal of Molecular Sciences, 2017, 18, 1806.	1.8	36
168	5-Hydroxycyclopenicillone, a New \hat{I}^2 -Amyloid Fibrillization Inhibitor from a Sponge-Derived Fungus Trichoderma sp. HPQJ-34. Marine Drugs, 2017, 15, 260.	2.2	26
169	5-Hydroxycyclopenicillone Inhibits \hat{l}^2 -Amyloid Oligomerization and Produces Anti- \hat{l}^2 -Amyloid Neuroprotective Effects In Vitro. Molecules, 2017, 22, 1651.	1.7	10
170	Nicotinamide Reduces Amyloid Precursor Protein and Presenilin 1 in Brain Tissues of Amyloid Beta-Tail Vein Injected Mice. Clinical Nutrition Research, 2017, 6, 130.	0.5	15
171	Cerebrospinal Fluid Biomarkers in Alzheimer's Diseaseâ€"From Brain Starch to Bench and Bedside. Diagnostics, 2017, 7, 42.	1.3	19
172	A Novel Genetic Screen Identifies Modifiers of Age-Dependent Amyloid \hat{l}^2 Toxicity in the Drosophila Brain. Frontiers in Aging Neuroscience, 2017, 9, 61.	1.7	12
173	Adiponectin Regulates the Polarization and Function of Microglia via PPAR- \hat{l}^3 Signaling Under Amyloid \hat{l}^2 Toxicity. Frontiers in Cellular Neuroscience, 2017, 11, 64.	1.8	46
174	Non-aggregated A \hat{I}^2 25-35 Upregulates Primary Astrocyte Proliferation In Vitro. Frontiers in Cellular Neuroscience, 2017, 11, 301.	1.8	3
175	Tau Protein in Oral Mucosa and Cognitive State: A Cross-sectional Study. Frontiers in Neurology, 2017, 8, 554.	1.1	8
176	Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson's Disease Relative to Alzheimer's Disease and Controls. Frontiers in Neurology, 2017, 8, 720.	1.1	44
177	Amyloid- \hat{l}^2 Impairs Vesicular Secretion in Neuronal and Astrocyte Peptidergic Transmission. Frontiers in Molecular Neuroscience, 2017, 10, 202.	1.4	9
178	Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2017, 10, 276.	1.4	87
179	Profiling microRNA from Brain by Microarray in a Transgenic Mouse Model of Alzheimer's Disease. BioMed Research International, 2017, 2017, 1-11.	0.9	34
180	The Italian Version of the Five-Word Test: A Simple Diagnostic Test for Dementia due to Alzheimer's Disease in Routine Clinical Practice. Behavioural Neurology, 2017, 2017, 1-6.	1.1	2
181	Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives. Journal of Diabetes Research, 2017, 2017, 1-7.	1.0	41
182	Neuroprotective Effects and Mechanism of $\langle i \rangle \hat{l}^2 \langle i \rangle$ -Asarone against $A \langle i \rangle \hat{l}^2 \langle i \rangle 1 \hat{a} \in (42-1)$ -Induced Injury in Astrocytes. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-14.	0.5	17
183	Seeking a New Paradigm for Alzheimer's Disease: Considering the Roles of Inflammation, Blood-Brain Barrier Dysfunction, and Prion Disease. International Journal of Alzheimer's Disease, 2017, 2017, 1-6.	1.1	4
184	Fucoxanthin, a Marine Carotenoid, Attenuates $\langle i \rangle \hat{l}^2 \langle i \rangle$ -Amyloid Oligomer-Induced Neurotoxicity Possibly via Regulating the PI3K/Akt and the ERK Pathways in SH-SY5Y Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	57

#	Article	IF	CITATIONS
185	MicroRNA-322 attenuates aluminum maltolate-induced apoptosis in the human SH-SY5Y neuroblastoma cell line. Molecular Medicine Reports, 2017, 16, 2199-2204.	1.1	13
186	Amyloid-Related Imaging Abnormalities inÂan Aged Squirrel Monkey with Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2017, 57, 519-530.	1.2	22
187	Dissociating Normal Aging from Alzheimer's Disease: A View from Cognitive Neuroscience. Journal of Alzheimer's Disease, 2017, 57, 331-352.	1.2	123
188	Acute exercise does not modify brain activity and memory performance in APP/PS1 mice. PLoS ONE, 2017, 12, e0178247.	1.1	18
189	Novel derivative of Paeonol, PaeononIsilatie sodium, alleviates behavioral damage and hippocampal dendritic injury in Alzheimer's disease concurrent with cofilin1/phosphorylated-cofilin1 and RAC1/CDC42 alterations in rats. PLoS ONE, 2017, 12, e0185102.	1.1	21
190	Traffic-Related Air Pollution and Neurodegenerative Diseases: Epidemiological and Experimental Evidence, and Potential Underlying Mechanisms. Advances in Neurotoxicology, 2017, 1, 1-46.	0.7	6
191	Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. BMC Geriatrics, 2017, 17, 210.	1.1	9
192	Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with \hat{l}^3 -secretase and regulates neuronal amyloid \hat{l}^2 -peptide levels. Alzheimer's Research and Therapy, 2017, 9, 57.	3.0	164
193	PKR involvement in Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 83.	3.0	52
194	Terapia musical en el manejo de s $ ilde{A}$ ntomas cognitivos, psicol $ ilde{A}^3$ gicos y conductuales de demencia: Una revisi $ ilde{A}^3$ n narrativa Revista De Neuro-psiquiatria, 2017, 80, 111.	0.0	0
195	Alzheimer's disease and osteoporosis. Tzu Chi Medical Journal, 2017, 29, 138.	0.4	27
196	Developmental Exposure to Metals and its Contribution to Age-Related Neurodegeneration. , 2017, , 217-229.		1
197	Influence of gut microbiota on neuropsychiatric disorders. World Journal of Gastroenterology, 2017, 23, 5486.	1.4	286
198	Cognitive Dysfunction in Diabetes Mellitus. , 2017, , 421-443.		2
199	Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer's disease. Molecular Medicine Reports, 2018, 17, 4113-4119.	1,1	17
200	Probing the Structure and Function Relationships of Presenilin by Substituted-Cysteine Accessibility Method. Methods in Enzymology, 2017, 584, 185-205.	0.4	10
201	Stoichiometric Zn2+ interferes with the self-association of $\hat{Al^2}42$: Insights from size distribution analysis. International Journal of Biological Macromolecules, 2018, 113, 631-639.	3.6	8
202	Cysteine Metabolism in Neuronal Redox Homeostasis. Trends in Pharmacological Sciences, 2018, 39, 513-524.	4.0	198

#	Article	IF	CITATIONS
203	Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice. Translational Psychiatry, 2018, 8, 53.	2.4	52
204	Drosophila Full-Length Amyloid Precursor Protein Is Required for Visual Working Memory and Prevents Age-Related Memory Impairment. Current Biology, 2018, 28, 817-823.e3.	1.8	27
205	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î² PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468
206	Anthocyanins as a potential pharmacological agent to manage memory deficit, oxidative stress and alterations in ion pump activity induced by experimental sporadic dementia of Alzheimer's type. Journal of Nutritional Biochemistry, 2018, 56, 193-204.	1.9	77
207	Challenges associated with biomarkerâ€based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357.	1.2	37
208	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. Journal of Alzheimer's Disease, 2018, 64, S3-S22.	1.2	108
209	Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis. Australasian Psychiatry, 2018, 26, 347-357.	0.4	131
210	Probing the Mint2 Protein–Protein Interaction Network Relevant to the Pathophysiology of Alzheimer's Disease. ChemBioChem, 2018, 19, 1119-1122.	1.3	8
211	Substituent effect of N-benzylated gramine derivatives that prevent the PP2A inhibition and dissipate the neuronal Ca2+ overload, as a multitarget strategy for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2018, 26, 2551-2560.	1.4	9
212	<scp>nNOS</scp> – <scp>CAPON</scp> interaction mediates amyloidâ€Î²â€induced neurotoxicity, especially in the early stages. Aging Cell, 2018, 17, e12754.	3.0	26
213	Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors. European Journal of Medicinal Chemistry, 2018, 147, 194-204.	2.6	17
214	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology, 2018, 90, e877-e886.	1.5	28
215	An Excitatory Neural Assembly Encodes Short-Term Memory in the Prefrontal Cortex. Cell Reports, 2018, 22, 1734-1744.	2.9	19
216	Vascular cognitive impairment. Nature Reviews Disease Primers, 2018, 4, 18003.	18.1	358
217	The pericyte–glia interface at the blood–brain barrier. Clinical Science, 2018, 132, 361-374.	1.8	63
218	Advancements of the <scp>sFIDA</scp> method for oligomerâ€based diagnostics of neurodegenerative diseases. FEBS Letters, 2018, 592, 516-534.	1.3	10
219	DNA methylation level of the neprilysin promoter in Alzheimer's disease brains. Neuroscience Letters, 2018, 670, 8-13.	1.0	10
220	Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study. Journal of Alzheimer's Disease, 2018, 61, 907-912.	1.2	23

#	Article	IF	CITATIONS
221	Characterization of a 3xTgâ€AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background. Synapse, 2018, 72, e22025.	0.6	16
222	In vivo and in vitro neuroprotective effects of Panax ginseng glycoproteins. International Journal of Biological Macromolecules, 2018, 113, 607-615.	3.6	18
223	Evaluating Peripersonal Space through the Functional Transcranial Doppler: Are We Paving the Way for Early Detecting Mild Cognitive Impairment to Dementia Conversion?. Journal of Alzheimer's Disease, 2018, 62, 133-143.	1.2	5
224	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. Journal of Neural Transmission, 2018, 125, 673-679.	1.4	31
226	Drug discovery, development and delivery in Alzheimer's disease. Pharmaceutical Research, 2018, 35, 3.	1.7	6
227	Long-term treadmill exercise attenuates Aβ burdens and astrocyte activation in APP/PS1 mouse model of Alzheimer's disease. Neuroscience Letters, 2018, 666, 70-77.	1.0	74
228	\hat{l}^2 -Ecdysterone protects SH-SY5Y cells against \hat{l}^2 -amyloid-induced apoptosis via c-Jun N-terminal kinase- and Akt-associated complementary pathways. Laboratory Investigation, 2018, 98, 489-499.	1.7	37
229	Dementia in Latin America. Neurology, 2018, 90, 222-231.	1.5	124
230	Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. Experimental Gerontology, 2018, 107, 169-177.	1.2	36
231	Alzheimer's disease biomarkerâ€guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Al² _{1–42} , totalâ€tau, phosphorylatedâ€tau, NFL, neurogranin, and YKLâ€40. Alzheimer's and Dementia, 2018, 14, 492-501.	0.4	91
232	Oligoethyleneoxy-Modified ^{99m} Tc-Labeled β-Amyloid Imaging Probes with Improved Brain Pharmacokinetics for Single-Photon Emission Computed Tomography. Journal of Medicinal Chemistry, 2018, 61, 1330-1339.	2.9	14
233	Rapidly Progressive Alzheimer's Disease: Contributions to Clinical-Pathological Definition and Diagnosis. Journal of Alzheimer's Disease, 2018, 63, 887-897.	1.2	16
234	Alzheimer's disease drug development pipeline: 2018. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 195-214.	1.8	469
235	Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its \hat{I} ±-Helical Conformation, and Inhibits \hat{I} 3-Secretase Nonselectively in Liposomes. ACS Chemical Neuroscience, 2018, 9, 1702-1713.	1.7	11
236	Proteomic differences between focal and diffuse traumatic brain injury in human brain tissue. Scientific Reports, 2018, 8, 6807.	1.6	37
237	Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 19.	2.4	126
238	Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer's dementia: a meta-analysis. Translational Neurodegeneration, 2018, 7, 9.	3.6	31
239	CSF biological antioxidant potentials may differentiate neurodegenerative diseases-A preliminary report. Neurology and Clinical Neuroscience, 2018, 6, 45-47.	0.2	2

#	Article	IF	Citations
240	Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 174-179.	0.6	3
241	A preclinical perspective on the enhanced vulnerability to Alzheimer's disease after early-life stress. Neurobiology of Stress, 2018, 8, 172-185.	1.9	45
242	Sortilin: a new player in dementia and Alzheimer-type neuropathology. Biochemistry and Cell Biology, 2018, 96, 491-497.	0.9	15
243	Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity. Neurolmage, 2018, 176, 246-258.	2.1	105
244	Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease. Dalton Transactions, 2018, 47, 7190-7205.	1.6	30
245	Visitâ€toâ€visit variability in blood pressure and Alzheimer's disease. Journal of Clinical Hypertension, 2018, 20, 918-924.	1.0	54
246	Targeting Amyloid- \hat{l}^2 Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid- \hat{l}^2 Production. Molecular Therapy, 2018, 26, 1539-1551.	3.7	27
247	Prevalence of the apolipoprotein E $\hat{l}\mu4$ allele in amyloid \hat{l}^2 positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
248	Design, synthesis and evaluation of pterostilbene \hat{l}^2 -amino alcohol derivatives as multifunctional agents for Alzheimer's disease treatment. Bioorganic Chemistry, 2018, 78, 298-306.	2.0	16
249	Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 103-107.	1.8	12
250	Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, S299-S312.	1.2	22
251	Microglia-Mediated Synapse Loss in Alzheimer's Disease. Journal of Neuroscience, 2018, 38, 2911-2919.	1.7	228
252	Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid- \hat{l}^2 3-42 (pE3- \hat{Al}^2). Journal of Alzheimer's Disease, 2018, 62, 1635-1649.	1.2	8
253	Primer in Genetics and Genomics, Article 7—Multifactorial Concepts: Gene–Gene Interactions. Biological Research for Nursing, 2018, 20, 359-364.	1.0	5
254	Unique expression pattern of KIBRA in the enteric nervous system of APP/PS1 mice. Neuroscience Letters, 2018, 675, 41-47.	1.0	7
255	APOEε4 Genotype and Hypertension Modify 8-year Cortical Thinning: Five Occasion Evidence from the Seattle Longitudinal Study. Cerebral Cortex, 2018, 28, 1934-1945.	1.6	21
256	The role of regulatory T cells in nervous system pathologies. Journal of Neuroscience Research, 2018, 96, 951-968.	1.3	64
257	Young Blood Plasma Administration to Fight Alzheimer's Disease?. Rejuvenation Research, 2018, 21, 178-181.	0.9	8

#	Article	IF	CITATIONS
258	Cognition and anatomy of adult Niemann–Pick disease type C: Insights for the Alzheimer field. Cognitive Neuropsychology, 2018, 35, 209-222.	0.4	13
259	Systemic Inflammation and Multimodal Biomarkers in Amnestic Mild Cognitive Impairment and Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 5689-5697.	1.9	36
260	Disturbances in the control of capillary flow in an aged APPswe/PS1î"E9 model of Alzheimer's disease. Neurobiology of Aging, 2018, 62, 82-94.	1.5	30
261	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
262	Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer's disease. European Journal of Epidemiology, 2018, 33, 657-666.	2.5	18
263	The age-related slow increase in amyloid pathology in APP.V717I mice activates microglia, but does not alter hippocampal neurogenesis. Neurobiology of Aging, 2018, 61, 112-123.	1.5	6
264	Higher Risk of Vascular Dementia in Myocardial Infarction Survivors. Circulation, 2018, 137, 567-577.	1.6	70
265	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. Proteomics - Clinical Applications, 2018, 12, 1700131.	0.8	87
266	Exposure to a national multimedia <scp>Alzheimer's</scp> disease awareness campaign: <scp>Assessing</scp> stigmatic beliefs towards persons with the disease. International Journal of Geriatric Psychiatry, 2018, 33, e336-e342.	1.3	6
267	Recent Advances in Computational Approaches for Designing Potential Anti-Alzheimer's Agents. Neuromethods, 2018, , 25-59.	0.2	3
268	Inhibition of \hat{I}^3 -Secretase Leads to an Increase in Presenilin-1. Molecular Neurobiology, 2018, 55, 5047-5058.	1.9	19
269	Motor function deficits in the 12 month-old female 5xFAD mouse model of Alzheimer's disease. Behavioural Brain Research, 2018, 337, 256-263.	1.2	76
270	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. Neurobiology of Aging, 2018, 61, 198-206.	1.5	44
271	Calmodulinâ€like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease. Journal of Neurochemistry, 2018, 144, 218-233.	2.1	12
272	Nucleic acid aptamers for neurodegenerative diseases. Biochimie, 2018, 145, 73-83.	1.3	35
273	Resveratrol, pterostilbene, and dementia. BioFactors, 2018, 44, 83-90.	2.6	86
274	Alzheimer Disease. Journal for Nurse Practitioners, 2018, 14, 129-135.	0.4	64
275	Gasotransmitter hydrogen sulfide signaling in neuronal health and disease. Biochemical Pharmacology, 2018, 149, 101-109.	2.0	175

#	Article	IF	CITATIONS
276	Cerebral vasoreactivity and intima-media thickness in Down syndrome: A case-control study. Journal of the Neurological Sciences, 2018, 385, 57-63.	0.3	2
277	Late age onset of amyotrophic lateral sclerosis is often not considered in elderly people. Acta Neurologica Scandinavica, 2018, 137, 329-334.	1.0	17
278	Genetics of Parkinson's disease and related disorders. Journal of Medical Genetics, 2018, 55, 73-80.	1.5	55
279	Novel recruitment models will drive Alzheimer's trial success. Alzheimer's and Dementia, 2018, 14, 117-119.	0.4	18
280	Simulating the effect of formation of amyloid plaques on aggregation of tau protein. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2018, 474, 20180511.	1.0	18
281	Acetazolamide for Antipsychotic-Associated Weight Gain in Schizophrenia. Journal of Clinical Psychopharmacology, 2018, 38, 652-653.	0.7	3
282	Tau in neurodegenerative disease. Annals of Translational Medicine, 2018, 6, 175-175.	0.7	140
283	Antemortem CSF A $<$ i $>$ Î $^2<$ (i $>$ 42/A $<$ i $>$ Î $^2<$ (i $>$ 40 ratio predicts Alzheimer's disease pathology better than A $<$ i $>$ Î $^2<$ (i $>$ 42 in rapidly progressive dementias. Annals of Clinical and Translational Neurology, 2019, 6, 263-273.	1.7	31
284	AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTH. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-6.	1.5	4
285	Common Variants in PLXNA4 and Correlation to CSF-related Phenotypes in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 946.	1.4	14
286	Alzheimer's disease is associated with prostate cancer: a population-based study. Oncotarget, 2018, 9, 7616-7622.	0.8	11
287	Clinical and Cognitive Features of Idiopathic Normal Pressure Hydrocephalus. , 2018, , .		0
289	Diazepam Toxicity Presenting as a Dementia Disorder. Journal of Alzheimer's Disease, 2018, 66, 935-938.	1.2	10
290	Visual Features in Alzheimer's Disease: From Basic Mechanisms to Clinical Overview. Neural Plasticity, 2018, 2018, 1-21.	1.0	31
291	Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine. Molecules, 2018, 23, 2207.	1.7	16
292	Crocetin attenuates inflammation and amyloid- \hat{l}^2 accumulation in APPsw transgenic mice. Immunity and Ageing, 2018, 15, 24.	1.8	35
293	Non-Invasive, Cost-Effective, Early Diagnosis of Mild Cognitive Impairment in an Outpatient Setting: Pilot Study., 2018, 2018, 13-16.		4
294	Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APPSWE/PS1ΔE9 Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 397.	1.8	26

#	Article	IF	Citations
295	Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review. International Journal of Molecular Sciences, 2018, 19, 3702.	1.8	45
296	MicroRNA-98 reduces amyloid \hat{l}^2 -protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer's disease mice. International Journal of Molecular Medicine, 2019, 43, 91-102.	1.8	40
298	Deep Profiling of the Aggregated Proteome in Alzheimer's Disease: From Pathology to Disease Mechanisms. Proteomes, 2018, 6, 46.	1.7	23
299	Artemisinin B Improves Learning and Memory Impairment in AD Dementia Mice by Suppressing Neuroinflammation. Neuroscience, 2018, 395, 1-12.	1.1	40
300	Levels of Cortisol in CSF Are Associated With SNAP-25 and Tau Pathology but Not Amyloid- \hat{l}^2 . Frontiers in Aging Neuroscience, 2018, 10, 383.	1.7	10
301	Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease: a feature selection ensemble combining stability and predictability. BMC Medical Informatics and Decision Making, 2018, 18, 137.	1.5	34
302	Gradual Disturbances of the Amplitude of Low-Frequency Fluctuations (ALFF) and Fractional ALFF in Alzheimer Spectrum. Frontiers in Neuroscience, 2018, 12, 975.	1.4	135
303	Therapeutic effect of Rho kinase inhibitor FSD‑C10 in a mouse model of Alzheimer's disease. Experimental and Therapeutic Medicine, 2018, 16, 3929-3938.	0.8	10
304	Dihydroquinoline Carbamate DQS1-02 as a Prodrug of a Potent Acetylcholinesterase Inhibitor for Alzheimer's Disease Therapy: Multigram-Scale Synthesis, Mechanism Investigations, in Vitro Safety Pharmacology, and Preliminary in Vivo Toxicology Profile. ACS Omega, 2018, 3, 18387-18397.	1.6	7
305	Probiotic Supplementation in Patients with Alzheimer's Dementia - An Explorative Intervention Study. Current Alzheimer Research, 2018, 15, 1106-1113.	0.7	181
306	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 124.	3.0	273
307	Advances in Resting State Neuroimaging of Mild Cognitive Impairment. Frontiers in Psychiatry, 2018, 9, 671.	1.3	14
308	Advances in developing novel therapeutic strategies for Alzheimer's disease. Molecular Neurodegeneration, 2018, 13, 64.	4.4	189
309	Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer's Disease. International Journal of Alzheimer's Disease, 2018, 2018, 1-9.	1.1	44
310	Current state of Alzheimer's fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
311	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 563-572.	1.2	52
312	The Multidisciplinary Approach to Alzheimer's Disease and Dementia. A Narrative Review of Non-Pharmacological Treatment. Frontiers in Neurology, 2018, 9, 1058.	1.1	164
314	microRNAs in Neurodegeneration: Current Findings and Potential Impacts. , 2018, 08, .		37

#	Article	IF	CITATIONS
315	Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. Acta Neuropathologica, 2018, 136, 699-708.	3.9	252
316	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652.	4.9	434
317	The Montreal Cognitive Assessment: Normative Data from a German-Speaking Cohort and Comparison with International Normative Samples. Journal of Alzheimer's Disease, 2018, 64, 643-655.	1.2	74
318	Association between hypertension and cognitive function: A crossâ€sectional study in people over 45 years old in China. Journal of Clinical Hypertension, 2018, 20, 1575-1583.	1.0	42
319	Gephyrin: a key regulatory protein of inhibitory synapses and beyond. Histochemistry and Cell Biology, 2018, 150, 489-508.	0.8	47
320	Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model. Cell Cycle, 2018, 17, 2321-2334.	1.3	7
321	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	3.0	64
322	Alzheimer's disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology, 2018, 158, 359-375.	2.0	59
323	Alzheimer's disease (AD) therapeutics – 2: Beyond amyloid – Re-defining AD and its causality to discover effective therapeutics. Biochemical Pharmacology, 2018, 158, 376-401.	2.0	24
324	A cross-species approach to disorders affecting brain and behaviour. Nature Reviews Neurology, 2018, 14, 677-686.	4.9	18
325	Design, synthesis and biological evaluation of tricyclic pyrazolo[1,5-< $i>c)[1,3]$ benzoxazin-5(5< $i>d)-one$ scaffolds as selective BuChE inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1506-1515.	2.5	13
326	The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. European Journal of Epidemiology, 2018, 33, 1229-1249.	2.5	43
327	rTMS for the treatment of Alzheimer's disease: where should we be stimulating?. Expert Review of Neurotherapeutics, 2018, 18, 903-905.	1.4	17
328	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	3.0	46
329	Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy. Frontiers in Pharmacology, 2018, 9, 1192.	1.6	185
330	Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathologica, 2018, 136, 663-689.	3.9	151
331	Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau <i>In Vivo</i> Iournal of Neuroscience, 2018, 38, 10595-10606.	1.7	66
332	Antisense Oligonucleotides in Psychiatric Disorders. Journal of Clinical Psychopharmacology, 2018, 38, 651-652.	0.7	3

#	Article	IF	Citations
333	The effects of fluorescent labels on A $\hat{1}^2$ ₄₂ aggregation detected by fluorescence correlation spectroscopy. Biopolymers, 2018, 109, e23237.	1.2	9
334	Re-thinking Alzheimer's disease therapeutic targets using gene-based tests. EBioMedicine, 2018, 37, 461-470.	2.7	28
335	Fighting the Cause of Alzheimer's and GNE Myopathy. Frontiers in Neuroscience, 2018, 12, 669.	1.4	7
336	Porphyrinic Metal–Organic Framework PCN-224 Nanoparticles for Near-Infrared-Induced Attenuation of Aggregation and Neurotoxicity of Alzheimer's Amyloid-β Peptide. ACS Applied Materials & Interfaces, 2018, 10, 36615-36621.	4.0	107
337	Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review. Current Genomics, 2018, 19, 522-602.	0.7	65
339	Screening for Cognitive Impairment in Geriatrics. Clinics in Geriatric Medicine, 2018, 34, 515-536.	1.0	29
340	Application of BÃ \odot zier Curves for Calculating Likelihood Ratios for Plasma Amyloid- \hat{l}^2 Biomarkers for Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 276.	1.7	1
341	The <scp>BACE</scp> â€l inhibitor <scp>CNP</scp> 520 for prevention trials in Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	112
342	Dehydroepiandrosterone (DHEA) and DHEA Sulfate: Roles in Brain Function and Disease. , 0, , .		2
343	Deoxyschizandrin attenuates Aβ1–42-induced cognitive impairments through up-regulation of AMPA receptors in mice. Phytochemistry Letters, 2018, 28, 24-31.	0.6	4
344	Vulnerability and resilience to Alzheimer's disease: early life conditions modulate neuropathology and determine cognitive reserve. Alzheimer's Research and Therapy, 2018, 10, 95.	3.0	79
345	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2018, , 1-26.		O
346	Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity. BMC Medical Genetics, 2018, 19, 75.	2.1	21
347	Sex Hormones and Alzheimer's Disease. , 2018, , .		2
348	The Hypothalamus in Alzheimer's Disease. , 2018, , .		1
349	Cerebrovascular disease and dementia. , 2018, , 161-167.		0
350	Defect of branched-chain amino acid metabolism promotes the development of Alzheimer's disease by targeting the mTOR signaling. Bioscience Reports, 2018, 38, .	1,1	50
351	MFG-E8 inhibits Aβ-induced microglial production of cathelicidin-related antimicrobial peptide: A suitable target against Alzheimer's disease. Cellular Immunology, 2018, 331, 59-66.	1.4	16

#	Article	IF	CITATIONS
352	Dissociation of cerebrospinal fluid amyloid- \hat{l}^2 and tau levels in patients with prolonged posttraumatic disorders of consciousness. Brain Injury, 2018, 32, 1056-1060.	0.6	14
353	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals A \hat{I}^2 Aggregation Dependent Anionic Lipid Accumulations and Metabolism. Analytical Chemistry, 2018, 90, 8130-8138.	3.2	39
354	Antisense oligonucleotides in neurological disorders. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641877693.	1.5	100
355	Whole-brain low-intensity pulsed ultrasound therapy markedly improves cognitive dysfunctions in mouse models of dementiaÂ-ÂCrucial roles of endothelial nitric oxide synthase. Brain Stimulation, 2018, 11, 959-973.	0.7	89
356	A patent review of butyrylcholinesterase inhibitors and reactivators 2010–2017. Expert Opinion on Therapeutic Patents, 2018, 28, 455-465.	2.4	31
357	Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology, 2018, 21, 748-757.	1.0	19
358	Is Targeting the Inflammasome a Way Forward for Neuroscience Drug Discovery?. SLAS Discovery, 2018, 23, 991-1017.	1.4	17
359	Agmatine attenuates depressive-like behavior and hippocampal oxidative stress following amyloid \hat{l}^2 (Al^21-40) administration in mice. Behavioural Brain Research, 2018, 353, 51-56.	1.2	23
360	Mass spectrometric characterization of intact desferalâ€conjugated monoclonal antibodies for immunoâ€positron emission tomography imaging. Rapid Communications in Mass Spectrometry, 2018, 32, 1643-1650.	0.7	0
361	Sex-dependent co-occurrence of hypoxia and β-amyloid plaques in hippocampus and entorhinal cortex is reversed by long-term treatment with ubiquinol and ascorbic acid in the 3 ŗ Tg-AD mouse model of Alzheimer's disease. Molecular and Cellular Neurosciences, 2018, 92, 67-81.	1.0	24
362	Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with APOE E-4. SSM - Population Health, 2018, 5, 171-179.	1.3	24
363	Role of Inflammasomes in Neuroimmune and Neurodegenerative Diseases: A Systematic Review. Mediators of Inflammation, 2018, 2018, 1-11.	1.4	52
364	Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
365	Application value of serum biomarkers for choosing memantine therapy for moderate AD. Journal of Neurology, 2018, 265, 1844-1849.	1.8	8
366	Neurocognitive Disorders. , 2018, , 139-165.		0
367	A systematic review and meta-analysis of structural magnetic resonance imaging studies investigating cognitive and social activity levels in older adults. Neuroscience and Biobehavioral Reviews, 2018, 93, 71-84.	2.9	37
368	The Role of Immunosenescence in Neurodegenerative Diseases. Mediators of Inflammation, 2018, 2018, 1-12.	1.4	91
369	Decreased generation of Câ€terminal fragments of ApoER2 and increased reelin expression in Alzheimer's disease. FASEB Journal, 2018, 32, 3536-3546.	0.2	23

#	Article	IF	CITATIONS
370	Decreased resting-state brain signal complexity in patients with mild cognitive impairment and Alzheimer's disease: a multi-scale entropy analysis. Biomedical Optics Express, 2018, 9, 1916.	1.5	58
371	Beneficial Effect of Multidomain Cognitive Training on the Neuropsychological Performance of Patients with Early-Stage Alzheimer's Disease. Neural Plasticity, 2018, 2018, 1-9.	1.0	43
372	Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions., 2018, 59, 3554.		22
373	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, 58.	3.0	21
374	Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7–NMDA Receptor Antagonists. Molecules, 2018, 23, 230.	1.7	20
375	Intracerebroventricular injection of Aβ1-42 combined with two-vessel occlusion accelerate Alzheimer's disease development in rats. Pathology Research and Practice, 2018, 214, 1583-1595.	1.0	11
376	Ocular Manifestations of Alzheimer's and Other Neurodegenerative Diseases: The Prospect of the Eye as a Tool for the Early Diagnosis of Alzheimer's Disease. Journal of Ophthalmology, 2018, 2018, 1-12.	0.6	69
377	A Review on Central Nervous System Effects of Gastrodin. Frontiers in Pharmacology, 2018, 9, 24.	1.6	231
378	Brain Stimulation in Alzheimer's Disease. Frontiers in Psychiatry, 2018, 9, 201.	1.3	98
379	EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. Frontiers in Aging Neuroscience, 2018, 10, 190.	1.7	48
380	Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease, 2018, 62, 1091-1111.	1.2	228
381	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimer's Research and Therapy, 2018, 10, 54.	3.0	24
382	Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection. European Journal of Medicinal Chemistry, 2018, 157, 294-309.	2.6	12
383	Cognitive and emotional alterations in App knock-in mouse models of ${\rm A}\hat{\rm I}^2$ amyloidosis. BMC Neuroscience, 2018, 19, 46.	0.8	51
384	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. Journal of Genetics, 2018, 97, 625-648.	0.4	7
385	A narrative review of problems with medicines use in people with dementia. Expert Opinion on Drug Safety, 2018, 17, 825-836.	1.0	17
386	PICALM Gene Methylation in Blood of Alzheimer's Disease Patients Is Associated with Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 283-292.	1.2	18
387	Gamma Band Neural Stimulation in Humans and the Promise of a New Modality to Prevent and Treat Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 65, 363-392.	1.2	63

#	Article	IF	Citations
388	Dementia and Alzheimer's disease risks in patients with autoimmune disorders. Geriatrics and Gerontology International, 2018, 18, 1350-1355.	0.7	35
389	Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes. Frontiers in Immunology, 2018, 9, 1351.	2.2	122
390	The Role of Genetics in Advancing Precision Medicine for Alzheimer's Diseaseâ€"A Narrative Review. Frontiers in Medicine, 2018, 5, 108.	1.2	61
391	Serum Hepatocyte Growth Factor Is Associated with Small Vessel Disease in Alzheimer's Dementia. Frontiers in Aging Neuroscience, 2018, 10, 8.	1.7	17
392	Dissecting Endoplasmic Reticulum Unfolded Protein Response (UPRER) in Managing Clandestine Modus Operandi of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 30.	1.7	29
393	Resting State BOLD Variability in Alzheimer's Disease: A Marker of Cognitive Decline or Cerebrovascular Status?. Frontiers in Aging Neuroscience, 2018, 10, 39.	1.7	40
394	Early-Life Stress Does Not Aggravate Spatial Memory or the Process of Hippocampal Neurogenesis in Adult and Middle-Aged APP/PS1 Mice. Frontiers in Aging Neuroscience, 2018, 10, 61.	1.7	13
395	Sex Differences in Healthspan Predict Lifespan in the 3xTg-AD Mouse Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 172.	1.7	46
396	miR-103 Promotes Neurite Outgrowth and Suppresses Cells Apoptosis by Targeting Prostaglandin-Endoperoxide Synthase 2 in Cellular Models of Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 91.	1.8	33
397	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37.	1.4	132
398	Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 362.	1.4	12
399	On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2018, 11, 87.	1.4	77
400	Site-specific structural order in Alzheimer's AÎ ² 42 fibrils. Royal Society Open Science, 2018, 5, 180166.	1.1	11
401	Amyloid-Mediated Cholinergic Dysfunction in Motor Impairment Related to Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 525-532.	1.2	59
402	Circadian Rhythm and Alzheimer's Disease. Medical Sciences (Basel, Switzerland), 2018, 6, 52.	1.3	42
403	Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals, 2018, 11, 44.	1.7	213
404	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	3.0	62
405	Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nature Reviews Endocrinology, 2018, 14, 591-604.	4.3	689

#	Article	IF	CITATIONS
406	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 156, 534-553.	2.6	38
407	Dendritic Tau in Alzheimer's Disease. Neuron, 2018, 99, 13-27.	3.8	178
408	Spontaneous development of Alzheimer's diseaseâ€associated brain pathology in a Shugoshinâ€1 mouse cohesinopathy model. Aging Cell, 2018, 17, e12797.	3.0	19
409	Specific deletion connexin43 in astrocyte ameliorates cognitive dysfunction in APP/PS1 mice. Life Sciences, 2018, 208, 175-191.	2.0	44
410	Amyloid- \hat{l}^2 Peptide Triggers Membrane Remodeling in Supported Lipid Bilayers Depending on Their Hydrophobic Thickness. Langmuir, 2018, 34, 9548-9560.	1.6	18
412	Modifiable dementia risk score to study heterogeneity in treatment effect of a dementia prevention trial: a post hoc analysis in the preDIVA trial using the LIBRA index. Alzheimer's Research and Therapy, 2018, 10, 62.	3.0	15
413	Inhaled Xenon Washout as a Biomarker of Alzheimer's Disease. Diagnostics, 2018, 8, 41.	1.3	12
414	Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. Neurobiology of Aging, 2018, 71, 171-178.	1.5	25
415	Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents. Current Alzheimer Research, 2018, 15, 964-974.	0.7	9
416	An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices. Journal of Visualized Experiments, 2018, , .	0.2	10
417	The role of heparan sulfates in protein aggregation and their potential impact on neurodegeneration. FEBS Letters, 2018, 592, 3806-3818.	1.3	63
418	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 9.	3.0	17
419	Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model. Alzheimer's Research and Therapy, 2018, 10, 10.	3.0	23
420	PM20D1 is aÂquantitative trait locus associated with Alzheimer's disease. Nature Medicine, 2018, 24, 598-603.	15.2	73
421	An arabinogalactan from fruits of Lycium barbarum L. inhibits production and aggregation of $A\hat{l}^2$ 42. Carbohydrate Polymers, 2018, 195, 643-651.	5.1	52
422	Step-by-Step Surgical Considerations and Techniques. , 2018, , 107-153.		0
423	Magnetic resonance imaging relaxation time in Alzheimer's disease. Brain Research Bulletin, 2018, 140, 176-189.	1.4	34
424	Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings. JAMA Ophthalmology, 2018, 136, 1242.	1.4	184

#	Article	IF	CITATIONS
425	Ginkgo biloba L. (Ginkgoaceae) Leaf Extract Medications From Different Providers Exhibit Differential Functional Effects on Mouse Frontal Cortex Neuronal Networks. Frontiers in Pharmacology, 2018, 9, 848.	1.6	10
426	A pectin from fruits of Lycium barbarum L. decreases \hat{l}^2 -amyloid peptide production through modulating APP processing. Carbohydrate Polymers, 2018, 201, 65-74.	5.1	32
427	Impact of atrial fibrillation on the rate of mild cognitive impairment in the elderly. Journal of the Neurological Sciences, 2018, 394, 75-77.	0.3	6
428	APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease. Neuroscience Letters, 2018, 685, 109-113.	1.0	20
429	Electroacupuncture Could Influence the Expression of IL- $1\hat{l}^2$ and NLRP3 Inflammasome in Hippocampus of Alzheimerâ \in TM s Disease Animal Model. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-7.	0.5	32
430	Biomarkers of dementia in obstructive sleep apnea. Sleep Medicine Reviews, 2018, 42, 139-148.	3.8	63
431	Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer's disease. Drug Delivery, 2018, 25, 1091-1102.	2.5	147
432	The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 520.	1.4	34
433	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	3.0	87
434	Current perspective for tube feeding in the elderly: from identifying malnutrition to providing of enteral nutrition. Clinical Interventions in Aging, 2018, Volume 13, 1353-1364.	1.3	16
435	Greater tau load and reduced cortical thickness in APOE Îμ4-negative Alzheimer's disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	3.0	56
436	Alzheimer Disease. Clinics in Geriatric Medicine, 2018, 34, 591-601.	1.0	44
437	Paradoxical effects of mutant ubiquitin on $\hat{Al^2}$ plaque formation in an Alzheimer mouse model. Neurobiology of Aging, 2018, 72, 62-71.	1.5	9
438	Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. Cell Metabolism, 2018, 27, 1176-1199.	7.2	721
439	Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer's Disease. , 2018, , 139-161.		1
440	Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomarkers in Medicine, 2018, 12, 799-812.	0.6	59
441	HSV-1-Specific IgG Subclasses Distribution and Serum Neutralizing Activity in Alzheimer's Disease and in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 63, 131-138.	1.2	14
442	Alzheimer's Dementia Drug Discovery. , 2018, , 587-591.		0

#	Article	IF	Citations
443	Sirtuins as Modifiers of Huntington's Disease (HD) Pathology. Progress in Molecular Biology and Translational Science, 2018, 154, 105-145.	0.9	17
444	Locomotor activity, emotionality, sensori-motor gating, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Brain Research Bulletin, 2018, 140, 347-354.	1.4	19
445	Detecting Circulating MicroRNAs as Biomarkers in Alzheimer's Disease. Methods in Molecular Biology, 2018, 1779, 471-484.	0.4	4
446	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. JAMA Neurology, 2018, 75, 1062.	4.5	102
447	Estudios farmacogenéticos en la enfermedad de Alzheimer. NeurologÃa, 2022, 37, 287-303.	0.3	5
448	The Pathway Coexpression Network: Revealing pathway relationships. PLoS Computational Biology, 2018, 14, e1006042.	1.5	41
449	Neural functions of bisecting GlcNAc. Glycoconjugate Journal, 2018, 35, 345-351.	1.4	33
450	The use of cerebrospinal fluid in biomarker studies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 3-20.	1.0	21
451	Diagnosis of Alzheimer's disease with Electroencephalography in a differential framework. PLoS ONE, 2018, 13, e0193607.	1.1	85
452	Non-cell Autonomous Degeneration. , 2018, , 415-440.		1
453	Dietary polyphenols: A novel strategy to modulate microbiota-gut-brain axis. Trends in Food Science and Technology, 2018, 78, 224-233.	7.8	90
454	DHA Selectively Protects SAMP-8-Associated Cognitive Deficits Through Inhibition of JNK. Molecular Neurobiology, 2019, 56, 1618-1627.	1.9	13
455	1H MRS spectroscopy in preclinical autosomal dominant Alzheimer disease. Brain Imaging and Behavior, 2019, 13, 925-932.	1.1	17
456	DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease. Molecular Neurobiology, 2019, 56, 2838-2844.	1.9	25
457	Chaperone-mediated autophagy: Advances from bench to bedside. Neurobiology of Disease, 2019, 122, 41-48.	2.1	28
458	Neuro-nutrients as anti-alzheimer's disease agents: A critical review. Critical Reviews in Food Science and Nutrition, 2019, 59, 2999-3018.	5.4	33
459	A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP β-CTFs, Not Aβ. Neuron, 2019, 104, 256-270.e5.	3.8	185
460	Driving Fitness in Different Forms of Dementia: An Update. Journal of the American Geriatrics Society, 2019, 67, 2186-2192.	1.3	23

#	Article	IF	Citations
461	Primary Care Mental Health in Older People. , 2019, , .		2
462	Possible neuromodulating role of different grape (Vitis vinifera L.) derived polyphenols against Alzheimer's dementia: treatment and mechanisms. Bulletin of the National Research Centre, 2019, 43, .	0.7	17
463	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 68.	3.0	44
464	Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible Biomarkers for Early Diagnosis. Frontiers in Neuroscience, 2019, 13, 925.	1.4	98
465	Ketogenic Diet in Alzheimer's Disease. International Journal of Molecular Sciences, 2019, 20, 3892.	1.8	193
466	cindr, the Drosophila Homolog of the CD2AP Alzheimer's Disease Risk Gene, Is Required for Synaptic Transmission and Proteostasis. Cell Reports, 2019, 28, 1799-1813.e5.	2.9	27
467	Health-Care Delivery for Older People with Dementia in Primary Care. , 2019, , 311-329.		12
468	Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model. Journal of Neuroinflammation, 2019, 16, 166.	3.1	27
469	Increased Incidence of Glaucoma in Sensorineural Hearing Loss: A Population-Based Cohort Study. International Journal of Environmental Research and Public Health, 2019, 16, 2907.	1.2	7
470	Circular RNA circ_0000950 promotes neuron apoptosis, suppresses neurite outgrowth and elevates inflammatory cytokines levels via directly sponging miR-103 in Alzheimer's disease. Cell Cycle, 2019, 18, 2197-2214.	1.3	65
471	Discovery of \hat{l} -sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies. European Journal of Medicinal Chemistry, 2019, 181, 111598.	2.6	32
472	Gamma secretase modulators and BACE inhibitors reduce ${\rm A\hat{l}^2}$ production without altering gene expression in Alzheimer's disease iPSC-derived neurons and mice. Molecular and Cellular Neurosciences, 2019, 100, 103392.	1.0	8
473	Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Research Reviews, 2019, 55, 100944.	5.0	314
474	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2019, , 1251-1275.		1
475	Ghrelin in Alzheimer's disease: Pathologic roles and therapeutic implications. Ageing Research Reviews, 2019, 55, 100945.	5.0	34
476	Pesticide exposure and cognitive function: Results from the Hellenic Longitudinal Investigation of Aging and Diet (HELIAD). Environmental Research, 2019, 177, 108632.	3.7	20
477	N-Glycan Profile of Cerebrospinal Fluids from Alzheimer's Disease Patients Using Liquid Chromatography with Mass Spectrometry. Journal of Proteome Research, 2019, 18, 3770-3779.	1.8	45
478	Electro-acupuncture therapy to improve spatial learning and memory in APPswe/PS1dE9 transgenic mice through the inhibition of the TLR4/MyD88 signaling pathway. Journal of Traditional Chinese Medical Sciences, 2019, 6, 184-192.	0.1	2

#	Article	IF	CITATIONS
479	Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents. ACS Chemical Neuroscience, 2019, 10, 3635-3661.	1.7	28
480	Nutrition and Metabolic Profiles in the Natural History of Dementia: Recent Insights from Systems Biology and Life Course Epidemiology. Current Nutrition Reports, 2019, 8, 256-269.	2.1	9
481	Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. Frontiers in Aging Neuroscience, 2019, 11, 175.	1.7	137
482	<p>Vitamin E and Alzheimer's disease: what do we know so far?</p> . Clinical Interventions in Aging, 2019, Volume 14, 1303-1317.	1.3	74
483	Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands. European Journal of Medicinal Chemistry, 2019, 180, 690-706.	2.6	26
484	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A \hat{l}^2 and Tau Species. Frontiers in Neuroscience, 2019, 13, 659.	1.4	198
485	Choline Supplementation Ameliorates Behavioral Deficits and Alzheimer's Diseaseâ€Like Pathology in Transgenic <i>APP/PS1</i> Mice. Molecular Nutrition and Food Research, 2019, 63, e1801407.	1.5	31
486	Methods to detect mitophagy in neurons during disease. Journal of Neuroscience Methods, 2019, 325, 108351.	1.3	5
487	A simple approach to quantitative determination of soluble amyloid- \hat{l}^2 peptides using a ratiometric fluorescence probe. Biosensors and Bioelectronics, 2019, 142, 111518.	5.3	19
488	Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 72, 1019-1039.	1.2	72
489	Effects of Aging, Cognitive Dysfunction, Brain Atrophy on Hemoglobin Concentrations and Optical Pathlength at Rest in the Prefrontal Cortex: A Time-Resolved Spectroscopy Study. Applied Sciences (Switzerland), 2019, 9, 2209.	1.3	2
490	Impaired hippocampal and thalamic acetylcholine release in P301L tau-transgenic mice. Brain Research Bulletin, 2019, 152, 134-142.	1.4	7
491	Hippocampal neurons in direct contact with astrocytes exposed to amyloid \hat{l}^2 25-35 exhibit reduced excitatory synaptic transmission. IBRO Reports, 2019, 7, 34-41.	0.3	6
492	Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer's disease. Neurolmage, 2019, 201, 116043.	2.1	38
493	Three Decades of Amyloid Beta Synthesis: Challenges and Advances. Frontiers in Chemistry, 2019, 7, 472.	1.8	15
494	Methylene Blue Blocks and Reverses the Inhibitory Effect of Tau on PMCA Function. International Journal of Molecular Sciences, 2019, 20, 3521.	1.8	12
495	A Snapshot on the Current Status of Alzheimer's Disease, Treatment Perspectives, <i>in-Vitro</i> and <i>in-Vivo</i> Research Studies and Future Opportunities. Chemical and Pharmaceutical Bulletin, 2019, 67, 1030-1041.	0.6	8
496	Therapeutic implications of anti-inflammatory natural products in Alzheimer's disease. , 2019, , 241-258.		6

#	ARTICLE	IF	Citations
497	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. Acta Neuropathologica Communications, 2019, 7, 120.	2.4	64
498	Ginsenoside Re Inhibits ROS/ASK-1 Dependent Mitochondrial Apoptosis Pathway and Activation of Nrf2-Antioxidant Response in Beta-Amyloid-Challenged SH-SY5Y Cells. Molecules, 2019, 24, 2687.	1.7	52
499	A Weighted Genetic Risk Score Based on Four APOE-Independent Alzheimer's Disease Risk Loci May Supplement APOE E4 for Better Disease Prediction. Journal of Molecular Neuroscience, 2019, 69, 433-443.	1.1	2
500	Retinal thickness as a potential biomarker in patients with amyloidâ€proven early―and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 463-471.	1.2	25
501	Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. International Journal of Molecular Sciences, 2019, 20, 3148.	1.8	37
502	Lessons Learned From Public Private Partnerships and Consortia: The ADNI Paradigm. Handbook of Behavioral Neuroscience, 2019, , 239-246.	0.7	0
503	Human amyloid- \hat{l}^2 enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization. Alzheimer's Research and Therapy, 2019, 11, 56.	3.0	16
504	Diagnostic Test Accuracy Studies in Dementia. , 2019, , .		18
505	Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?. Journal of Molecular Neuroscience, 2019, 69, 343-350.	1.1	15
506	Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2019, 62, 6645-6664.	2.9	38
507	Emerging links between cell competition and Alzheimer's disease. Journal of Cell Science, 2019, 132, .	1.2	12
508	Metal lons in Alzheimer's Disease: A Key Role or Not?. Accounts of Chemical Research, 2019, 52, 2026-2035.	7.6	216
509	Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. Alzheimer's Research and Therapy, 2019, 11, 60.	3.0	40
510	Intersection of pathological tau and microglia at the synapse. Acta Neuropathologica Communications, 2019, 7, 109.	2.4	119
511	Distinct Brain Regions in Physiological and Pathological Brain Aging. Frontiers in Aging Neuroscience, 2019, 11, 147.	1.7	15
512	Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease. Planta Medica, 2019, 85, 1316-1325.	0.7	25
513	The Impact of Pharmacogenomics in Personalized Medicine. Advances in Biochemical Engineering/Biotechnology, 2019, 171, 369-394.	0.6	13
514	In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 4492-4501.	1.7	37

#	Article	IF	CITATIONS
515	Autocatalytic amplification of Alzheimer-associated A \hat{l}^2 42 peptide aggregation in human cerebrospinal fluid. Communications Biology, 2019, 2, 365.	2.0	46
516	Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline Investigation of the SILCODE Study. Journal of Alzheimer's Disease, 2019, 72, 443-454.	1.2	25
517	Toward a Sequential Strategy for Diagnosing Neurocognitive Disorders: A Consensus from the "Act On Dementia―European Joint Action. Journal of Alzheimer's Disease, 2019, 72, 363-372.	1.2	6
518	Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. Frontiers in Pharmacology, 2019, 10, 1044.	1.6	33
519	Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 169-178.	1.2	28
520	Future horizons in Alzheimer's disease research. Progress in Molecular Biology and Translational Science, 2019, 168, 223-241.	0.9	19
521	Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study. Journal of Clinical Medicine, 2019, 8, 1893.	1.0	31
522	Neural oscillations during cognitive processes in an App knock-in mouse model of Alzheimer's disease pathology. Scientific Reports, 2019, 9, 16363.	1.6	13
523	Intermittent Fasting: a Promising Approach for Preventing Vascular Dementia. Journal of Lipid and Atherosclerosis, 2019, 8, 1.	1.1	10
524	When Does Alzheimer′s Disease Really Start? The Role of Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5536.	1.8	57
525	Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 495-504.	0.7	0
526	Flotillin is a Novel Diagnostic Blood Marker of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 72, 1165-1176.	1.2	21
527	Increased incidence of age-related macular degeneration in sensorineural hearing loss: AÂpopulation-based cohort study. PLoS ONE, 2019, 14, e0222919.	1.1	1
528	A Human Embryonic Stem Cell Model of A \hat{l}^2 -Dependent Chronic Progressive Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 1007.	1.4	6
529	Long Non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation While Stimulates Neurite Outgrowth and Its Correlation With MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 596-612.	0.7	85
530	Hydrogen sulfide signaling in mitochondria and disease. FASEB Journal, 2019, 33, 13098-13125.	0.2	162
531	A Brief Ischemic Postconditioning Protects Against Amyloid-β Peptide Neurotoxicity by Downregulating MLK3-MKK3/6-P38MAPK Signal in Rat Hippocampus. Journal of Alzheimer's Disease, 2019, 71, 671-684.	1.2	7
532	Gangliosides: Treatment Avenues in Neurodegenerative Disease. Frontiers in Neurology, 2019, 10, 859.	1.1	79

#	Article	IF	Citations
533	Knockdown of IncRNA SNHG1 attenuated A \hat{I}^2 25-35-inudced neuronal injury via regulating KREMEN1 by acting as a ceRNA of miR-137 in neuronal cells. Biochemical and Biophysical Research Communications, 2019, 518, 438-444.	1.0	53
534	Cofilin 2 in Serum as a Novel Biomarker for Alzheimer's Disease in Han Chinese. Frontiers in Aging Neuroscience, 2019, 11, 214.	1.7	12
535	Brain Iron Metabolism and CNS Diseases. Advances in Experimental Medicine and Biology, 2019, , .	0.8	11
536	Investigating the Relationship Between Type 2 Diabetes and Dementia Using Electronic Medical Records in the GoDARTS Bioresource. Diabetes Care, 2019, 42, 1973-1980.	4.3	14
537	Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 619-627.	1.2	45
538	Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. Journal of Alzheimer's Disease, 2019, 71, 1037-1048.	1.2	22
539	Directed evolution of a 6-phosphogluconate dehydrogenase for operating an enzymatic fuel cell at lowered anodic pHs. Journal of Electroanalytical Chemistry, 2019, 851, 113444.	1.9	10
540	ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. Alzheimer's Research and Therapy, 2019, 11, 77.	3.0	16
541	Targeting Autophagy for the Treatment of Alzheimer's Disease: Challenges and Opportunities. Frontiers in Molecular Neuroscience, 2019, 12, 203.	1.4	106
542	A positive allosteric modulator of mGluR5 promotes neuroprotective effects in mouse models of Alzheimer's disease. Neuropharmacology, 2019, 160, 107785.	2.0	18
543	Interaction between the progression of Alzheimer's disease and fractal degradation. Neurobiology of Aging, 2019, 83, 21-30.	1.5	22
544	Nutrients in the Prevention of Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-20.	1.9	66
545	A novel kit for early diagnosis of Alzheimer's disease using a fluorescent nanoparticle imaging. Scientific Reports, 2019, 9, 13184.	1.6	17
546	Effects of acupuncture on patients with Alzheimer's disease. Medicine (United States), 2019, 98, e14242.	0.4	9
547	Discordant amyloid- \hat{l}^2 PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	3.0	40
548	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
549	Stress granules and neurodegeneration. Nature Reviews Neuroscience, 2019, 20, 649-666.	4.9	452
550	Accelerated Ovarian Failure as a Unique Model to Study Peri-Menopause Influence on Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 242.	1.7	25

#	Article	IF	CITATIONS
551	Discovery of a series of selective and cell permeable beta-secretase (BACE1) inhibitors by fragment linking with the assistance of STD-NMR. Bioorganic Chemistry, 2019, 92, 103253.	2.0	8
552	Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms. Value in Health, 2019, 22, 1063-1069.	0.1	11
553	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 69-73.	1.2	13
554	Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer's disease. Neuropharmacology, 2019, 148, 332-346.	2.0	70
555	Expression Profiles of Long Noncoding RNAs in Intranasal LPS-Mediated Alzheimer's Disease Model in Mice. BioMed Research International, 2019, 2019, 1-14.	0.9	26
556	Metabolite Profile of Alzheimer's Disease in the Frontal Cortex as Analyzed by HRMAS 1H NMR. Frontiers in Aging Neuroscience, 2018, 10, 424.	1.7	12
557	Novel compound VB-037 inhibits $\hat{Al^2}$ aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease. Neurochemistry International, 2019, 125, 175-186.	1.9	17
558	Soluble TREM1 concentrations are increased and positively correlated with total tau levels in the plasma of patients with Alzheimer's disease. Aging Clinical and Experimental Research, 2019, 31, 1801-1805.	1.4	21
559	Comparison of Intensity- and Polarization-based Contrast in Amyloid-beta Plaques as Observed by Optical Coherence Tomography. Applied Sciences (Switzerland), 2019, 9, 2100.	1.3	4
560	Neuroprotection by glucoseâ€6â€phosphate dehydrogenase and the pentose phosphate pathway. Journal of Cellular Biochemistry, 2019, 120, 14285-14295.	1.2	47
561	<p>Long-term icariin treatment ameliorates cognitive deficits via CD4⁺ T cell-mediated immuno-inflammatory responses in APP/PS1 mice</p> . Clinical Interventions in Aging, 2019, Volume 14, 817-826.	1.3	21
562	Elecsys \hat{A}^{\otimes} Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
563	Perifovea retinal thickness as an ophthalmic biomarker for mild cognitive impairment and early Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 405-414.	1.2	16
564	A rare functional variant of SHARPIN attenuates the inflammatory response and associates with increased risk of late-onset Alzheimer's disease. Molecular Medicine, 2019, 25, 20.	1.9	33
565	Proteomic signatures of neuroinflammation in Alzheimer's disease, multiple sclerosis and ischemic stroke. Expert Review of Proteomics, 2019, 16, 601-611.	1.3	14
566	Enabling biodegradable functional biomaterials for the management of neurological disorders. Advanced Drug Delivery Reviews, 2019, 148, 219-238.	6.6	22
567	Endolysosome and Autolysosome Dysfunction in Alzheimer's Disease: Where Intracellular and Extracellular Meet. CNS Drugs, 2019, 33, 639-648.	2.7	23
568	The costs of dementia subtypes to California Medicare feeâ€forâ€service, 2015. Alzheimer's and Dementia, 2019, 15, 899-906.	0.4	35

#	Article	IF	CITATIONS
569	Amyloid Precursor Protein (APP) and GABAergic Neurotransmission. Cells, 2019, 8, 550.	1.8	24
570	Incidence and characteristics of uncommon dementia subtypes: Results from 10 years of clinical surveillance by the Registry of Dementia of Girona., 2019, 15, 917-926.		7
571	Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches. Expert Opinion on Drug Discovery, 2019, 14, 879-891.	2.5	60
572	Gamma Band Light Stimulation in Human Case Studies: Groundwork for Potential Alzheimer's Disease Treatment. Journal of Alzheimer's Disease, 2019, 70, 171-185.	1.2	43
573	Adiponectin suppresses amyloid- \hat{l}^2 oligomer (A \hat{l}^2 O)-induced inflammatory response of microglia via AdipoR1-AMPK-NF- \hat{l}^2 B signaling pathway. Journal of Neuroinflammation, 2019, 16, 110.	3.1	78
574	A Bird's-Eye View of the Multiple Biochemical Mechanisms that Propel Pathology of Alzheimer's Disease: Recent Advances and Mechanistic Perspectives on How to Halt the Disease Progression Targeting Multiple Pathways. Journal of Alzheimer's Disease, 2019, 69, 631-649.	1.2	14
575	Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2019, 69, 1031-1039.	1.2	38
577	Efficient acylation of gastrodin by <i> Aspergillus oryzae < /i > whole-cells in non-aqueous media. RSC Advances, 2019, 9, 16701-16712.</i>	1.7	7
578	Electroacupuncture Mitigates Hippocampal Cognitive Impairments by Reducing BACE1 Deposition and Activating PKA in APP/PS1 Double Transgenic Mice. Neural Plasticity, 2019, 2019, 1-12.	1.0	19
579	Oxymatrine can attenuate pathological deficits of Alzheimer's disease mice through regulation of neuroinflammation. Journal of Neuroimmunology, 2019, 334, 576978.	1.1	15
580	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
581	Efficient synthesis and preliminary biological evaluations of trifluoromethylated imidazo[1,2- <i>a</i>) pyrimidines and benzimidazo[1,2- <i>a</i>) pyrimidines. New Journal of Chemistry, 2019, 43, 9961-9968.	1.4	13
582	α7 nicotinic ACh receptors are necessary for memory recovery and neuroprotection promoted by attention training in amyloidâ€Î²â€infused mice. British Journal of Pharmacology, 2019, 176, 3193-3205.	2.7	14
583	Gray matter T1â€w/T2â€w ratios are higher in Alzheimer's disease. Human Brain Mapping, 2019, 40, 3900-3909.	1.9	33
584	Protective effect of potassium 2-(l-hydroxypentyl)-benzoate on hippocampal neurons, synapses and dystrophic axons in APP/PS1 mice. Psychopharmacology, 2019, 236, 2761-2771.	1.5	5
585	Tooth Loss and Alzheimer's Disease. Current Oral Health Reports, 2019, 6, 82-88.	0.5	5
586	Generation and validation of algorithms to identify subjects with dementia using administrative data. Neurological Sciences, 2019, 40, 2155-2161.	0.9	1
587	A frontline defense against neurodegenerative diseases:the development of early disease detection methods. Expert Review of Molecular Diagnostics, 2019, 19, 559-563.	1.5	12

#	Article	IF	CITATIONS
588	S.21.03 Amyloid-beta effects on synapses and memory require AMPA-receptor subunit GluA3. European Neuropsychopharmacology, 2019, 29, S26-S27.	0.3	0
589	Gut Microbiota Disorder, Gut Epithelial and Blood–Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways. NeuroMolecular Medicine, 2019, 21, 205-226.	1.8	41
590	Age and sex differences in motivation and spatial working memory in 3xTg-AD mice in the Hebb–Williams maze. Behavioural Brain Research, 2019, 370, 111937.	1.2	16
591	The synthesis and biological evaluation of novel gardenamide A derivatives as multifunctional neuroprotective agents. MedChemComm, 2019, 10, 1180-1186.	3.5	2
592	Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Frontiers in Neuroscience, 2019, 13, 446.	1.4	122
593	The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes. Advances in Experimental Medicine and Biology, 2019, 1128, 45-83.	0.8	39
594	A model of lipid dysregulation and altered nutrient status in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 139-145.	1.8	4
595	Multi-target design strategies for the improved treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 176, 228-247.	2.6	148
596	Tortuous Paths of Insulin Signaling and Mitochondria in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2019, 1128, 161-183.	0.8	5
597	Neuronal Cells Rearrangement During Aging and Neurodegenerative Disease: Metabolism, Oxidative Stress and Organelles Dynamic. Frontiers in Molecular Neuroscience, 2019, 12, 132.	1.4	148
598	Cognitive-enhancing and ameliorative effects of acanthoside B in a scopolamine-induced amnesic mouse model through regulation of oxidative/inflammatory/cholinergic systems and activation of the TrkB/CREB/BDNF pathway. Food and Chemical Toxicology, 2019, 129, 444-457.	1.8	27
599	Dementia in Women. Medical Clinics of North America, 2019, 103, 713-721.	1.1	11
600	A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice. Journal of Biological Chemistry, 2019, 294, 9760-9770.	1.6	32
601	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 383-391.	1.2	53
602	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimer's Research and Therapy, 2019, 11, 45.	3.0	19
603	Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate in Alzheimer's Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2019, 11, 61.	1.7	26
604	Fluorescence Chemicals To Detect Insoluble and Soluble Amyloid- \hat{l}^2 Aggregates. ACS Chemical Neuroscience, 2019, 10, 2647-2657.	1.7	39
605	Epilepsy Associated with Alzheimer's Disease and Other Adult Neurodegenrative Disorders. , 2019, , 783-789.		0

#	Article	IF	CITATIONS
606	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2019, 76, 791.	4.5	436
607	ASAF: altered spontaneous activity fingerprinting in Alzheimer's disease based on multisite fMRI. Science Bulletin, 2019, 64, 998-1010.	4.3	24
608	A Brief History of Simulation Neuroscience. Frontiers in Neuroinformatics, 2019, 13, 32.	1.3	47
609	Using Turmeric Oil as a Solvent Improves the Distribution of Sesaminâ€Sesamolin in the Serum and Brain of Mice. Lipids, 2019, 54, 311-320.	0.7	12
610	Personalized risk for clinical progression in cognitively normal subjectsâ€"the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	3.0	30
611	Rivastigmine and metabolite analogues with putative Alzheimer's disease-modifying properties in a Caenorhabditis elegans model. Communications Chemistry, 2019, 2, .	2.0	25
612	Amyloid \hat{l}^2 -dependent mitochondrial toxicity in mouse microglia requires P2X7 receptor expression and is prevented by nimodipine. Scientific Reports, 2019, 9, 6475.	1.6	45
613	Exposure to fluoride aggravates the impairment in learning and memory and neuropathological lesions in mice carrying the APP/PS1 double-transgenic mutation. Alzheimer's Research and Therapy, 2019, 11, 35.	3.0	25
614	Metformin treatment improves the spatial memory of aged mice in an ⟨i⟩APOE⟨/i⟩ genotype–dependent manner. FASEB Journal, 2019, 33, 7748-7757.	0.2	29
615	Outcomes and clinical implications of intranasal insulin administration to the central nervous system. Experimental Neurology, 2019, 317, 180-190.	2.0	29
616	Beta-blockers and salbutamol limited emotional memory disturbance and damage induced by orchiectomy in the rat hippocampus. Life Sciences, 2019, 224, 128-137.	2.0	11
617	Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. Clinica Chimica Acta, 2019, 494, 79-93.	0.5	30
618	Genetic Overlap Between Alzheimer's Disease and Bipolar Disorder Implicates the MARK2 and VAC14 Genes. Frontiers in Neuroscience, 2019, 13, 220.	1.4	42
619	Ethical and social implications of using predictive modeling for Alzheimer's disease prevention: a systematic literature review protocol. BMJ Open, 2019, 9, e026468.	0.8	3
620	New flavonoid – <i>N</i> , <i>N</i> -dibenzyl(<i>N</i> -methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 712-727.	2.5	27
621	Nanomaterials for Drug Delivery to the Central Nervous System. Nanomaterials, 2019, 9, 371.	1.9	96
622	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. Aging Cell, 2019, 18, e12887.	3.0	28
623	Potential Diagnostic Value of Red Blood Cells î±-Synuclein Heteroaggregates in Alzheimer's Disease. Molecular Neurobiology, 2019, 56, 6451-6459.	1.9	24

#	Article	IF	CITATIONS
624	Evolution of brain atrophy subtypes during aging predicts long-term cognitive decline and future Alzheimer's clinical syndrome. Neurobiology of Aging, 2019, 79, 22-29.	1.5	13
625	High-throughput epitope profiling of antibodies in the plasma of Alzheimer's disease patients using random peptide microarrays. Scientific Reports, 2019, 9, 4587.	1.6	12
626	White matter microstructural abnormalities and default network degeneration are associated with early memory deficit in Alzheimer's disease continuum. Scientific Reports, 2019, 9, 4749.	1.6	31
627	Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease. Scientific Reports, 2019, 9, 5223.	1.6	14
628	A blood-based signature of cerebrospinal fluid Aβ1–42 status. Scientific Reports, 2019, 9, 4163.	1.6	21
629	Nr <scp>CAM</scp> is a marker for substrateâ€selective activation of <scp>ADAM</scp> 10 in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, .	3.3	38
630	Relative risk for Alzheimer disease based on complete family history. Neurology, 2019, 92, e1745-e1753.	1.5	45
631	What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and healthâ€care professionals? A systematic review. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 231-247.	1.2	49
632	Mechanism of amyloid protein aggregation and the role of inhibitors. Pure and Applied Chemistry, 2019, 91, 211-229.	0.9	68
633	Physical Activity from Childhood to Adulthood and Cognitive Performance in Midlife. Medicine and Science in Sports and Exercise, 2019, 51, 882-890.	0.2	20
634	The Hypothalamus in Alzheimer's Disease: A Golgi and Electron and Microscope Study. , 0, , .		0
635	A Synthetic Pro-Drug Peptide Reverses Amyloid-β-Induced Toxicity in the Rat Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 499-512.	1.2	10
636	Oral health care for patients with Alzheimer's disease: An update. Special Care in Dentistry, 2019, 39, 262-273.	0.4	42
637	Protein Chimera-based Ca2+ Rewiring as a Treatment Modality for Neurodegeneration. Current Psychopharmacology, 2019, 8, 27-40.	0.1	0
638	Interval timing is disrupted in female 5xFAD mice: An indication of altered memory processes. Journal of Neuroscience Research, 2019, 97, 817-827.	1.3	16
639	Neurovascular and Cognitive Dysfunction in Hypertension. Circulation Research, 2019, 124, 1025-1044.	2.0	284
640	Astrocyte Heterogeneity: Impact to Brain Aging and Disease. Frontiers in Aging Neuroscience, 2019, 11, 59.	1.7	256
641	Gout and the risk of Alzheimer′s disease: A Mendelian randomization study. International Journal of Rheumatic Diseases, 2019, 22, 1046-1051.	0.9	13

#	Article	IF	CITATIONS
642	Dispiropyrrolidinyl-piperidone embedded indeno [1,2-b] quinoxaline heterocyclic hybrids: Synthesis, cholinesterase inhibitory activity and their molecular docking simulation. Bioorganic and Medicinal Chemistry, 2019, 27, 2621-2628.	1.4	38
643	APOEε4 and the long arm of social inequity: estimated effects of socio-economic status and sex on the timing of dementia onset. Ageing and Society, 2019, 39, 1951-1975.	1.2	6
644	Neuroimaging in Dementias. Seminars in Neurology, 2019, 39, 188-199.	0.5	14
645	Interpretation of Biomarker Data in Diagnosis of Primary Dementias. Seminars in Neurology, 2019, 39, 200-212.	0.5	1
646	Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer's disease model. Nature Neuroscience, 2019, 22, 719-728.	7.1	577
647	The Impact of Chronic Intestinal Inflammation on Brain Disorders: the Microbiota-Gut-Brain Axis. Molecular Neurobiology, 2019, 56, 6941-6951.	1.9	41
648	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of Aging, 2019, 79, 50-58.	1.5	41
649	Jia-Wei-Kai-Xin-San, an Herbal Medicine Formula, Ameliorates Cognitive Deficits via Modulating Metabolism of Beta Amyloid Protein and Neurotrophic Factors in Hippocampus of AÎ ² 1-42 Induced Cognitive Deficit Mice. Frontiers in Pharmacology, 2019, 10, 258.	1.6	9
650	Search for biomarkers of Alzheimerâ€s disease: Recent insights, current challenges and future prospects. Clinical Biochemistry, 2019, 72, 39-51.	0.8	17
651	Pharmacokinetic Characterizations of Ginsenoside Ocotillol, RT ₅ and F ₁₁ , the Promising Agents for Alzheimer's Disease from American Ginseng, in Rats and Beagle Dogs. Pharmacology, 2019, 104, 7-20.	0.9	10
652	PTCD1 Is Required for Mitochondrial Oxidative-Phosphorylation: Possible Genetic Association with Alzheimer's Disease. Journal of Neuroscience, 2019, 39, 4636-4656.	1.7	26
654	Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy. Molecules, 2019, 24, 1264.	1.7	6
655	Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe/PS1dE9 mice. Neuropharmacology, 2019, 150, 175-183.	2.0	30
656	Iron treatment inhibits $\hat{A^2}42$ deposition inâvivo and reduces $\hat{A^2}42/\hat{A^2}40$ ratio. Biochemical and Biophysical Research Communications, 2019, 512, 653-658.	1.0	6
657	Medical foods in Alzheimer's disease. Food Science and Human Wellness, 2019, 8, 1-7.	2.2	19
658	Natural Killer Cells and Alzheimer's Disease. , 2019, , 1-17.		0
659	Innovative Therapy for Alzheimer's Disease-With Focus on Biodelivery of NGF. Frontiers in Neuroscience, 2019, 13, 38.	1.4	103
660	Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 2019, 33, 436-448.	2.0	33

#	Article	IF	CITATIONS
661	Formulation Strategies to Improve Nose-to-Brain Delivery of Donepezil. Pharmaceutics, 2019, 11, 64.	2.0	55
662	Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects against $\hat{Al^2}$ toxicity via attenuating $\hat{Al^2}$ -induced endoplasmic reticulum stress. Journal of Neuroinflammation, 2019, 16, 35.	3.1	48
663	Atrial Fibrillation and Risk of Dementia: Epidemiology, Mechanisms, and Effect of Anticoagulation. Frontiers in Neuroscience, 2019, 13, 18.	1.4	53
664	A walk through tau therapeutic strategies. Acta Neuropathologica Communications, 2019, 7, 22.	2.4	211
665	Intrinsic origin of amyloid aggregation: Behavior of histidine (ÎμÎμÎμ) and (ÎÎÎ) tautomer homodimers of Aβ (1–40). Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 795-801.	1.1	27
666	Repeated cold exposures protect a mouse model of Alzheimer's disease against cold-induced tau phosphorylation. Molecular Metabolism, 2019, 22, 110-120.	3.0	24
667	Circadian rhythms of cardiovascular autonomic function: Physiology and clinical implications in neurodegenerative diseases. Autonomic Neuroscience: Basic and Clinical, 2019, 217, 91-101.	1.4	29
668	Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology, 2019, , .	0.8	6
669	Lymphocytes, Platelets, Erythrocytes, and Exosomes as Possible Biomarkers for Alzheimer's Disease Clinical Diagnosis. Advances in Experimental Medicine and Biology, 2019, 1118, 71-82.	0.8	18
670	Stable isotope labeling derivatization coupled with magnetic dispersive solid phase extraction for the determination of hydroxyl-containing cholesterol and metabolites by in vivo microdialysis and ultra-high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2019, 1594, 23-33.	1.8	22
671	Memantine Differentially Regulates Tau Phosphorylation Induced by Chronic Restraint Stress of Varying Duration in Mice. Neural Plasticity, 2019, 2019, 1-18.	1.0	11
672	Rapamycin regulates cholesterol biosynthesis and cytoplasmic ribosomal proteins in hippocampus and temporal lobe of APP/PS1 mouse. Journal of the Neurological Sciences, 2019, 399, 125-139.	0.3	13
673	Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity. Scientific Reports, 2019, 9, 2254.	1.6	26
674	The Role of Biomarkers in Alzheimer's Disease Drug Development. Advances in Experimental Medicine and Biology, 2019, 1118, 29-61.	0.8	84
675	Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease. International Journal of Molecular Sciences, 2019, 20, 719.	1.8	121
676	Frontiers in Probing Alzheimer's Disease Biomarkers with Fluorescent Small Molecules. ACS Central Science, 2019, 5, 209-217.	5.3	72
677	Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study. Medical Hypotheses, 2019, 125, 94-99.	0.8	25
678	Expression of telomere repeat binding factor 1 and TRF2 in Alzheimer's disease and correlation with clinical parameters. Neurological Research, 2019, 41, 504-509.	0.6	8

#	Article	IF	CITATIONS
679	Recovery Intervention to Promote Social Connectedness through Social Recreational Programs for Persons with Dementia: A Critical Analysis. , 2019, , .		2
680	An Examination of Factors Influencing Equitable Access to Dementia Care and Support Programs among Migrants and Refugees Living with Dementia: A Literature Review., 2019,,.		2
681	Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. BMJ Open, 2019, 9, e028188.	0.8	62
682	Complexity Analysis of EEG Signal in Patients with Cognitive Impairment Using the Hjorth Descriptor. , 2019, , .		2
683	Papel de la microbiota intestinal en el desarrollo de diferentes enfermedades neurológicas. NeurologÃa, 2022, 37, 492-498.	0.3	21
684	Inhibition of acetylcholinesterase activity and βâ€'amyloid oligomer formation by 6â€'bromotryptamine�A, a multiâ€'target antiâ€'Alzheimer's molecule. Oncology Letters, 2020, 19, 1593-1601.	0.8	11
685	Insoluble $\hat{Al^2}$ overexpression in an <i>App</i> knock-in mouse model alters microstructure and gamma oscillations in the prefrontal cortex, and impacts on anxiety-related behaviours. DMM Disease Models and Mechanisms, 2019, 12, .	1,2	25
686	Cre-inducible Adeno Associated Virus-mediated Expression of P301L Mutant Tau Causes Motor Deficits and Neuronal Degeneration in the Substantia Nigra. Neuroscience, 2019, 422, 65-74.	1.1	6
687	Systemic Immune Dyshomeostasis Model and Pathways in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 290.	1.7	14
688	Resting State BOLD Variability Is Linked to White Matter Vascular Burden in Healthy Aging but Not in Older Adults With Subjective Cognitive Decline. Frontiers in Human Neuroscience, 2019, 13, 429.	1.0	14
690	CZYH Alleviates $\langle i \rangle \hat{l}^2 \langle j \rangle$ -Amyloid-Induced Cognitive Impairment and Inflammation Response via Modulation of JNK and NF- $\langle i \rangle \hat{l}^2 \langle j \rangle$ B Pathway in Rats. Behavioural Neurology, 2019, 2019, 1-10.	1.1	3
691	Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 72, 981-1017.	1.2	115
692	Exploring the Role of P2X Receptors in Alzheimer's Disease. Frontiers in Pharmacology, 2019, 10, 1330.	1.6	23
693	Nanomaterials towards Biosensing of Alzheimer's Disease Biomarkers. Nanomaterials, 2019, 9, 1663.	1.9	54
694	Exosomal Transport and Progression of Neurodegeneration in Amyotrophic Lateral Sclerosis. Neurochemical Journal, 2019, 13, 229-239.	0.2	2
695	Long Noncoding RNA NEAT1 Aggravates \hat{A}^2 -Induced Neuronal Damage by Targeting miR-107 in Alzheimer's Disease. Yonsei Medical Journal, 2019, 60, 640.	0.9	81
696	Focused ultrasound-induced blood-brain barrier opening improves adult hippocampal neurogenesis and cognitive function in a cholinergic degeneration dementia rat model. Alzheimer's Research and Therapy, 2019, 11, 110.	3.0	58
697	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123

#	Article	IF	Citations
698	EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 102.	3.0	17
699	Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines, 2019, 7, 97.	1.4	161
700	Upregulation of the Sarco-Endoplasmic Reticulum Calcium ATPase 1 Truncated Isoform Plays a Pathogenic Role in Alzheimer's Disease. Cells, 2019, 8, 1539.	1.8	9
701	A Review on MS-Based Blood Biomarkers for Alzheimer's Disease. Neurology and Therapy, 2019, 8, 113-127.	1.4	35
702	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	7.1	242
703	Methylphenidate-Induced Raynaud Phenomenon Developed After Increasing Methylphenidate in an Adult With Attention-Deficit Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2019, 39, 178-179.	0.7	5
704	TOMM40 polymorphism is associated with resting-state functional MRI results in patients with Alzheimer's disease. NeuroReport, 2019, 30, 1068-1073.	0.6	2
705	Dose-Dependent Efficacy of Tandospirone for an Oldest-Old Patient With Behavioral and Psychological Symptoms of Dementia. Journal of Clinical Psychopharmacology, 2019, 39, 176-178.	0.7	2
706	Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ, The, 2019, 367, l6217.	3.0	162
707	Tau PET Distributional Pattern in AD Patients with Visuospatial Dysfunction. Current Alzheimer Research, 2019, 16, 1055-1062.	0.7	0
708	Alzheimer Disease-associated Cortical Atrophy Does not Differ Between Chinese and Whites. Alzheimer Disease and Associated Disorders, 2019, 33, 186-193.	0.6	7
709	Effects of Acupuncture on Alzheimer's Disease: Evidence from Neuroimaging Studies. Chinese Journal of Integrative Medicine, 2019, 25, 631-640.	0.7	33
710	Interactions of Selective Serotonin Reuptake Inhibitors with \hat{l}^2 -Amyloid. ACS Chemical Neuroscience, 2019, 10, 226-234.	1.7	16
711	Neural tissue microphysiological systems in the era of patient-derived pluripotent stem cells. , 2019, , 249-296.		3
712	Beta-propeller protein-associated neurodegeneration (BPAN) as a genetically simple model of multifaceted neuropathology resulting from defects in autophagy. Reviews in the Neurosciences, 2019, 30, 261-277.	1.4	18
713	Motor deficits in 16-month-old male and female 3xTg-AD mice. Behavioural Brain Research, 2019, 356, 305-313.	1.2	32
714	Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease. Proteomics - Clinical Applications, 2019, 13, e1800105.	0.8	82
715	Glutaminyl cyclase inhibitor contributes to the regulation of HSP70, HSP90, actin, and ribosome on gene and protein levels in vitro. Journal of Cellular Biochemistry, 2019, 120, 9460-9471.	1.2	3

#	Article	IF	Citations
716	Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases. Expert Opinion on Therapeutic Targets, 2019, 23, 117-126.	1.5	32
717	Low Phytanic Acid-Concentrated DHA Prevents Cognitive Deficit and Regulates Alzheimer Disease Mediators in an ApoEâ^'/â^' Mice Experimental Model. Nutrients, 2019, 11, 11.	1.7	32
718	Meditation on the Soles of the Feet Practice Provides Some Control of Aggression for Individuals with Alzheimer's Disease. Mindfulness, 2019, 10, 1232-1242.	1.6	11
719	Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis. International Psychogeriatrics, 2019, 31, 1627-1633.	0.6	10
720	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17.	1.0	82
721	Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.4	232
722	MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation. Brain, 2019, 142, 176-192.	3.7	44
723	Pathological Changes in Alzheimer's Disease Analyzed Using Induced Pluripotent Stem Cell-Derived Human Microglia-Like Cells. Journal of Alzheimer's Disease, 2019, 67, 357-368.	1.2	28
724	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 1-9.	1.2	14
725	Pseudoginsenoside-F11 alleviates cognitive deficits and Alzheimer's disease-type pathologies in SAMP8 mice. Pharmacological Research, 2019, 139, 512-523.	3.1	37
726	A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using ¹⁸ F-FDG PET of the Brain. Radiology, 2019, 290, 456-464.	3.6	413
727	Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease–specific regions. Neurobiology of Aging, 2019, 75, 109-116.	1.5	22
728	Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 922-930.	1.7	6
729	Impairments of attention in Alzheimer's disease. Current Opinion in Psychology, 2019, 29, 41-48.	2.5	23
730	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	4.5	66
731	Preventing Alzheimer's Disease: Why Not Targeting the Muscle First?. Journal of the American Medical Directors Association, 2019, 20, 101-102.	1.2	2
732	Amyloid-ß promotes neurotoxicity by Cdk5-induced p53 stabilization. Neuropharmacology, 2019, 146, 19-27.	2.0	40
733	Purinergic signaling in Alzheimer's disease. Brain Research Bulletin, 2019, 151, 25-37.	1.4	20

#	Article	IF	CITATIONS
734	Mitochondria as central regulators of neural stem cell fate and cognitive function. Nature Reviews Neuroscience, 2019, 20, 34-48.	4.9	246
735	Mutation screening in Chinese patients with familial Alzheimer's disease by whole-exome sequencing. Neurobiology of Aging, 2019, 76, 215.e15-215.e21.	1.5	30
736	Neurotoxicity of air pollution: Role of neuroinflammation. Advances in Neurotoxicology, 2019, , 195-221.	0.7	1
737	Analysis of the interaction of para-sulfonatocalix[8]arene with free amino acids and a six residue segment of β-amyloid peptide as a potential treatment for Alzheimer's disease. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2019, 93, 265-273.	0.9	4
738	Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer's disease. Sleep, 2019, 42, .	0.6	42
739	Thiazolidinedione as an alternative to facilitate oral administration in geriatric patients with Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2019, 129, 173-180.	1.9	10
740	Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. Neurobiology of Aging, 2019, 76, 125-132.	1.5	121
741	The C677T polymorphism of the methylenetetrahydrofolate reductase gene and susceptibility to late-onset Alzheimer's disease. Open Medicine (Poland), 2019, 14, 32-40.	0.6	5
742	<i>In vivo</i> molecular imaging of neuroinflammation in Alzheimer's disease. Journal of Neurochemistry, 2019, 149, 438-451.	2.1	70
743	Blood-based biomarkers for Alzheimer's diseaseâ€"An update. Journal of Neuroscience Methods, 2019, 319, 2-6.	1.3	87
744	Current Perspectives and Mechanisms of Relationship between Intestinal Microbiota Dysfunction and Dementia: A Review. Dementia and Geriatric Cognitive Disorders Extra, 2019, 8, 360-381.	0.6	11
745	A Numerical Study of Sensitivity Coefficients for a Model of Amyloid Precursor Protein and Tubulin-Associated Unit Protein Transport and Agglomeration in Neurons at the Onset of Alzheimer's Disease. Journal of Biomechanical Engineering, 2019, 141, .	0.6	5
746	Insulin growth factor 2 (IGF2) as an emergent target in psychiatric and neurological disorders. Review. Neuroscience Research, 2019, 149, 1-13.	1.0	38
747	In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies. Neurobiology of Aging, 2019, 74, 171-181.	1.5	21
748	Hippocampal transcriptome profiling combined with protein-protein interaction analysis elucidates Alzheimer's disease pathways and genes. Neurobiology of Aging, 2019, 74, 225-233.	1.5	30
749	Detecting perfusion deficit in Alzheimer's disease and mild cognitive impairment patients by restingâ€state fMRI. Journal of Magnetic Resonance Imaging, 2019, 49, 1099-1104.	1.9	16
750	Nanotherapeutic strategies for the treatment of neurodegenerative diseases. , 2019, , 321-356.		14
751	Nature and implications of sex differences in AD pathology. Nature Reviews Neurology, 2019, 15, 6-8.	4.9	17

#	Article	IF	Citations
752	Curcumin in tissue engineering: A traditional remedy for modern medicine. BioFactors, 2019, 45, 135-151.	2.6	53
753	Mouse models of Alzheimer's disease cause rarefaction of pial collaterals and increased severity of ischemic stroke. Angiogenesis, 2019, 22, 263-279.	3.7	48
754	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. Acta Neuropathologica, 2019, 137, 279-296.	3.9	128
755	Incidence of prescription vitamin B12 use in relation to diagnosis of Alzheimer's disease among community-dwelling persons. Zeitschrift Fur Gesundheitswissenschaften, 2019, 27, 775-779.	0.8	0
756	Unsupervised excitation: GABAergic dysfunctions in Alzheimer's disease. Brain Research, 2019, 1707, 216-226.	1.1	76
757	GRK5 influences the phosphorylation of tau via GSK3 \hat{l}^2 and contributes to Alzheimer's disease. Journal of Cellular Physiology, 2019, 234, 10411-10420.	2.0	16
758	Sex differences in the timing behavior performance of $3xTg$ -AD and wild-type mice in the peak interval procedure. Behavioural Brain Research, 2019, 360, 235-243.	1.2	21
7 59	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. ACS Chemical Neuroscience, 2019, 10, 279-294.	1.7	18
760	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 458-467.	1.1	30
761	Factors Associated with the Quality of Life of People with Dementia and with Quality of Life-Improving Interventions: Scoping Review. Dementia, 2019, 18, 1507-1537.	1.0	19
762	The Nun Study and Alzheimer's disease: Quality of vocation as a potential protective factor?. Dementia, 2019, 18, 1651-1662.	1.0	5
763	Rapid discovery of quality-markers from Kaixin San using chinmedomics analysis approach. Phytomedicine, 2019, 54, 371-381.	2.3	43
764	Ageâ€related deterioration of motor function in male and female 5xFAD mice from 3 to 16 months of age. Genes, Brain and Behavior, 2020, 19, e12538.	1.1	58
765	Caregiver identity theory and predictors of burden and depression: Findings from the REACH II study. Aging and Mental Health, 2020, 24, 212-220.	1.5	15
766	Whisker exploration behaviours in the 5xFAD mouse are affected by sex and retinal degeneration. Genes, Brain and Behavior, 2020, 19, e12532.	1.1	14
767	MicroRNAs and nervous system diseases: network insights and computational challenges. Briefings in Bioinformatics, 2020, 21, 863-875.	3.2	13
768	Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy, 2020, 16, 52-69.	4.3	193
769	Comparative analysis of methods of volume adjustment in hippocampal volumetry for the diagnosis of Alzheimer disease. Journal of Neuroradiology, 2020, 47, 161-165.	0.6	6

#	ARTICLE	IF	CITATIONS
770	Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183064.	1.4	38
771	What is strain in neurodegenerative diseases?. Cellular and Molecular Life Sciences, 2020, 77, 665-676.	2.4	12
772	Competitive electrochemical immunosensor for the detection of unfolded p53 protein in blood as biomarker for Alzheimer's disease. Analytica Chimica Acta, 2020, 1093, 28-34.	2.6	40
773	Test–retest repeatability of [¹⁸ F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 2464-2474.	2.4	23
774	The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review. CNS and Neurological Disorders - Drug Targets, 2020, 18, 657-667.	0.8	11
775	Pattern Recognition to Identify Stroke in the Cognitive Profile: Secondary Analyses of a Prospective Cohort Study. Cerebrovascular Diseases Extra, 2020, 9, 114-122.	0.5	5
776	Characterizing Alzheimer's Disease With Image and Genetic Biomarkers Using Supervised Topic Models. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 1180-1187.	3.9	8
777	Dementia in China: epidemiology, clinical management, and research advances. Lancet Neurology, The, 2020, 19, 81-92.	4.9	412
778	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. Neurobiology of Disease, 2020, 134, 104645.	2.1	16
779	Outer membrane vesicles enhance tau phosphorylation and contribute to cognitive impairment. Journal of Cellular Physiology, 2020, 235, 4843-4855.	2.0	54
781	Insights into the Authentic Active Ingredients and Action Sites of Oral Exogenous Glutathione in the Treatment of Ischemic Brain Injury Based on Pharmacokinetic-Pharmacodynamic Studies. Drug Metabolism and Disposition, 2020, 48, 52-62.	1.7	6
782	Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E750-E764.	1.8	36
783	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. Health Expectations, 2020, 23, 52-62.	1.1	20
784	Polyphenols in the management of brain disorders: Modulation of the microbiota-gut-brain axis. Advances in Food and Nutrition Research, 2020, 91, 1-27.	1.5	32
785	Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer's disease. Science of the Total Environment, 2020, 700, 134836.	3.9	67
786	Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease. Talanta, 2020, 211, 120700.	2.9	36
787	Recent Progress in Autocatalytic Ceria Nanoparticles-Based Translational Research on Brain Diseases. ACS Applied Nano Materials, 2020, 3, 1043-1062.	2.4	27
788	Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations. RSC Advances, 2020, 10, 215-227.	1.7	50

#	Article	IF	CITATIONS
789	Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression. Neuron, 2020, 105, 975-991.e7.	3.8	287
790	Single-layer exfoliated reduced graphene oxide-antibody Tau sensor for detection in human serum. Sensors and Actuators B: Chemical, 2020, 308, 127692.	4.0	25
791	Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer's disease. Neuroscience Letters, 2020, 717, 134699.	1.0	8
792	Endosomal dysfunction impacts extracellular vesicle release: Central role in $\hat{A^2}$ pathology. Ageing Research Reviews, 2020, 58, 101006.	5.0	29
793	Modeling Sporadic Alzheimer's Disease by Efficient Direct Reprogramming of the Elderly Derived Disease Dermal Fibroblasts into Neural Stem Cells. Journal of Alzheimer's Disease, 2020, 73, 919-933.	1.2	7
794	Phosphorylation Signaling in APP Processing in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 209.	1.8	51
795	Environmental lead exposure aggravates the progression of Alzheimer's disease in mice by targeting on blood brain barrier. Toxicology Letters, 2020, 319, 138-147.	0.4	33
796	Purpose in life is a robust protective factor of reported cognitive decline among late middle-aged adults: The Emory Healthy Aging Study. Journal of Affective Disorders, 2020, 263, 310-317.	2.0	25
797	Alzheimer's Disease and Parkinson's Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals. Journal of the American College of Nutrition, 2020, 39, 16-27.	1.1	85
798	Self-assembly hollow manganese Prussian white nanocapsules attenuate Tau-related neuropathology and cognitive decline. Biomaterials, 2020, 231, 119678.	5.7	37
799	Symbol Comprehension in Patients With Alzheimer Disease Dementia, Mild Cognitive Impairment, and Major Depressive Disorder. Alzheimer Disease and Associated Disorders, 2020, 34, 85-93.	0.6	7
800	Design and synthesis of benzodiazepine-1,2,3-triazole hybrid derivatives as selective butyrylcholinesterase inhibitors. Molecular Diversity, 2020, 24, 997-1013.	2.1	17
801	Targeting the uncertainty of predictions at patient-level using an ensemble of classifiers coupled with calibration methods, Venn-ABERS, and Conformal Predictors: A case study in AD. Journal of Biomedical Informatics, 2020, 101, 103350.	2.5	11
802	Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease. Neuroscience Letters, 2020, 715, 134658.	1.0	18
803	Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors. European Journal of Medicinal Chemistry, 2020, 187, 111961.	2.6	21
804	Ethnicity-specific and overlapping alterations of brain hydroxymethylome in Alzheimer's disease. Human Molecular Genetics, 2020, 29, 149-158.	1.4	11
805	Amyloid, APP, and Electrical Activity of the Brain. Neuroscientist, 2020, 26, 231-251.	2.6	36
806	Repetitive transcranial magnetic stimulation for cognitive impairment in Alzheimer's disease: a meta-analysis of randomized controlled trials. Journal of Neurology, 2020, 267, 791-801.	1.8	41

#	Article	IF	CITATIONS
807	Pâ€glycoprotein: a role in the export of amyloidâ€Î² in Alzheimer's disease?. FEBS Journal, 2020, 287, 612-625.	2.2	62
809	Microvascular pericytes in brain-associated vascular disease. Biomedicine and Pharmacotherapy, 2020, 121, 109633.	2.5	25
810	Modifying the progression of Alzheimer's and Parkinson's disease with deep brain stimulation. Neuropharmacology, 2020, 171, 107860.	2.0	45
811	N-myc downstream-regulated gene 2 deficiency aggravates memory impairment in Alzheimer's disease. Behavioural Brain Research, 2020, 379, 112384.	1.2	10
812	miR-16-5p and miR-19b-3p prevent amyloid \hat{l}^2 -induced injury by targeting BACE1 in SH-SY5Y cells. NeuroReport, 2020, 31, 205-212.	0.6	28
813	The Combined Therapy of Berberine Treatment with IncRNA BACE1-AS Depletion Attenuates Aβ25–35 Induced Neuronal Injury Through Regulating the Expression of miR-132-3p in Neuronal Cells. Neurochemical Research, 2020, 45, 741-751.	1.6	34
814	Interrelationship between Alzheimer's disease and cardiac dysfunction: the brain–heart continuum?. Acta Biochimica Et Biophysica Sinica, 2020, 52, 1-8.	0.9	38
815	Use of multilayer network modularity and spatiotemporal network switching rate to explore changes of functional brain networks in Alzheimer's disease. , 2020, 2020, 1104-1107.		1
816	Integrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimer's disease. Science Advances, 2020, 6, .	4.7	56
817	Metabolic Defects Caused by High-Fat Diet Modify Disease Risk through Inflammatory and Amyloidogenic Pathways in a Mouse Model of Alzheimer's Disease. Nutrients, 2020, 12, 2977.	1.7	18
818	Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcome in Alzheimer's disease. Drug Discovery Today, 2020, 25, 2110-2129.	3.2	12
819	Nutrition and exercise interventions could ameliorate age-related cognitive decline: a meta-analysis of randomized controlled trials. Aging Clinical and Experimental Research, 2020, 33, 1799-1809.	1.4	11
820	Metabolic Dysregulation Contributes to the Progression of Alzheimer's Disease. Frontiers in Neuroscience, 2020, 14, 530219.	1.4	94
821	Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview. NanoImpact, 2020, 20, 100251.	2.4	78
822	Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease. Neurochemistry International, 2020, 141, 104881.	1.9	17
823	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer's Disease is Affected by Aβ-ImmunoTherapy and Cognitive Stimulation. Pharmaceutics, 2020, 12, 944.	2.0	17
824	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Communications, 2020, 2, fcaa102.	1.5	11
825	Histone deacetylase-6 modulates amyloid beta-induced cognitive dysfunction rats by regulating PTK2B NeuroReport, 2020, 31, 754-761.	0.6	4

#	Article	IF	CITATIONS
826	Detecting Oxidative Stress Biomarkers in Neurodegenerative Disease Models and Patients. Methods and Protocols, 2020, 3, 66.	0.9	19
827	Nanostructured Lipid Carriers Made of \hat{l} ©-3 Polyunsaturated Fatty Acids: In Vitro Evaluation of Emerging Nanocarriers to Treat Neurodegenerative Diseases. Pharmaceutics, 2020, 12, 928.	2.0	8
828	The involvement of NLRP3 inflammasome in the treatment of Alzheimer's disease. Ageing Research Reviews, 2020, 64, 101192.	5.0	107
829	Blood-Brain Barrier Permeable Chitosan Oligosaccharides Interfere with Î ² -Amyloid Aggregation and Alleviate Î ² -Amyloid Protein Mediated Neurotoxicity and Neuroinflammation in a Dose- and Degree of Polymerization-Dependent Manner. Marine Drugs, 2020, 18, 488.	2.2	25
830	Relationship between Wine Consumption, Diet and Microbiome Modulation in Alzheimer's Disease. Nutrients, 2020, 12, 3082.	1.7	27
831	Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12104.	1.2	27
832	Nitrogenâ€Doped Carbonized Polymer Dots: A Potent Scavenger and Detector Targeting Alzheimer's βâ€Amyloid Plaques. Small, 2020, 16, e2002804.	5.2	46
833	The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. International Journal of Pharmaceutics, 2020, 589, 119832.	2.6	27
834	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 88.	3.0	20
835	Environmental and Cognitive Enrichment in Childhood as Protective Factors in the Adult and Aging Brain. Frontiers in Psychology, 2020, 11, 1814.	1.1	16
836	Rhodamine-Based Metal Chelator: A Potent Inhibitor of Metal-Catalyzed Amyloid Toxicity. ACS Omega, 2020, 5, 18958-18967.	1.6	14
837	Stroke and Alzheimer's Disease: A Mendelian Randomization Study. Frontiers in Genetics, 2020, 11, 581.	1.1	9
838	Shexiang Baoxin Pill, a Traditional Chinese Herbal Formula, Rescues the Cognitive Impairments in APP/PS1 Transgenic Mice. Frontiers in Pharmacology, 2020, 11, 1045.	1.6	7
839	The Role of Oxidative Stress in Parkinson's Disease. Antioxidants, 2020, 9, 597.	2.2	130
840	Treatment of Neuroblastoma Cells with Inhibitors of Protein Disulfide Isomerase Upregulates NQO1 Activity. Chemical Research in Toxicology, 2020, 33, 2099-2107.	1.7	5
841	Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908.	2.9	199
842	Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacological Research, 2020, 160, 105078.	3.1	54
843	The extracellular vesicle of gut microbial Paenalcaligenes hominis is a risk factor for vagus nerve-mediated cognitive impairment. Microbiome, 2020, 8, 107.	4.9	91

#	Article	IF	CITATIONS
844	Bradykinesia in Alzheimer's disease and its neurophysiological substrates. Clinical Neurophysiology, 2020, 131, 850-858.	0.7	36
845	Connectome Signatures of Hyperexcitation in Cognitively Intact Middle-Aged Female APOE-ε4 Carriers. Cerebral Cortex, 2020, 30, 6350-6362.	1.6	11
846	Protective Effect and Mechanism of Fruit Extract of $\langle i \rangle$ Aegle marmelos $\langle i \rangle$ Against Amyloid- \hat{l}^2 Toxicity in a Transgenic $\langle i \rangle$ Caenorhabditis elegans $\langle i \rangle$. Natural Product Communications, 2020, 15, 1934578X2093351.	0.2	0
847	Advances in Tissue Engineering and Innovative Fabrication Techniques for 3-D-Structures: Translational Applications in Neurodegenerative Diseases. Cells, 2020, 9, 1636.	1.8	35
848	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. Journal of Personalized Medicine, 2020, 10, 221.	1.1	20
849	Behavioral, neuromorphological, and neurobiochemical effects induced by omega-3 fatty acids following basal forebrain cholinergic depletion in aged mice. Alzheimer's Research and Therapy, 2020, 12, 150.	3.0	16
850	Association of Genes Involved in the Metabolic Pathways of Amyloid-β and Tau Proteins With Sporadic Late-Onset Alzheimer's Disease in the Southern Han Chinese Population. Frontiers in Aging Neuroscience, 2020, 12, 584801.	1.7	4
851	Critical Review of the Alzheimer's Disease Non-Transgenic Models: Can They Contribute to Disease Treatment?. Journal of Alzheimer's Disease, 2021, 82, S227-S250.	1.2	6
852	Cerebrospinal Fluid and Serum d-Serine Levels in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 3840.	1.0	11
853	A Novel Nanosystem Realizing Curcumin Delivery Based on Fe3O4@Carbon Dots Nanocomposite for Alzheimer's Disease Therapy. Frontiers in Bioengineering and Biotechnology, 2020, 8, 614906.	2.0	34
854	Optical spectroscopy and microscopy techniques for assessment of neurological diseases. Applied Spectroscopy Reviews, 2020, , 1-40.	3.4	2
855	Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders. Journal of Medicinal Chemistry, 2020, 63, 14017-14044.	2.9	10
856	Exploring the Use of Dimethyl Fumarate as Microglia Modulator for Neurodegenerative Diseases Treatment. Antioxidants, 2020, 9, 700.	2.2	30
857	IncRNA SNHG1 Knockdown Alleviates Amyloid-β-Induced Neuronal Injury by Regulating ZNF217 via Sponging miR-361-3p in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 85-98.	1.2	33
858	Tau induces PSD95–neuronal NOS uncoupling and neurovascular dysfunction independent of neurodegeneration. Nature Neuroscience, 2020, 23, 1079-1089.	7.1	78
859	Engulfment of Toxic Amyloid \hat{l}^2 -protein in Neurons and Astrocytes Mediated by MEGF10. Neuroscience, 2020, 443, 1-7.	1.1	14
860	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 63.	1.1	13
861	Molecular basis for the inhibitory effects of 5-hydroxycyclopenicillone on the conformational transition of AÎ ² 40 monomer. Journal of Biomolecular Structure and Dynamics, 2020, 39, 1-12.	2.0	2

#	ARTICLE	IF	CITATIONS
862	Reduction of advanced tau-mediated memory deficits by the MAP kinase p38 \hat{l}^3 . Acta Neuropathologica, 2020, 140, 279-294.	3.9	24
863	MicroRNA-Based Multitarget Approach for Alzheimer's Disease: Discovery of the First-In-Class Dual Inhibitor of Acetylcholinesterase and MicroRNA-15b Biogenesis. Journal of Medicinal Chemistry, 2020, 63, 9695-9704.	2.9	17
864	Predicting Alzheimer's disease progression using deep recurrent neural networks. NeuroImage, 2020, 222, 117203.	2.1	76
865	Computational Modeling of Catecholamines Dysfunction in Alzheimer's Disease at Pre-Plaque Stage. Journal of Alzheimer's Disease, 2020, 77, 275-290.	1.2	15
866	Sequestering Ability of a Synthetic Chelating Agent towards Copper(II) and Iron(III): A Detailed Theoretical and Experimental Analysis. Chemistry - an Asian Journal, 2020, 15, 3266-3274.	1.7	3
867	Guanosine Neuroprotection of Presynaptic Mitochondrial Calcium Homeostasis in a Mouse Study with Amyloid- \hat{l}^2 Oligomers. Molecular Neurobiology, 2020, 57, 4790-4809.	1.9	14
868	Indoloquinoxaline derivatives as promising multi-functional anti-Alzheimer agents. Journal of Biomolecular Structure and Dynamics, 2022, 40, 2498-2515.	2.0	10
869	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140537.	1.1	19
870	Beyond Alzheimer's disease: Can bilingualism be a more generalized protective factor in neurodegeneration?. Neuropsychologia, 2020, 147, 107593.	0.7	17
871	Isolation and Sequencing of Cu-, Fe-, and Zn-Binding Whey Peptides for Potential Neuroprotective Applications as Multitargeted Compounds. Journal of Agricultural and Food Chemistry, 2020, 68, 12433-12443.	2.4	6
872	Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer's Disease. Sensors, 2020, 20, 4748.	2.1	36
873	DL0410 ameliorates cognitive disorder in SAMP8 mice by promoting mitochondrial dynamics and the NMDAR-CREB-BDNF pathway. Acta Pharmacologica Sinica, 2021, 42, 1055-1068.	2.8	22
874	Locus Coeruleus and neurovascular unit: From its role in physiology to its potential role in Alzheimer's disease pathogenesis. Journal of Neuroscience Research, 2020, 98, 2406-2434.	1.3	38
875	Benzo(a)pyrene exposure induced neuronal loss, plaque deposition, and cognitive decline in APP/PS1 mice. Journal of Neuroinflammation, 2020, 17, 258.	3.1	19
876	The two faces of synaptic failure in AppNL-G-F knock-in mice. Alzheimer's Research and Therapy, 2020, 12, 100.	3.0	25
877	Certification of Amyloid-Beta ($A\hat{I}^2$) Certified Reference Materials by Amino Acid-Based Isotope Dilution High-Performance Liquid Chromatography Mass Spectrometry and Sulfur-Based High-Performance Liquid Chromatography Isotope Dilution Inductively Coupled Plasma Mass Spectrometry. Analytical Chemistry. 2020. 92. 13229-13237.	3.2	14
878	Tryptophan-galactosylamine conjugates inhibit and disaggregate amyloid fibrils of AÎ ² 42 and hIAPP peptides while reducing their toxicity. Communications Biology, 2020, 3, 484.	2.0	27
879	Protein Biomarkers for the Diagnosis of Alzheimer's Disease at Different Stages of Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 6749.	1.8	4

#	Article	IF	CITATIONS
880	Neuro-protective roles of long non-coding RNA MALAT1 in Alzheimer's disease with the involvement of the microRNA-30b/CNR1 network and the following PI3K/AKT activation. Experimental and Molecular Pathology, 2020, 117, 104545.	0.9	51
881	Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer's disease. BMC Medical Genetics, 2020, 21, 181.	2.1	6
882	Effect of Herbal Medicinal Compounds on Alzheimer's Disease Pathology in APP/PS1 Transgenic Mouse Model. Natural Product Communications, 2020, 15, 1934578X2094898.	0.2	1
883	Mitochondrial Dysfunction and Alzheimer's Disease: Role of Microglia. Frontiers in Aging Neuroscience, 2020, 12, 252.	1.7	95
884	Sex differences in CSF biomarkers vary by Alzheimer disease stage and <i>APOE</i> $\hat{l}\mu4$ genotype. Neurology, 2020, 95, e2378-e2388.	1.5	48
885	Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimer's Research and Therapy, 2020, 12, 102.	3.0	7
886	α-Lipoic Acid Maintains Brain Glucose Metabolism via BDNF/TrkB/HIF-1α Signaling Pathway in P301S Mice. Frontiers in Aging Neuroscience, 2020, 12, 262.	1.7	14
887	PET Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction. Antioxidants, 2020, 9, 861.	2.2	25
888	Development of a Tau-Targeted Drug Delivery System Using a Multifunctional Nanoscale Metal–Organic Framework for Alzheimer's Disease Therapy. ACS Applied Materials & Interfaces, 2020, 12, 44447-44458.	4.0	46
889	Microglia-targeting nanotherapeutics for neurodegenerative diseases. APL Bioengineering, 2020, 4, 030902.	3.3	49
890	Sex differences in dementia: on the potentially mediating effects of educational attainment and experiences of psychological distress. BMC Psychiatry, 2020, 20, 434.	1.1	19
891	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI. BMC Geriatrics, 2020, 20, 337.	1.1	12
892	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1143-1155.	1.2	13
893	Current Biomarkers for Alzheimer's Disease: From CSF to Blood. Journal of Personalized Medicine, 2020, 10, 85.	1.1	42
894	Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 5858.	1.8	79
895	The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. Frontiers in Immunology, 2020, 11, 604179.	2.2	337
896	Nutraceutical Approaches of Autophagy and Neuroinflammation in Alzheimer's Disease: A Systematic Review. Molecules, 2020, 25, 6018.	1.7	28
897	Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment. Frontiers in Neuroscience, 2020, 14, 556137.	1.4	20

#	Article	IF	CITATIONS
898	Circulating Insulin-Like Growth Factor I is Involved in the Effect of High Fat Diet on Peripheral Amyloid \hat{l}^2 Clearance. International Journal of Molecular Sciences, 2020, 21, 9675.	1.8	8
899	The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. International Journal of Molecular Sciences, 2020, 21, 9739.	1.8	585
900	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, S91-S107.	1.2	13
901	Targeting MicroRNA-125b Promotes Neurite Outgrowth but Represses Cell Apoptosis and Inflammation via Blocking PTGS2 and CDK5 in a FOXQ1-Dependent Way in Alzheimer Disease. Frontiers in Cellular Neuroscience, 2020, 14, 587747.	1.8	15
902	Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale. Cells, 2020, 9, 2642.	1.8	32
903	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	3.0	14
904	Common aspects between glaucoma and brain neurodegeneration. Mutation Research - Reviews in Mutation Research, 2020, 786, 108323.	2.4	8
905	Polyvalent Biotinylated Aptamer Scaffold for Rapid and Sensitive Detection of Tau Proteins. Analytical Chemistry, 2020, 92, 15162-15168.	3.2	14
906	Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy. Frontiers in Molecular Neuroscience, 2020, 13, 570223.	1.4	10
907	The genetics of circulating BDNF: towards understanding the role of BDNF in brain structure and function in middle and old ages. Brain Communications, 2020, 2, fcaa176.	1.5	14
908	Pattern Recognition to Objectively Differentiate the Etiology of Cognitive Decline: Analysis of the Impact of Stroke and Alzheimer's Disease. Neuroepidemiology, 2020, 54, 446-453.	1,1	2
909	The Evolving Role of Ophthalmology Clinics in Screening for Early Alzheimer's Disease: A Review. Vision (Switzerland), 2020, 4, 46.	0.5	6
910	Development and validation of an interpretable deep learning framework for Alzheimer's disease classification. Brain, 2020, 143, 1920-1933.	3.7	219
911	The Impairment of Number Transcoding Abilities in Individuals with Amnestic Mild Cognitive Impairment and Alzheimer Disease. Cognitive and Behavioral Neurology, 2020, 33, 33-44.	0.5	0
912	Dynamic network connectivity predicts subjective cognitive decline: the Sino-Longitudinal Cognitive impairment and dementia study. Brain Imaging and Behavior, 2020, 14, 2692-2707.	1,1	16
913	miR-34a-5p and miR-125b-5p attenuate $\hat{Al^2}$ -induced neurotoxicity through targeting BACE1. Journal of the Neurological Sciences, 2020, 413, 116793.	0.3	45
914	<scp>Grabâ€AD</scp> : Generalizability and reproducibility of altered brain activity and diagnostic classification in Alzheimer's Disease. Human Brain Mapping, 2020, 41, 3379-3391.	1.9	38
915	Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. International Journal of Molecular Sciences, 2020, 21, 3523.	1.8	24

#	Article	IF	CITATIONS
916	Deficits in Mitochondrial Spare Respiratory Capacity Contribute to the Neuropsychological Changes of Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 32.	1.1	20
917	Gelsemine, a natural alkaloid extracted from Gelsemium elegans Benth. alleviates neuroinflammation and cognitive impairments in $\hat{Al^2}$ oligomer-treated mice. Psychopharmacology, 2020, 237, 2111-2124.	1.5	18
918	Biotin, coenzyme Q10, and their combination ameliorate aluminium chlorideâ€induced Alzheimer's disease via attenuating neuroinflammation and improving brain insulin signaling. Journal of Biochemical and Molecular Toxicology, 2020, 34, e22519.	1.4	21
919	Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. Trends in Microbiology, 2020, 28, 808-820.	3.5	132
920	Amyloid Metabolism and Amyloid-Targeting Blood-Based Biomarkers of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 75, 685-696.	1.2	9
921	Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice. Translational Neurodegeneration, 2020, 9, 18.	3.6	12
922	A novel phytochemical from Dipteris wallichii inhibits human β-secretase 1: Implications for the treatment of Alzheimer's disease. Medical Hypotheses, 2020, 143, 109839.	0.8	8
923	White Matter Brain Network Research in Alzheimer's Disease Using Persistent Features. Molecules, 2020, 25, 2472.	1.7	11
924	The Positive Side of the Alzheimer's Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1. Molecules, 2020, 25, 2439.	1.7	37
925	Acupuncture therapy for Alzheimer's disease. Medicine (United States), 2020, 99, e20244.	0.4	3
926	Opposite Roles of Î- and μ-Opioid Receptors in BACE1 Regulation and Alzheimer's Injury. Frontiers in Cellular Neuroscience, 2020, 14, 88.	1.8	10
927	Usefulness of beeswax recycling by-products in the treatment of \hat{l}^2 -amyloid toxicity in a C. elegans model of Alzheimer. Mediterranean Journal of Nutrition and Metabolism, 2020, 13, 163-173.	0.2	3
928	Physicochemical evaluation of new tetrahydroacridine and iodobenzoic acid hybrids as the next step in the design of potential drugs for treating Alzheimer's disease. Biomedical Chromatography, 2020, 34, e4906.	0.8	2
929	Tetraspanin 7 and its closest paralog tetraspanin 6: membrane organizers with key functions in brain development, viral infection, innate immunity, diabetes and cancer. Medical Microbiology and Immunology, 2020, 209, 427-436.	2.6	18
930	New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 3765.	1.8	6
931	Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. International Journal of Molecular Sciences, 2020, 21, 3802.	1.8	24
932	A <i>TOMM40/APOE</i> allele encoding <i>APOE</i> êE3 predicts high likelihood of lateâ€onset Alzheimer's disease in autopsy cases. Molecular Genetics & Genomic Medicine, 2020, 8, e1317.	0.6	8
933	The compensatory phenomenon of the functional connectome related to pathological biomarkers in individuals with subjective cognitive decline. Translational Neurodegeneration, 2020, 9, 21.	3.6	46

#	Article	IF	CITATIONS
934	SPON1 Can Reduce Amyloid Beta and Reverse Cognitive Impairment and Memory Dysfunction in Alzheimer's Disease Mouse Model. Cells, 2020, 9, 1275.	1.8	8
935	Exercise benefits on Alzheimer's disease: State-of-the-science. Ageing Research Reviews, 2020, 62, 101108.	5.0	153
936	Selective neuronal vulnerability in Alzheimer's disease. Ageing Research Reviews, 2020, 62, 101114.	5.0	9
937	Lack of association between <i>LGMN</i> and Alzheimer's disease in the Southern Han Chinese population. European Journal of Neuroscience, 2020, 52, 4009-4017.	1.2	4
938	Towards a Redefinition of Cognitive Frailty. Journal of Alzheimer's Disease, 2020, 76, 831-843.	1.2	27
939	Blood Biomarkers: Democratizing Alzheimer's Diagnostics. Neuron, 2020, 106, 881-883.	3.8	38
940	Dual Targeting of Monomeric Tau and \hat{l}_{\pm} -Synuclein Aggregation: A New Multitarget Therapeutic Strategy for Neurodegeneration. ACS Chemical Neuroscience, 2020, 11, 2051-2057.	1.7	13
941	Prognostic value of ATN Alzheimer biomarkers: 60â€month followâ€up results from the Argentine Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12026.	1.2	20
942	Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course. Journal of Neurology, 2020, 267, 2941-2948.	1.8	38
943	Pharmacogenetic studies in Alzheimer disease. NeurologÃa (English Edition), 2022, 37, 287-303.	0.2	4
944	Binding modes of thioflavin T and Congo red to the fibril structure of amyloid-β(1–42). Chemical Communications, 2020, 56, 7589-7592.	2.2	38
945	The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases. Translational Neurodegeneration, 2020, 9, 22.	3.6	62
946	Oral Health Status in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Data from the Zabút Aging Project. Journal of Alzheimer's Disease, 2022, 87, 173-183.	1.2	18
947	Low vision and the risk of dementia: a nationwide population-based cohort study. Scientific Reports, 2020, 10, 9109.	1.6	32
948	Quantitative Analysis of 7 Compounds in <i>Diospyros lotus</i> Leaf Extract and Its Biological Effects on Neuroprotection and Antineuroinflammation. Natural Product Communications, 2020, 15, 1934578X2092485.	0.2	2
949	Three-dimensional real time imaging of amyloid \hat{l}^2 aggregation on living cells. Scientific Reports, 2020, 10, 9742.	1.6	15
950	From combinations to multitargetâ€directed ligands: A continuum in Alzheimer's disease polypharmacology. Medicinal Research Reviews, 2021, 41, 2606-2633.	5.0	88
951	Brain metabolomics study for the protective effects of Rhodiola crenulata extract on Alzheimer's disease by HPLC coupled with Fourier transformâ€ion cyclotron resonance mass spectrometry. Journal of Separation Science, 2020, 43, 3216-3223.	1.3	6

#	Article	IF	Citations
952	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. Dementia and Geriatric Cognitive Disorders, 2020, 49, 22-37.	0.7	5
953	A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease. Clinical Proteomics, 2020, 17, 21.	1.1	40
954	Intact olfactory memory in the 5xFAD mouse model of Alzheimer's disease from 3 to 15 months of age. Behavioural Brain Research, 2020, 393, 112731.	1.2	19
955	Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs. Neuropharmacology, 2020, 177, 108099.	2.0	22
956	Plasma transferrin and hemopexin are associated with altered Aβ uptake and cognitive decline in Alzheimer's disease pathology. Alzheimer's Research and Therapy, 2020, 12, 72.	3.0	19
957	In vitro Models of Neurodegenerative Diseases. Frontiers in Cell and Developmental Biology, 2020, 8, 328.	1.8	149
958	Expedition into Taurine Biology: Structural Insights and Therapeutic Perspective of Taurine in Neurodegenerative Diseases. Biomolecules, 2020, 10, 863.	1.8	18
959	The structure-based optimization of $\hat{\Gamma}$ -sultone-fused pyrazoles as selective BuChE inhibitors. European Journal of Medicinal Chemistry, 2020, 201, 112273.	2.6	14
960	A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer's disease. Journal of Neuroinflammation, 2020, 17, 84.	3.1	34
961	Type 1 Interleukin-4 Signaling Obliterates Mouse Astroglia in vivo but Not in vitro. Frontiers in Cell and Developmental Biology, 2020, 8, 114.	1.8	16
962	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. Frontiers in Neurology, 2020, 11, 149.	1.1	14
963	C-Reactive Protein and Its Structural Isoforms: An Evolutionary Conserved Marker and Central Player in Inflammatory Diseases and Beyond. Sub-Cellular Biochemistry, 2020, 94, 499-520.	1.0	46
964	Non-polyphenolic natural inhibitors of amyloid aggregation. European Journal of Medicinal Chemistry, 2020, 192, 112197.	2.6	44
965	Discovery of small molecules for the treatment of Alzheimer's disease. , 2020, , 289-322.		1
966	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 21.	3.0	183
967	APP Maturation and Intracellular Localization Are Controlled by a Specific Inhibitor of 37/67 kDa Laminin-1 Receptor in Neuronal Cells. International Journal of Molecular Sciences, 2020, 21, 1738.	1.8	9
968	Neuroimmune Connections in Aging and Neurodegenerative Diseases. Trends in Immunology, 2020, 41, 300-312.	2.9	111
969	Phytosterols of marine algae: Insights into the potential health benefits and molecular pharmacology. Phytomedicine, 2020, 69, 153201.	2.3	85

#	Article	IF	CITATIONS
970	Transcriptomic and Network Analysis Identifies Shared and Unique Pathways across Dementia Spectrum Disorders. International Journal of Molecular Sciences, 2020, 21, 2050.	1.8	17
971	Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. PLoS ONE, 2020, 15, e0229819.	1.1	92
972	Early Diagnosis of Alzheimer's Disease in Blood Using a Disposable Electrochemical Microfluidic Platform. ACS Sensors, 2020, 5, 1010-1019.	4.0	40
973	Neuropathological Mechanisms Associated with Pesticides in Alzheimer's Disease. Toxics, 2020, 8, 21.	1.6	40
974	Applying deep learning models to structural MRI for stage prediction of Alzheimer's disease. Turkish Journal of Electrical Engineering and Computer Sciences, 2020, 28, 196-210.	0.9	28
975	Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders., 2020, 210, 107523.		206
976	Alzheimer's Disease: From Amyloid to Autoimmune Hypothesis. Neuroscientist, 2020, 26, 455-470.	2.6	17
977	Current and Future Treatments in Alzheimer Disease: An Update. Journal of Central Nervous System Disease, 2020, 12, 117957352090739.	0.7	413
978	<p>Rhynchophylline Loaded-mPEG-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer's Disease</p> . International Journal of Nanomedicine, 2020, Volume 15, 1149-1160.	3.3	50
979	Neurorehabilitation in aging through neurologic music therapy. , 2020, , 351-382.		4
980	SFPQ and Tau: critical factors contributing to rapid progression of Alzheimer's disease. Acta Neuropathologica, 2020, 140, 317-339.	3.9	45
981	Inhibition of mTORC1 improves STZ-induced AD-like impairments in mice. Brain Research Bulletin, 2020, 162, 166-179.	1.4	7
982	Cellular senescence and Alzheimer disease: the egg and the chicken scenario. Nature Reviews Neuroscience, 2020, 21, 433-444.	4.9	132
983	Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia. Frontiers in Neurology, 2020, 11, 560.	1.1	4
984	Community memory screening as a strategy for recruiting older adults into Alzheimer's disease research. Alzheimer's Research and Therapy, 2020, 12, 78.	3.0	4
985	Poor oral health conditions and cognitive decline: Studies in humans and rats. PLoS ONE, 2020, 15, e0234659.	1.1	13
986	Neurodevelopmental Consequences of Pediatric Cancer and Its Treatment: The Role of Sleep. Brain Sciences, 2020, 10, 411.	1.1	18
987	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63

#	Article	IF	CITATIONS
988	Diffusion-weighted MRI in neurodegenerative and psychiatric animal models: Experimental strategies and main outcomes. Journal of Neuroscience Methods, 2020, 343, 108814.	1.3	3
989	Amyloid-β42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson's Disease. Journal of Alzheimer's Disease, 2020, 76, 1171-1178.	1.2	11
990	Assessing the Utility of Language and Voice Biomarkers to Predict Cognitive Impairment in the Framingham Heart Study Cognitive Aging Cohort Data. Journal of Alzheimer's Disease, 2020, 76, 905-922.	1.2	16
991	A Pooled Analysis of Three Randomized Phase I/IIa Clinical Trials Confirms Absence of a Clinically Relevant Effect on the QTc Interval by Umibecestat. Clinical and Translational Science, 2020, 13, 1316-1326.	1.5	6
992	Relationship between Urinary Alzheimer-Associated Neuronal Thread Protein and Apolipoprotein Epsilon 4 Allele in the Cognitively Normal Population. Neural Plasticity, 2020, 2020, 1-10.	1.0	6
993	Neurodegeneration of Trigeminal Mesencephalic Neurons by the Tooth Loss Triggers the Progression of Alzheimer's Disease in 3×Tg-AD Model Mice. Journal of Alzheimer's Disease, 2020, 76, 1443-1459.	1.2	22
994	Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration. Translational Neurodegeneration, 2020, 9, 25.	3.6	33
995	The Essential Functions and Detection of Bisecting GlcNAc in Cell Biology. Frontiers in Chemistry, 2020, 8, 511.	1.8	29
996	Potential Bidirectional Relationship Between Periodontitis and Alzheimer's Disease. Frontiers in Physiology, 2020, 11, 683.	1.3	49
997	Effect of Colloidal Aqueous Solution of Fullerene (C60) in the Presence of a P-Glycoprotein Inhibitor (Verapamil) on Spatial Memory and Hippocampal Expression of Sirtuin6, SELADIN1, and AQP1 Genes in a Rat Model of Alzheimer's Disease. ACS Chemical Neuroscience, 2020, 11, 2549-2565.	1.7	10
998	Relationship Between Exercise and Alzheimer's Disease: A Narrative Literature Review. Frontiers in Neuroscience, 2020, 14, 131.	1.4	96
999	Blood and Lymphatic Vasculatures On-Chip Platforms and Their Applications for Organ-Specific In Vitro Modeling. Micromachines, 2020, 11, 147.	1.4	33
1000	CSB6B prevents \hat{l}^2 -amyloid-associated neuroinflammation and cognitive impairments via inhibiting NF- \hat{l}^2 B and NLRP3 in microglia cells. International Immunopharmacology, 2020, 81, 106263.	1.7	23
1001	APOE-amyloid interaction: Therapeutic targets. Neurobiology of Disease, 2020, 138, 104784.	2.1	65
1002	Memoryâ€enhancing effects of <i>lshige foliacea</i> extract: In vitro and in vivo study. Journal of Food Biochemistry, 2020, 44, e13162.	1.2	15
1003	Definition and Concept of Vascular Cognitive Impairment. Stroke Revisited, 2020, , 1-14.	0.2	2
1004	Amyloidogenic Peptides in Human Neuro-Degenerative Diseases and in Microorganisms: A Sorrow Shared Is a Sorrow Halved?. Molecules, 2020, 25, 925.	1.7	9
1005	Multifunctional memantine nitrate significantly protects against glutamate-induced excitotoxicity via inhibiting calcium influx and attenuating PI3K/Akt/GSK3beta pathway. Chemico-Biological Interactions, 2020, 325, 109020.	1.7	21

#	Article	IF	CITATIONS
1006	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	1.8	43
1007	Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Pharmacopsychiatry, 2020, 53, 109-114.	1.7	11
1008	Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2020, 28, 115374.	1.4	27
1009	Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in a Chinese Cohort. Neuroscience Bulletin, 2020, 36, 696-704.	1.5	19
1010	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2020, 20, 421-441.	1.5	42
1011	Progression of Alzheimer's disease and effect of scFvâ€h3D6 immunotherapy in the 3xTgâ€AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy. NMR in Biomedicine, 2020, 33, e4263.	1.6	13
1012	Does the CD33 rs3865444 Polymorphism Confer Susceptibility to Alzheimer's Disease?. Journal of Molecular Neuroscience, 2020, 70, 851-860.	1.1	23
1013	Preparation, Optimization, and Evaluation of Methoxy Poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf Chemical Neuroscience, 2020, 11, 783-795.	50 467 To 1.7	d (glycol)- <i> 25</i>
1014	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 73, 1585-1595.	1.2	25
1015	Reduced Hippocampal Glutamate and Posterior Cingulate N-Acetyl Aspartate in Mild Cognitive Impairment and Alzheimer's Disease Is Associated with Episodic Memory Performance and White Matter Integrity in the Cingulum: A Pilot Study. Journal of Alzheimer's Disease, 2020, 73, 1385-1405.	1.2	37
1016	Ginnalin A Inhibits Aggregation, Reverses Fibrillogenesis, and Alleviates Cytotoxicity of Amyloid $\hat{l}^2(1\hat{a}\in 42)$. ACS Chemical Neuroscience, 2020, 11, 638-647.	1.7	39
1017	Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. Clinical Pharmacology and Therapeutics, 2020, 107, 796-805.	2.3	14
1018	miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells, 2020, 9, 276.	1.8	693
1019	Neuroinflammation and Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches. International Journal of Molecular Sciences, 2020, 21, 701.	1.8	108
1020	Axonal Endoplasmic Reticulum Dynamics and Its Roles in Neurodegeneration. Frontiers in Neuroscience, 2020, 14, 48.	1.4	79
1021	Protein-protein interactions underlying the behavioral and psychological symptoms of dementia (BPSD) and Alzheimer's disease. PLoS ONE, 2020, 15, e0226021.	1.1	13
1022	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. PLoS ONE, 2020, 15, e0227282.	1.1	19
1023	Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. Protein and Peptide Letters, 2020, 27, 484-511.	0.4	25

#	Article	IF	CITATIONS
1024	Tannic Acid Ameliorates STZ-Induced Alzheimer's Disease-Like Impairment of Memory, Neuroinflammation, Neuronal Death and Modulates Akt Expression. Neurotoxicity Research, 2020, 37, 1009-1017.	1.3	26
1025	Synthesis, inÂvitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 198, 112368.	2.6	18
1026	Preventive Electroacupuncture Ameliorates D-Galactose-Induced Alzheimer's Disease-Like Pathology and Memory Deficits Probably via Inhibition of GSK3 < i>β < /i> /mTOR Signaling Pathway. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-12.	0.5	12
1027	Glucose, glycolysis, and neurodegenerative diseases. Journal of Cellular Physiology, 2020, 235, 7653-7662.	2.0	98
1028	Omega-3 fatty acids and mental health. Global Health Journal (Amsterdam, Netherlands), 2020, 4, 18-30.	1.9	70
1029	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nature Communications, 2020, 11, 1683.	5.8	252
1030	Reliability and concurrent validity of Alzheimer's disease assessment scale - Cognitive subscale, Chinese version (ADAS-Cog-C) among Chinese community-dwelling older people population. Clinical Neuropsychologist, 2020, 34, 43-53.	1.5	11
1031	Prevalence of the Preclinical Stages of Alzheimer's Disease in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2020, 75, 483-492.	1.2	1
1032	d-glutamate and Gut Microbiota in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 2676.	1.8	86
1033	Using NMR spectroscopy to investigate the role played by copper in prion diseases. Neurological Sciences, 2020, 41, 2389-2406.	0.9	10
1034	Mitophagy and iron: two actors sharing the stage in age-associated neuronal pathologies. Mechanisms of Ageing and Development, 2020, 188, 111252.	2.2	15
1035	Relationship between executive dysfunction and neuropsychiatric symptoms and impaired instrumental activities of daily living among patients with very mild Alzheimer's disease. International Journal of Geriatric Psychiatry, 2020, 35, 877-887.	1.3	9
1036	Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology, 2020, , .	0.8	5
1037	Mechanisms of Electroacupuncture on Alzheimer's Disease: A Review of Animal Studies. Chinese Journal of Integrative Medicine, 2020, 26, 473-480.	0.7	16
1039	The Cognitiveâ€Functional Composite is sensitive to clinical progression in early dementia: Longitudinal findings from the Catchâ€Cog study cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12020.	1.8	18
1040	Circular RNA expression profile of Alzheimer's disease and its clinical significance as biomarkers for the disease risk and progression. International Journal of Biochemistry and Cell Biology, 2020, 123, 105747.	1.2	52
1041	Shenqi Yizhi granules protect hippocampus of AD transgenic mice by modulating on multiple pathological processes. Journal of Ethnopharmacology, 2020, 263, 112869.	2.0	9
1042	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 94, e2026-e2036.	1.5	42

#	Article	IF	CITATIONS
1043	Interaction between Angiotensin Receptor and \hat{l}^2 -Adrenergic Receptor Regulates the Production of Amyloid \hat{l}^2 -Protein. Biological and Pharmaceutical Bulletin, 2020, 43, 731-735.	0.6	1
1044	Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty. Frontiers in Pharmacology, 2020, 11, 261.	1.6	48
1045	Multi-View Based Multi-Model Learning for MCI Diagnosis. Brain Sciences, 2020, 10, 181.	1.1	11
1046	The Genetics of Alzheimer's Disease in the Chinese Population. International Journal of Molecular Sciences, 2020, 21, 2381.	1.8	10
1047	Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework. Molecular Psychiatry, 2021, 26, 1075-1097.	4.1	42
1048	Effects of Porphyromonas gingivalis and Its Underlying Mechanisms on Alzheimer-Like Tau Hyperphosphorylation in Sprague-Dawley Rats. Journal of Molecular Neuroscience, 2021, 71, 89-100.	1.1	21
1049	The <i>ARNTL</i> polymorphism rs900147 is associated with the risk of Alzheimer's disease and amnestic mild cognitive impairment in a Chinese population. Biological Rhythm Research, 2021, 52, 146-152.	0.4	0
1050	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. Medicinal Research Reviews, 2021, 41, 2689-2745.	5.0	26
1051	The Efficacy and Safety of Tube Feeding in Advanced Dementia Patients: A Systemic Review and Meta-Analysis Study. Journal of the American Medical Directors Association, 2021, 22, 357-363.	1.2	31
1052	Association between periodontitis and Alzheimer's disease and its impact on the self-perceived oral health status: a case-control study. Clinical Oral Investigations, 2021, 25, 555-562.	1.4	13
1053	Alzheimer's disease genetic risk and sleep phenotypes in healthy young men: association with more slow waves and daytime sleepiness. Sleep, 2021, 44, .	0.6	6
1054	Olfactory impairment and the risk of cognitive decline and dementia in older adults: a meta-analysis. Brazilian Journal of Otorhinolaryngology, 2021, 87, 94-102.	0.4	11
1055	Mechanisms of neuronal survival safeguarded by endocytosis and autophagy. Journal of Neurochemistry, 2021, 157, 263-296.	2.1	25
1056	Genistein attenuates amyloid-beta-induced cognitive impairment in rats by modulation of hippocampal synaptotoxicity and hyperphosphorylation of Tau. Journal of Nutritional Biochemistry, 2021, 87, 108525.	1.9	27
1057	Sigma ligands as potent inhibitors of ${\rm A\hat{l}^2}$ and ${\rm A\hat{l}^2Os}$ in neurons and promising therapeutic agents of Alzheimer's disease. Neuropharmacology, 2021, 190, 108342.	2.0	8
1058	L-3-n-Butylphthalide Effectively Improves the Glymphatic Clearance and Reduce Amyloid-β Deposition in Alzheimer's Transgenic Mice. Journal of Molecular Neuroscience, 2021, 71, 1266-1274.	1.1	9
1059	Implications of Oligomeric Amyloid-Beta (oAl̂² ₄₂) Signaling through l̂±7l̂²2-Nicotinic Acetylcholine Receptors (nAChRs) on Basal Forebrain Cholinergic Neuronal Intrinsic Excitability and Cognitive Decline. Journal of Neuroscience, 2021, 41, 555-575.	1.7	26
1060	Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases. Archives of Biochemistry and Biophysics, 2021, 697, 108702.	1.4	12

#	Article	IF	Citations
1061	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	4.5	176
1062	Dual-specificity phosphatases in mental and neurological disorders. Progress in Neurobiology, 2021, 198, 101906.	2.8	19
1063	Harpertrioate A, an A,B,D- <i>seco</i> -Limonoid with Promising Biological Activity against Alzheimer's Disease from Twigs of <i>Harrisonia perforata</i> (Blanco) Merr Organic Letters, 2021, 23, 262-267.	2.4	15
1064	Clinical relevance of brain atrophy subtypes categorization in memory clinics. Alzheimer's and Dementia, 2021, 17, 641-652.	0.4	14
1065	Protein Interaction Network Biology in Neuroscience. Proteomics, 2021, 21, e1900311.	1.3	13
1066	Pathogenic and protective roles of extracellular vesicles in neurodegenerative diseases. Journal of Biochemistry, 2021, 169, 181-186.	0.9	9
1067	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 729-741.	1.2	10
1068	Enhanced Neuronal Activity and Asynchronous Calcium Transients Revealed in a 3D Organoid Model of Alzheimer's Disease. ACS Biomaterials Science and Engineering, 2021, 7, 254-264.	2.6	37
1069	Nut Consumption for Cognitive Performance: A Systematic Review. Advances in Nutrition, 2021, 12, 777-792.	2.9	48
1070	Effect of QTC-4-MeOBnE Treatment on Memory, Neurodegeneration, and Neurogenesis in a Streptozotocin-Induced Mouse Model of Alzheimer's Disease. ACS Chemical Neuroscience, 2021, 12, 109-122.	1.7	15
1071	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathologica, 2021, 141, 217-233.	3.9	33
1072	Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 3-13.	0.9	17
1073	Association of healthy lifestyle with cognitive function among Chinese older adults. European Journal of Clinical Nutrition, 2021, 75, 325-334.	1.3	35
1074	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	1.6	34
1075	Comparison between touchscreen operant chambers and water maze to detect early prefrontal dysfunction in mice. Genes, Brain and Behavior, 2021, 20, e12695.	1.1	10
1076	Targeting increased levels of APP in Down syndrome: Posiphenâ€mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimer's and Dementia, 2021, 17, 271-292.	0.4	25
1077	Polysialylation and disease. Molecular Aspects of Medicine, 2021, 79, 100892.	2.7	42
1078	Sleep inhibition induced by amyloid $\hat{a} \in \hat{i}^2$ oligomers is mediated by the cellular prion protein. Journal of Sleep Research, 2021, 30, e13187.	1.7	5

#	Article	IF	CITATIONS
1079	Early life stress amplifies fear responses and hippocampal synaptic potentiation in the APPswe/PS1dE9 Alzheimer mouse model. Neuroscience, 2021, 454, 151-161.	1.1	8
1080	Using a Discourse Task to Explore Semantic Ability in Persons With Cognitive Impairment. Frontiers in Aging Neuroscience, 2020, 12, 607449.	1.7	9
1081	Future of the aging brain: Bridging the gap between research and policy. Aging Brain, 2021, 1, 100002.	0.7	2
1082	Pâ€tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12190.	1.2	34
1083	The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis. Advances in Experimental Medicine and Biology, 2021, 1301, 41-57.	0.8	80
1084	Intranasal Insulin for Alzheimer's Disease. CNS Drugs, 2021, 35, 21-37.	2.7	67
1085	Inhibition of Amyloid Î ² -Induced Lipid Membrane Permeation andÂAmyloid Î ² Aggregation by K162. ACS Chemical Neuroscience, 2021, 12, 531-541.	1.7	14
1086	Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2020, 7, 501104.	1.2	17
1087	Research Advantages in Marine Microbial Acetylcholinesterase Inhibitors Against Alzheimer's Disease: An Overview. International Journal of Advanced Research in Science, Communication and Technology, 0, , 123-130.	0.0	0
1088	Canine induced pluripotent stem cells: an inÂvitro approach to validate the dog as a large animal model for Alzheimer's disease. , 2021, , 77-91.		0
1089	Sulforaphane inhibits the production of $\hat{Al^2}$ partially through the activation of Nrf2-regulated oxidative stress. Food and Function, 2021, 12, 11482-11490.	2.1	6
1090	New approaches to symptomatic treatments for Alzheimer's disease. Molecular Neurodegeneration, 2021, 16, 2.	4.4	96
1091	Racial Differences in Alzheimer's Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2. Journal of Alzheimer's Disease, 2021, 79, 543-557.	1.2	8
1092	Consumption of Oleic Acid on the Preservation of Cognitive Functions in Japanese Elderly Individuals. Nutrients, 2021, 13, 284.	1.7	18
1093	Fecal Fungal Dysbiosis in Chinese Patients With Alzheimer's Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 631460.	1.8	23
1094	Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with Dementia. , 2021, 12, 954.		46
1095	Clinically Applicable Quantitative Magnetic Resonance Morphologic Measurements of Grey Matter Changes in the Human Brain. Brain Sciences, 2021, 11, 55.	1.1	3
1096	Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues. Advances in Experimental Medicine and Biology, 2021, 1297, 43-64.	0.8	1

#	Article	IF	CITATIONS
1097	Effects of Exercise in the Treatment of Alzheimer's Disease: An Umbrella Review of Systematic Reviews and Meta-Analyses. Journal of Aging and Physical Activity, 2022, 30, 535-551.	0.5	8
1098	Progress in human embryonic stem cell research and aging. , 2021, , 9-52.		0
1099	Progression of neuropsychiatric symptoms in young-onset versus late-onset Alzheimer's disease. GeroScience, 2021, 43, 213-223.	2.1	18
1100	Restoration of the reduced CLSP activity alleviates memory impairment in Alzheimer disease. Translational Psychiatry, 2021, 11, 44.	2.4	2
1101	Acting Before; A Combined Strategy to Counteract the Onset and Progression of Dementia. Current Alzheimer Research, 2021, 17, 790-804.	0.7	5
1102	Applications in medicine: mental health., 2021,, 689-721.		1
1103	Serum amino acid profiles in patients with mild cognitive impairment and in patients with mild dementia or moderate dementia. Amino Acids, 2021, 53, 97-109.	1.2	4
1104	Evaluation of Sodium (²³ Na) MR-imaging as a Biomarker and Predictor for Neurodegenerative Changes in Patients With Alzheimer's Disease. In Vivo, 2021, 35, 429-435.	0.6	14
1105	Design and synthesis of benzyl aminocoumarin and its anti-Alzheimer's activity. New Journal of Chemistry, 2021, 45, 17287-17300.	1.4	7
1106	The Involvement of Cellular Glycans in Alzheimer's Disease. , 2021, , 287-293.		0
1107	MicroRNA-146a inhibition promotes total neurite outgrowth and suppresses cell apoptosis, inflammation, and STAT1/MYC pathway in PC12 and cortical neuron cellular Alzheimer's disease models. Brazilian Journal of Medical and Biological Research, 2021, 54, e9665.	0.7	8
1108	The relationship between heart disease and cognitive impairment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 177, 377-391.	1.0	7
1109	Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis. Annals of Nuclear Medicine, 2021, 35, 139-147.	1.2	3
1110	Neurocognitive Disorders. , 2021, , 49-71.		0
1111	Comprehensive review of Alzheimer's disease drugs (conventional, newer, and plant-derived) with focus on Bacopa monnieri. , 2021, , 227-248.		0
1112	Role of food or food component in brain health. , 2021, , 3-13.		1
1113	ADAM10 as a biomarker for Alzheimer's disease. , 2021, , 249-258.		0
1114	Subgingival microbiota in a population with and without cognitive dysfunction. Journal of Oral Microbiology, 2021, 13, 1854552.	1.2	24

#	Article	IF	CITATIONS
1116	Peptides and Proteins., 2021,, 79-117.		1
1117	Structure–activity relationship, <i>in vitro</i> and <i>in vivo</i> evaluation of novel dienyl sulphonyl fluorides as selective BuChE inhibitors for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1860-1873.	2.5	5
1118	A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2021, 1331, 167-191.	0.8	10
1119	Journey on Naphthoquinone and Anthraquinone Derivatives: New Insights in Alzheimer's Disease. Pharmaceuticals, 2021, 14, 33.	1.7	44
1120	Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond. RSC Advances, 2021, 11, 20403-20422.	1.7	6
1122	Impact of dementia literacy interventions for non-health-professionals: systematic review and meta-analysis. Aging and Mental Health, 2022, 26, 442-456.	1.5	4
1123	The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis. International Journal of Neuroscience, 2021, , 1-9.	0.8	2
1124	The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease. Diagnostics, 2021, 11, 371.	1.3	24
1125	AD Resemblance Atrophy Index as a Diagnostic Biomarker for Alzheimer's Disease: A Retrospective Clinical and Biological Validation. Journal of Alzheimer's Disease, 2021, 79, 1023-1032.	1.2	14
1126	In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research and Therapy, 2021, 13, 35.	3.0	47
1127	Gastrodin as a multi-target protective compound reverses learning memory deficits and AD-like pathology in APP/PS1 transgenic mice. Journal of Functional Foods, 2021, 77, 104324.	1.6	9
1128	Plasma <scp>d</scp> -glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches. Journal of Psychopharmacology, 2021, 35, 265-272.	2.0	24
1129	Tacrine – Benzothiazoles: Novel class of potential multitarget anti-Alzheimeŕs drugs dealing with cholinergic, amyloid and mitochondrial systems. Bioorganic Chemistry, 2021, 107, 104596.	2.0	17
1130	Alphaâ€lipoic acid ameliorates tauopathyâ€induced oxidative stress, apoptosis, and behavioral deficits through the balance of DIAP1/DrICE ratio and redox homeostasis: Age is a determinant factor. Metabolic Brain Disease, 2021, 36, 669-683.	1.4	3
1131	Coronary Artery Calcium and Cognitive Function in Dutch Adults: Crossâ€Sectional Results of the Populationâ€Based ImaLife Study. Journal of the American Heart Association, 2021, 10, e018172.	1.6	5
1132	Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. Brain Sciences, 2021, 11, 215.	1.1	58
1133	Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation. Cell Communication and Signaling, 2021, 19, 16.	2.7	30
1134	Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer's Disease Murine Models. Antioxidants, 2021, 10, 218.	2.2	15

#	Article	IF	CITATIONS
1135	High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease. Amino Acids, 2021, 53, 435-449.	1.2	14
1136	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. Alzheimer's Research and Therapy, 2021, 13, 47.	3.0	32
1137	Identification of aplysinopsin as a blood-brain barrier permeable scaffold for anti-cholinesterase and anti-BACE-1 activity. Bioorganic Chemistry, 2021, 107, 104568.	2.0	12
1138	Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. The Cochrane Library, 2021, 2021, .	1.5	11
1139	Efficient manipulation of gene dosage in human iPSCs using CRISPR/Cas9 nickases. Communications Biology, 2021, 4, 195.	2.0	6
1140	Stem Cell Therapies in Alzheimer's Disease: Applications for Disease Modeling. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 207-217.	1.3	22
1141	Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 1687.	1.8	61
1142	The Role of Butyrylcholinesterase and Iron in the Regulation of Cholinergic Network and Cognitive Dysfunction in Alzheimer's Disease Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 2033.	1.8	22
1143	Late-in-life neurodegeneration after chronic sleep loss in young adult mice. Sleep, 2021, 44, .	0.6	28
1144	Diagnostic accuracy of the UDS 3.0 neuropsychological battery in a cohort with Alzheimer's disease in Colombia. Applied Neuropsychology Adult, 2022, 29, 1543-1551.	0.7	6
1145	An elaborative NMR based plasma metabolomics study revealed metabolic derangements in patients with mild cognitive impairment: a study on north Indian population. Metabolic Brain Disease, 2021, 36, 957-968.	1.4	8
1146	Alzheimer Disease Clinical Trials Targeting Amyloid. Neurologist, 2021, 26, 52-61.	0.4	19
1147	miR-351-5p/Miro2 axis contributes to hippocampal neural progenitor cell death via unbalanced mitochondrial fission. Molecular Therapy - Nucleic Acids, 2021, 23, 643-656.	2.3	13
1148	Amyloid- \hat{l}^2 and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. European Journal of Medicinal Chemistry, 2021, 214, 113209.	2.6	33
1149	Advances in Central Nervous System Organoids: A Focus on Organoid-Based Models for Motor Neuron Disease. Tissue Engineering - Part C: Methods, 2021, 27, 213-224.	1.1	15
1150	Nanomarker for Early Detection of Alzheimer's Disease Combining Ab initio DFT Simulations and Molecular Docking Approach. Biophysica, 2021, 1, 76-86.	0.6	4
1151	Imaging Biomarkers for Monitoring the Inflammatory Redox Landscape in the Brain. Antioxidants, 2021, 10, 528.	2.2	8
1152	Assessing the Progression of Alzheimer's Disease in Real-World Settings in Three European Countries. Journal of Alzheimer's Disease, 2021, 80, 749-759.	1.2	4

#	Article	IF	CITATIONS
1153	Prognostic plasma exosomal microRNA biomarkers in patients with substance use disorders presenting comorbid with anxiety and depression. Scientific Reports, 2021, 11, 6271.	1.6	20
1154	The Roles of MicroRNAs in Male Infertility. International Journal of Molecular Sciences, 2021, 22, 2910.	1.8	27
1155	Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arquivos Brasileiros De Cardiologia, 2021, 116, 516-658.	0.3	340
1156	α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. Journal of Alzheimer's Disease, 2021, 80, 885-893.	1.2	9
1157	Neuroprotection with Bacopa monnieri–A review of experimental evidence. Molecular Biology Reports, 2021, 48, 2653-2668.	1.0	17
1158	Elevated CSF LRG and Decreased Alzheimer's Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus. Journal of Clinical Medicine, 2021, 10, 1105.	1.0	12
1159	Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models. Cell Calcium, 2021, 94, 102362.	1.1	23
1160	Role of mitophagy in mitochondrial quality control: Mechanisms and potential implications for neurodegenerative diseases. Pharmacological Research, 2021, 165, 105433.	3.1	23
1161	Proteomics Landscape of Alzheimer's Disease. Proteomes, 2021, 9, 13.	1.7	7
1162	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 3136.	1.8	17
1163	A Transient Survival Model of Alteration of Electrophysiological Properties Due to Amyloid Beta Toxicity Based on SH-SY5Y Cell Line. Current Alzheimer Research, 2021, 17, 1208-1213.	0.7	0
1164	Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein. Journal of Alzheimer's Disease, 2021, 80, 813-829.	1.2	2
1165	Oral Treponema denticola Infection Induces Aβ1–40 and Aβ1–42 Accumulation in the Hippocampus of C57BL/6 Mice. Journal of Molecular Neuroscience, 2021, 71, 1506-1514.	1.1	25
1166	Clusterin inhibits Aβ 42 aggregation through a "strawberry model―as detected by FRETâ€FCS. Journal of Neurochemistry, 2021, 158, 444-454.	2.1	2
1167	Brain energy metabolism in intracerebroventricularly administered streptozotocin mouse model of Alzheimer's disease: A ¹ H-[¹³ C]-NMR study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2344-2355.	2.4	8
1169	Roles and Mechanisms of Axon-Guidance Molecules in Alzheimer's Disease. Molecular Neurobiology, 2021, 58, 3290-3307.	1.9	27
1170	The seed oil of <i>Paeonia ludlowii</i> ameliorates Aβ25â€35â€induced Alzheimer's disease in rats. Food Science and Nutrition, 2021, 9, 2402-2413.	1.5	6
1171	Early identification of Alzheimer's disease in mouse models: Application of deep neural network algorithm to cognitive behavioral parameters. IScience, 2021, 24, 102198.	1.9	14

#	Article	IF	CITATIONS
1172	The Main Alkaloids in Uncaria rhynchophylla and Their Anti-Alzheimer's Disease Mechanism Determined by a Network Pharmacology Approach. International Journal of Molecular Sciences, 2021, 22, 3612.	1.8	39
1173	Normal levels of KIF5 but reduced KLC1 levels in both Alzheimer disease and Alzheimer disease in Down syndrome: evidence suggesting defects in anterograde transport. Alzheimer's Research and Therapy, 2021, 13, 59.	3.0	8
1174	Platelets transport \hat{l}^2 -amyloid from the peripheral blood into the brain by destroying the blood-brain barrier to accelerate the process of Alzheimer's disease in mouse models. Aging, 2021, 13, 7644-7659.	1.4	22
1175	Segmental structural dynamics in A \hat{l}^2 42 globulomers. Biochemical and Biophysical Research Communications, 2021, 545, 119-124.	1.0	6
1176	2'-Hydroxy-4',5'-dimethyl-4-dimethylaminochalcone, a novel fluorescent flavonoid with capacity to detect aluminium in cells and modulate Alzheimer's disease targets. Journal of Photochemistry and Photobiology A: Chemistry, 2021, 409, 113137.	2.0	13
1177	Increased MANF Expression in the Inferior Temporal Gyrus in Patients With Alzheimer Disease. Frontiers in Aging Neuroscience, 2021, 13, 639318.	1.7	8
1178	Phenotyping Neuropsychiatric Symptoms Profiles of Alzheimer's Disease Using Cluster Analysis on EEG Power. Frontiers in Aging Neuroscience, 2021, 13, 623930.	1.7	4
1179	Comparison of memory, affective behavior, and neuropathology in APPNLGF knock-in mice to 5xFAD and APP/PS1 mice. Behavioural Brain Research, 2021, 404, 113192.	1.2	30
1180	The MCP-1 A-2518G polymorphism increases the risk of Alzheimer's disease: A case-control study. Neuroscience Letters, 2021, 749, 135710.	1.0	5
1181	Sexâ€specific alterations in NAD+ metabolism in 3xTg Alzheimer's disease mouse brain assessed by quantitative targeted LCâ€MS. Journal of Neurochemistry, 2021, 159, 378-388.	2.1	21
1182	Growth differentiation factor 11: a "rejuvenation factor―involved in regulation of age-related diseases?. Aging, 2021, 13, 12258-12272.	1.4	15
1183	COVID-19 and Alzheimer's disease: how one crisis worsens the other. Translational Neurodegeneration, 2021, 10, 15.	3.6	74
1184	Is heart failure with preserved ejection fraction a â€~dementia' of the heart?. Heart Failure Reviews, 2022, 27, 587-594.	1.7	7
1185	Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central $\hat{Al^2}$ reduction. European Journal of Medicinal Chemistry, 2021, 216, 113270.	2.6	7
1186	Synergistic Association between Plasma Aβ _{1–42} and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. ACS Chemical Neuroscience, 2021, 12, 1376-1383.	1.7	9
1187	An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band. Current Alzheimer Research, 2021, 18, 45-55.	0.7	14
1188	Conducting public involvement in dementia research: The contribution of the European Working Group of People with Dementia to the ROADMAP project. Health Expectations, 2021, 24, 757-765.	1.1	8
1189	Impacts of Iron Metabolism Dysregulation on Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 80, 1439-1450.	1.2	10

#	Article	IF	Citations
1190	A Grape Juice Supplemented with Natural Grape Extracts Is Well Accepted by Consumers and Reduces Brain Oxidative Stress. Antioxidants, 2021, 10, 677.	2.2	4
1191	State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia—A Short Review and Diagnostic Algorithm. Diagnostics, 2021, 11, 788.	1.3	9
1192	Alzheimer's Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. Current Neuropharmacology, 2021, 19, 498-512.	1.4	16
1193	Alzheimer's disease and its treatment by different approaches: A review. European Journal of Medicinal Chemistry, 2021, 216, 113320.	2.6	199
1194	The role of P2X7R in neuroinflammation and implications in Alzheimer's disease. Life Sciences, 2021, 271, 119187.	2.0	16
1195	Alzheimer's disease. Lancet, The, 2021, 397, 1577-1590.	6.3	1,530
1196	Chromeno [3,4-b] xanthones as First-in-Class AChE and AÎ 2 Aggregation Dual-Inhibitors. International Journal of Molecular Sciences, 2021, 22, 4145.	1.8	8
1197	Novel noninvasive biomarkers of prodromal Alzheimer disease: The role of optical coherence tomography and optical coherence tomography–angiography. European Journal of Neurology, 2021, 28, 2185-2191.	1.7	11
1198	Protein Footprinting via Covalent Protein Painting Reveals Structural Changes of the Proteome in Alzheimer's Disease. Journal of Proteome Research, 2021, 20, 2762-2771.	1.8	34
1199	Administration of Bifidobacterium breve Improves the Brain Function of $\hat{Al^2}1$ -42-Treated Mice via the Modulation of the Gut Microbiome. Nutrients, 2021, 13, 1602.	1.7	41
1200	Role of the gut microbiota in the development of various neurological diseases. NeurologÃa (English) Tj ETQq0 0	0 rgBT /O	veglock 10 Tf
1201	Methylation factor MRPL15 identified as a potential biological target in Alzheimer's disease. Aging, 2021, 13, 13560-13570.	1.4	2
1202	Magnetically driven treatments: optimizing performance by mitigation of eddy currents. Nanomedicine, 2021, 16, 895-907.	1.7	2
1203	Evaluation relationships between subjective wellbeing, personality traits, and Alzheimer's disease: A two-sample Mendelian randomization study. Journal of Psychiatric Research, 2021, 137, 498-505.	1.5	3
1204	Nanomedicine against Alzheimer's and Parkinson's Disease. Current Pharmaceutical Design, 2021, 27, 1507-1545.	0.9	7
1205	Repurposing beta-3 adrenergic receptor agonists for Alzheimer's disease: beneficial effects in a mouse model. Alzheimer's Research and Therapy, 2021, 13, 103.	3.0	17
1206	Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: The CABLE study. Alzheimer's and Dementia, 2022, 18, 53-64.	0.4	22
1207	Role of natural products for the treatment of Alzheimer's disease. European Journal of Pharmacology, 2021, 898, 173974.	1.7	74

#	Article	IF	CITATIONS
1208	The Density of Group I mGlu5 Receptors Is Reduced along the Neuronal Surface of Hippocampal Cells in a Mouse Model of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 5867.	1.8	8
1209	Assessing the Possible Influence of Residues of Ractopamine, a Livestock Feed Additive, in Meat on Alzheimer Disease. Dementia and Geriatric Cognitive Disorders Extra, 2021, 11, 110-113.	0.6	6
1211	Connexins as therapeutic targets in neurological and neuropsychiatric disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166098.	1.8	13
1212	CircRNAs: role in human diseases and potential use as biomarkers. Cell Death and Disease, 2021, 12, 468.	2.7	191
1213	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1998-2008.	0.4	25
1214	The Roles of Peroxiredoxin 6 in Brain Diseases. Molecular Neurobiology, 2021, 58, 4348-4364.	1.9	20
1215	Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies. Translational Neurodegeneration, 2021, 10, 16.	3.6	39
1216	Age related weight loss in female 5xFAD mice from 3 to 12 months of age. Behavioural Brain Research, 2021, 406, 113214.	1.2	19
1217	Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 4914.	1.8	76
1218	A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 626636.	1.4	59
1219	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. Journal of Alzheimer's Disease, 2021, 82, 71-105.	1.2	21
1220	A Graph Gaussian Embedding Method for Predicting Alzheimer's Disease Progression With MEG Brain Networks. IEEE Transactions on Biomedical Engineering, 2021, 68, 1579-1588.	2.5	19
1221	Identification of key transcriptome biomarkers based on a vital gene module associated with pathological changes in Alzheimer's disease. Aging, 2021, 13, 14940-14967.	1.4	19
1222	Decreased pH in the aging brain and Alzheimer's disease. Neurobiology of Aging, 2021, 101, 40-49.	1.5	46
1223	Oxidase Reactivity of Cull Bound to N-Truncated \hat{A}^2 Peptides Promoted by Dopamine. International Journal of Molecular Sciences, 2021, 22, 5190.	1.8	3
1224	\hat{l}^2 -Amyloid in Cerebrospinal Fluid: How to Keep It Floating (Not Sticking) by Standardization of Preanalytic Processes and Collection Tubes. journal of applied laboratory medicine, The, 2021, 6, 1155-1164.	0.6	3
1225	Cortical plasticity is correlated with cognitive improvement in Alzheimer's disease patients after rTMS treatment. Brain Stimulation, 2021, 14, 503-510.	0.7	62
1226	Top-Down Proteomics of Human Saliva Highlights Anti-inflammatory, Antioxidant, and Antimicrobial Defense Responses in Alzheimer Disease. Frontiers in Neuroscience, 2021, 15, 668852.	1.4	20

#	Article	IF	CITATIONS
1227	Inflammasome NLRP3 Potentially Links Obesity-Associated Low-Grade Systemic Inflammation and Insulin Resistance with Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 5603.	1.8	25
1228	3'-O-Acetyl-24-Epi-7,8-Didehydrocimigenol-3-O-β-DXylopryranoside Decreases Amyloid Beta Production in Amyloid Precursor Protein-Transfected HeLa Cells. Biomolecules and Therapeutics, 2021, 29, 290-294.	1.1	1
1229	Sirtuin 2 (SIRT2): Confusing Roles in the Pathophysiology of Neurological Disorders. Frontiers in Neuroscience, 2021, 15, 614107.	1.4	27
1230	Cardiovascular Risk Factor Trajectories Since Childhood and Cognitive Performance in Midlife: The Cardiovascular Risk in Young Finns Study. Circulation, 2021, 143, 1949-1961.	1.6	29
1231	Nutraceuticals-based therapeutic approach: recent advances to combat pathogenesis of Alzheimer's disease. Expert Review of Neurotherapeutics, 2021, 21, 625-642.	1.4	19
1232	ERO1-PDI Redox Signaling in Health and Disease. Antioxidants and Redox Signaling, 2021, 35, 1093-1115.	2.5	9
1233	Identification of a peptide that crosses the blood-cerebrospinal fluid barrier by phage display technology. Amino Acids, 2021, 53, 1181-1186.	1.2	4
1234	Genetic profiles of familial late-onset Alzheimer's disease in China: The Shanghai FLOAD study. Genes and Diseases, 2022, 9, 1639-1649.	1.5	4
1235	"Dialogue―between the Human Microbiome and the Brain. Biochemistry, 0, , .	0.8	2
1236	Differential DNA Methylation of the Genes for Amyloid Precursor Protein, Tau, and Neurofilaments in Human Traumatic Brain Injury. Journal of Neurotrauma, 2021, 38, 1679-1688.	1.7	18
1237	Aducanumab: The first targeted Alzheimer's therapy. Drug Discoveries and Therapeutics, 2021, 15, 166-168.	0.6	40
1238	Association of Sleep With Risk of Alzheimer's Disease Mortality: NIH-AARP Diet and Health Study. Journal of Applied Gerontology, 2022, 41, 1057-1065.	1.0	4
1239	Novel Pyridineâ€Containing Sultones: Structureâ€Activity Relationship and Biological Evaluation as Selective AChE Inhibitors for the Treatment of Alzheimer's disease. ChemMedChem, 2021, 16, 3189-3200.	1.6	6
1240	Alix: A Candidate Serum Biomarker of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 669612.	1.7	1
1241	Semantic verbal fluency: network analysis in Alzheimer's and Parkinson's disease. Journal of Cognitive Psychology, 2021, 33, 557-567.	0.4	2
1242	Cholesterol and Alzheimer's Disease; From Risk Genes to Pathological Effects. Frontiers in Aging Neuroscience, 2021, 13, 690372.	1.7	110
1243	Changes of Regional Neural Activity Homogeneity in Preclinical Alzheimer's Disease: Compensation and Dysfunction. Frontiers in Neuroscience, 2021, 15, 646414.	1.4	16
1244	Following spatial Aβ aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. Science Advances, 2021, 7, .	4.7	22

#	Article	IF	CITATIONS
1245	Autonomic Imbalance and Risk of Dementia and Stroke: The Framingham Study. Stroke, 2021, 52, 2068-2076.	1.0	22
1246	Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis. Antioxidants, 2021, 10, 1043.	2.2	13
1247	Differences in in vitro microglial accumulation of the energy metabolism tracers [18F]FDG and [18F]BCPP-EF during LPS- and IL4 stimulation. Scientific Reports, 2021, 11, 13200.	1.6	6
1248	The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer's Disease. Medical Science Monitor, 2021, 27, e933084.	0.5	10
1249	Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review. Clinical Therapeutics, 2021, 43, 953-965.	1.1	34
1250	Discovery of 7-O-1, 2, 3-triazole hesperetin derivatives as multi-target-directed ligands against Alzheimer's disease. Chemico-Biological Interactions, 2021, 342, 109489.	1.7	9
1251	New frontiers in Alzheimer's disease diagnostic: Monoamines and their derivatives in biological fluids. Experimental Gerontology, 2021, 152, 111452.	1.2	10
1252	The Olfactory System as Marker of Neurodegeneration in Aging, Neurological and Neuropsychiatric Disorders. International Journal of Environmental Research and Public Health, 2021, 18, 6976.	1.2	17
1253	Local Functional MR Change Pattern and Its Association With Cognitive Function in Objectively-Defined Subtle Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 684918.	1.7	19
1254	Sex Difference in Network Topology and Education Correlated With Sex Difference in Cognition During the Disease Process of Alzheimer. Frontiers in Aging Neuroscience, 2021, 13, 639529.	1.7	12
1255	Biological Function of Long Non-coding RNA (LncRNA) Xist. Frontiers in Cell and Developmental Biology, 2021, 9, 645647.	1.8	94
1256	ADVIAN: Alzheimer's Disease VGG-Inspired Attention Network Based on Convolutional Block Attention Module and Multiple Way Data Augmentation. Frontiers in Aging Neuroscience, 2021, 13, 687456.	1.7	46
1257	Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease. Acta Pharmaceutica Sinica B, 2022, 12, 511-531.	5.7	26
1258	Physical performance across the cognitive spectrum and between dementia subtypes in a population-based sample of older adults: The HUNT study. Archives of Gerontology and Geriatrics, 2021, 95, 104400.	1.4	19
1259	A simple methyl substitution of 3-acetylcoumarin thiosemicarbazone enhances cellular autophagy flux, reduces inflammation and ameliorates rough eye phenotype in the Drosophila model of Alzheimer's disease. Journal of Molecular Structure, 2021, 1235, 130265.	1.8	7
1260	Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer's disease. Neuron, 2021, 109, 2292-2307.e5.	3.8	154
1261	Life Course Adiposity and Alzheimer's Disease: A Mendelian Randomization Study. Journal of Alzheimer's Disease, 2021, 82, 503-512.	1.2	10
1262	The Association Between Plasma α-Synuclein (α-syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE Îμ4) Alleles and Cognitive Decline in 60 Patients with Alzheimer's Disease Compared with 28 Age-Matched Normal Individuals. Medical Science Monitor, 2021, 27, e932998.	0.5	4

#	Article	IF	CITATIONS
1263	Innate immune memory mediates increased susceptibility to Alzheimer's disease-like pathology in sepsis surviving mice. Brain, Behavior, and Immunity, 2021, 95, 287-298.	2.0	18
1264	Probiotics for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Foods, 2021, 10, 1672.	1.9	33
1265	The Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research. Frontiers in Cellular Neuroscience, 2021, 15, 698172.	1.8	50
1266	A Concise Overview of Biosensing Technologies for the Detection of Alzheimer's Disease Biomarkers. Current Pharmaceutical Biotechnology, 2021, 22, .	0.9	7
1267	Supplementation with ribonucleotide-based ingredient (Ribodiet $\hat{A}^{@}$) lessens oxidative stress, brain inflammation, and amyloid pathology in a murine model of Alzheimer. Biomedicine and Pharmacotherapy, 2021, 139, 111579.	2.5	8
1268	The complexity of Alzheimer's disease: an evolving puzzle. Physiological Reviews, 2021, 101, 1047-1081.	13.1	110
1269	Effects of the Clock Modulator Nobiletin on Circadian Rhythms and Pathophysiology in Female Mice of an Alzheimer's Disease Model. Biomolecules, 2021, 11, 1004.	1.8	27
1270	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	1.8	34
1271	Improving Diagnostic Workup Following Traumatic Spinal Cord Injury: Advances in Biomarkers. Current Neurology and Neuroscience Reports, 2021, 21, 49.	2.0	9
1272	Preclinical and clinical study on [18F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 652-663.	3.3	6
1273	Technological readiness and implementation of genomicâ€driven precision medicine for complex diseases. Journal of Internal Medicine, 2021, 290, 602-620.	2.7	18
1274	Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase. Biomedicine and Pharmacotherapy, 2021, 139, 111609.	2.5	54
1275	Necroptosis: A Novel Pathway in Neuroinflammation. Frontiers in Pharmacology, 2021, 12, 701564.	1.6	58
1276	When Does Alzheimer's Disease Really Start? The Role of Biomarkers. Focus (American Psychiatric) Tj ETQq1	1 0.78431	4 rgBT /Ove
1277	Altered Gut Microbiota in Adults with Subjective Cognitive Decline: The SILCODE Study. Journal of Alzheimer's Disease, 2021, 82, 513-526.	1.2	29
1278	Integrated Analysis of Weighted Gene Coexpression Network Analysis Identifying Six Genes as Novel Biomarkers for Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-16.	1.9	18
1279	Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 123.	3.0	39
1280	Morphological, Structural, and Functional Networks Highlight the Role of the Cortical-Subcortical Circuit in Individuals With Subjective Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 688113.	1.7	13

#	ARTICLE	IF	CITATIONS
1281	Effects of Noninvasive Brain Stimulation (NIBS) on Cognitive Impairment in Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2021, 35, 278-288.	0.6	12
1282	Recent trends in artificial intelligence-driven identification and development of anti-neurodegenerative therapeutic agents. Molecular Diversity, 2021, 25, 1517-1539.	2.1	8
1283	Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. International Journal of Molecular Sciences, 2021, 22, 8208.	1.8	62
1284	Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 700280.	1.7	11
1285	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	0.9	11
1286	Risk Assessment During Longitudinal Progression of Cognition in Older Adults: A Community-based Bayesian Networks Model. Current Alzheimer Research, 2021, 18, 232-242.	0.7	5
1287	Suppression of amyloidâ€Î² secretion from neurons by <i>cis</i> à€9, <i>trans</i> à€11â€octadecadienoic acid, an isomer of conjugated linoleic acid. Journal of Neurochemistry, 2021, 159, 603-617.	2.1	3
1288	AND-Logic Strategy for Accurate Analysis of Alzheimer's Disease via Fluorescent Probe Lighted Up by Two Specific Biomarkers. Analytical Chemistry, 2021, 93, 11337-11345.	3.2	32
1289	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. Molecules, 2021, 26, 5091.	1.7	23
1290	Altered expression of costimulatory molecules in dementias. European Archives of Psychiatry and Clinical Neuroscience, 2021 , , 1 .	1.8	1
1291	Association between handgrip strength and cognition in a Chinese population with Alzheimer's disease and mild cognitive impairment. BMC Geriatrics, 2021, 21, 459.	1.1	15
1292	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. Frontiers in Neurology, 2021, 12, 694329.	1.1	8
1293	Strategic approaches to target the enzymes using natural compounds for the management of Alzheimer's disease: A review. CNS and Neurological Disorders - Drug Targets, 2021, 20, .	0.8	1
1294	N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer's disease. Bioorganic Chemistry, 2021, 113, 105013.	2.0	9
1295	Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. Molecular Neurodegeneration, 2021, 16, 55.	4.4	95
1296	Stress Granules Modulate SYK to Cause Tau-Associated Neurocognitive Deterioration in 5XFAD Mouse After Anesthesia and Surgery. Frontiers in Aging Neuroscience, 2021, 13, 718701.	1.7	2
1297	Differences in Multimodal Electroencephalogram and Clinical Correlations Between Early-Onset Alzheimer's Disease and Frontotemporal Dementia. Frontiers in Neuroscience, 2021, 15, 687053.	1.4	8
1298	Cognitive Dysfunction in White Matter Disorders: New Perspectives in Treatment and Recovery. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 349-355.	0.9	10

#	Article	IF	CITATIONS
1299	An electrochemical aptasensor based on AuPt alloy nanoparticles for ultrasensitive detection of amyloid- \hat{l}^2 oligomers. Talanta, 2021, 231, 122360.	2.9	30
1300	5-Lipoxygenase as an emerging target against age-related brain disorders. Ageing Research Reviews, 2021, 69, 101359.	5.0	11
1301	The Age of Brain Organoids: Tailoring Cell Identity and Functionality for Normal Brain Development and Disease Modeling. Frontiers in Neuroscience, 2021, 15, 674563.	1.4	18
1302	Glaucoma Is Not Associated With Alzheimer's Disease or Dementia: A Meta-Analysis of Cohort Studies. Frontiers in Medicine, 2021, 8, 688551.	1.2	8
1303	Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. Molecular Cell, 2021, 81, 4209-4227.e12.	4.5	84
1304	The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. Frontiers in Cell and Developmental Biology, 2021, 9, 683459.	1.8	94
1305	The relationship between cholinergic system brain structure and function in healthy adults and patients with mild cognitive impairment. Scientific Reports, 2021, 11, 16080.	1.6	12
1306	Identification of ortho catechol-containing isoflavone as a privileged scaffold that directly prevents the aggregation of both amyloid \hat{l}^2 plaques and tau-mediated neurofibrillary tangles and its in vivo evaluation. Bioorganic Chemistry, 2021, 113, 105022.	2.0	7
1307	Connectome-based model predicts episodic memory performance in individuals with subjective cognitive decline and amnestic mild cognitive impairment. Behavioural Brain Research, 2021, 411, 113387.	1.2	9
1308	5-HT1A Partial Agonist Tandospirone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home. Clinical Psychopharmacology and Neuroscience, 2021, 19, 514-520.	0.9	2
1309	Current status and future directions of clinical applications using iPS cells—focus on Japan. FEBS Journal, 2022, 289, 7274-7291.	2.2	13
1310	Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer's disease. Journal of Nanobiotechnology, 2021, 19, 249.	4.2	4
1311	Inhibition of interleukin- $1\hat{l}^2$ plays a protective role in Alzheimerâ \in TM s disease by promoting microRNA-9-5p and downregulating targeting protein for xenopus kinesin-like protein 2. International Immunopharmacology, 2021, 97, 107578.	1.7	7
1312	Loosening ER–Mitochondria Coupling by the Expression of the Presenilin 2 Loop Domain. Cells, 2021, 10, 1968.	1.8	7
1313	Losing Our Minds?., 2021,, 198-210.		0
1314	Widespread Reduced Density of Noradrenergic Locus Coeruleus Axons in the App Knock-In Mouse Model of Amyloid-Î ² Amyloidosis. Journal of Alzheimer's Disease, 2021, 82, 1513-1530.	1.2	7
1315	Serum Metabolites Differentiate Amnestic Mild Cognitive Impairment From Healthy Controls and Predict Early Alzheimer's Disease via Untargeted Lipidomics Analysis. Frontiers in Neurology, 2021, 12, 704582.	1.1	3
1316	Neuroticism Is Associated with Tau Pathology in Cognitively Unimpaired Individuals with Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 82, 1809-1822.	1.2	10

#	Article	IF	Citations
1317	Mesenchymal Stem Cell Therapy for Alzheimer's Disease. Stem Cells International, 2021, 2021, 1-12.	1.2	29
1318	Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer's patients. Cell Stem Cell, 2021, 28, 1533-1548.e6.	5.2	119
1319	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. Journal of Trace Elements in Medicine and Biology, 2021, 67, 126779.	1.5	60
1320	Research Progress on Mechanism of Neuroprotective Roles of Apelin-13 in Prevention and Treatment of Alzheimer〙s Disease. Neurochemical Research, 2022, 47, 205-217.	1.6	13
1321	Sirtuins as Potential Therapeutic Targets for Mitigating Neuroinflammation Associated With Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2021, 15, 746631.	1.8	20
1322	Cortical structure and the risk for Alzheimer's disease: a bidirectional Mendelian randomization study. Translational Psychiatry, 2021, 11, 476.	2.4	26
1323	Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3 \hat{l}^2 and Nrf2-Keap1-HO-1 pathways in vitro and in vivo murine models of Alzheimer's disease. Journal of Advanced Research, 2021, 34, 1-12.	4.4	30
1324	Cognitive improvement effects of <i>Momordica charantia</i> in amyloid beta-induced Alzheimer's disease mouse model. Journal of Applied Biological Chemistry, 2021, 64, 299-307.	0.2	1
1325	Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010–2020). European Journal of Medicinal Chemistry, 2021, 226, 113874.	2.6	25
1326	Running exercise protects spinophilinâ€immunoreactive puncta and neurons in the medial prefrontal cortex of APP/PS1 transgenic mice. Journal of Comparative Neurology, 2022, 530, 858-870.	0.9	5
1327	Extracellular vesicles in the treatment of neurological disorders. Neurobiology of Disease, 2021, 157, 105445.	2.1	28
1328	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. Translational Neurodegeneration, 2021, 10, 37.	3.6	8
1329	Development of curcumin-based amyloid \hat{l}^2 aggregation inhibitors for Alzheimer's disease using the SAR matrix approach. Bioorganic and Medicinal Chemistry, 2021, 46, 116357.	1.4	6
1330	A Pilot Tool of the Virtual Scenario Initial Dementia Cognitive Screening (VSIDCS) with a Cultural Exhibition for Improving the Standard Traditional Test. Healthcare (Switzerland), 2021, 9, 1160.	1.0	1
1331	Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-Î ² . Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158980.	1.2	14
1332	Effects of Low-Intensity Transcranial Pulsed Ultrasound Treatment in a Model of Alzheimer's Disease. Ultrasound in Medicine and Biology, 2021, 47, 2646-2656.	0.7	8
1333	Plasma p-tau181 Level Predicts Neurodegeneration and Progression to Alzheimer's Dementia: A Longitudinal Study. Frontiers in Neurology, 2021, 12, 695696.	1.1	24
1334	Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment. , 2022, 231, 107979.		26

#	Article	IF	CITATIONS
1335	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462.	5.0	18
1336	Replenishment of TCA cycle intermediates provides photoreceptor resilience against neurodegeneration during progression of retinitis pigmentosa. JCI Insight, 2021, 6, .	2.3	14
1337	Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review. Journal of Alzheimer's Disease, 2021, 84, 1-15.	1.2	6
1338	Diet enriched in omegaâ€3 fatty acids alleviates olfactory system deficits in APOE4 transgenic mice. European Journal of Neuroscience, 2021, 54, 7092-7108.	1.2	2
1339	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. Journal of Alzheimer's Disease, 2021, 83, 1367-1377.	1.2	0
1340	PTENα is responsible for protection of brain against oxidative stress during aging. FASEB Journal, 2021, 35, e21943.	0.2	4
1341	Kyphosis and bizarre patterns impair spontaneous gait performance in end-of-life mice with Alzheimer's disease pathology while gait is preserved in normal aging. Neuroscience Letters, 2022, 767, 136280.	1.0	3
1342	Salivary Lactoferrin Expression in a Mouse Model of Alzheimer's Disease. Frontiers in Immunology, 2021, 12, 749468.	2.2	9
1343	Amyloid toxicity in a Drosophila Alzheimer's model is ameliorated by autophagy activation. Neurobiology of Aging, 2021, 105, 137-147.	1.5	5
1344	A 3-Gene-Based Diagnostic Signature in Alzheimer's Disease. European Neurology, 2022, 85, 6-13.	0.6	7
1345	Non-Canonical Roles of Tau and Their Contribution to Synaptic Dysfunction. International Journal of Molecular Sciences, 2021, 22, 10145.	1.8	8
1346	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease. Frontiers in Pharmacology, 2021, 12, 748021.	1.6	13
1348	Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). European Journal of Medicinal Chemistry, 2021, 221, 113492.	2.6	37
1350	Keeping zombies alive: The ER-mitochondria Ca2+ transfer in cellular senescence. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 119099.	1.9	18
1351	Chronic agomelatine treatment alleviates icvA \hat{l}^2 -induced anxiety and depressive-like behavior through affecting A \hat{l}^2 metabolism in the hippocampus in a rat model of Alzheimer's disease. Physiology and Behavior, 2021, 239, 113525.	1.0	5
1352	Synthesis and evaluation of curcumin-based near-infrared fluorescent probes for the in vivo optical imaging of amyloid- \hat{l}^2 plaques. Bioorganic Chemistry, 2021, 115, 105167.	2.0	17
1353	Climate change and neurodegenerative diseases. Environmental Research, 2021, 201, 111511.	3.7	38
1354	Acoustic aggregation-induced separation for enhanced fluorescence detection of Alzheimer's biomarker. Talanta, 2021, 233, 122517.	2.9	17

#	Article	IF	CITATIONS
1355	DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model. Brain Research Bulletin, 2021, 175, 136-149.	1.4	6
1356	Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42. Neurobiology of Aging, 2021, 107, 42-52.	1.5	2
1357	The effect and underlying mechanisms of garlic extract against cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of experimental animal studies. Journal of Ethnopharmacology, 2021, 280, 114423.	2.0	14
1358	CircLPAR1/miR-212-3p/ZNF217 feedback loop promotes amyloid β-induced neuronal injury in Alzheimer's Disease. Brain Research, 2021, 1770, 147622.	1.1	21
1359	Chicoric acid encapsulated within ferritin inhibits tau phosphorylation by regulating AMPK and GluT1 signaling cascade. Journal of Functional Foods, 2021, 86, 104681.	1.6	8
1360	A mass spectrometric approach to study the interaction of amyloid \hat{l}^2 peptides with human \hat{l}_2 -2-macroglobulin. Biochimie, 2021, 191, 62-68.	1.3	4
1361	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2021, 108, 146-154.	1.5	6
1362	Ubiquinol Supplementation Improves Gender-Dependent Cerebral Vasoreactivity and Ameliorates Chronic Inflammation and Endothelial Dysfunction in Patients with Mild Cognitive Impairment. Antioxidants, 2021, 10, 143.	2.2	6
1363	Comparing CSF amyloidâ€beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12182.	1,2	26
1364	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12189.	1.8	15
1365	Eicosapentaenoic Acid Is Associated with Decreased Incidence of Alzheimer's Dementia in the Oldest Old. Nutrients, 2021, 13, 461.	1.7	18
1366	Peripheral Leukocytosis Predicts Cognitive Decline but Not Behavioral Disturbances: A Nationwide Study of Alzheimer's and Parkinson's Disease Patients. Dementia and Geriatric Cognitive Disorders, 2021, 50, 143-152.	0.7	6
1367	Intranasal insulin. Journal of Neuroendocrinology, 2021, 33, e12934.	1.2	44
1368	Alzheimer's Disease Diagnosis via Deep Factorization Machine Models. Lecture Notes in Computer Science, 2021, , 624-633.	1.0	2
1369	The Differential Influence of Immune, Endocytotic, and Lipid Metabolism Genes on Amyloid Deposition and Neurodegeneration in Subjects at Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 127-139.	1,2	8
1370	Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. Clinical Chemistry, 2021, 67, 1628-1639.	1.5	20
1371	Disrupted balance of long and short-range functional connectivity density in Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients: a resting-state fMRI study. Annals of Translational Medicine, 2021, 9, 65-65.	0.7	22
1372	Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. Journal of Personalized Medicine, 2021, 11, 47.	1.1	9

#	Article	IF	Citations
1373	The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-9.	1.5	115
1374	Deep brain stimulation in Alzheimer's disease. International Review of Neurobiology, 2021, 159, 69-87.	0.9	5
1375	Quantification of the Trans-Synaptic Partners Neuroligin-Neurexin in CSF of Neurodegenerative Diseases by Parallel Reaction Monitoring Mass Spectrometry. SSRN Electronic Journal, 0, , .	0.4	0
1376	Dutch Brain Research Registry for study participant recruitment: Design and first results. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12132.	1.8	23
1378	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimer's and Dementia, 2021, 17, 1365-1382.	0.4	43
1379	What patients want to know, and what we actually tell them: The ABIDE project. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12113.	1.8	9
1380	Epidemiology and Risk Factors of Alzheimer's Disease: A Focus on Diet. Neuromethods, 2018, , 15-42.	0.2	7
1381	Population-Based Approaches to Alzheimer's Disease Prevention. Methods in Molecular Biology, 2018, 1750, 15-29.	0.4	3
1382	Assessment of Competence in Older Adults. Handbooks in Health, Work, and Disability, 2018, , 433-459.	0.0	1
1383	DNA Methylation in Neuronal Development and Disease. RNA Technologies, 2019, , 103-140.	0.2	1
1384	Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline During Normal and Pathological Brain Aging. Advances in Experimental Medicine and Biology, 2020, 1260, 159-174.	0.8	28
1385	A Wide and Deep Neural Network for Survival Analysis from Anatomical Shape and Tabular Clinical Data. Communications in Computer and Information Science, 2020, , 453-464.	0.4	12
1386	Modulation of CNS Functions by Deep Brain Stimulation: Insights Provided byÂMolecular Imaging. , 2021, , 1177-1244.		3
1387	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
1388	Relation Between Cognitive Function and Baseline Concentrations of Hemoglobin in Prefrontal Cortex of Elderly People Measured by Time-Resolved Near-Infrared Spectroscopy. Advances in Experimental Medicine and Biology, 2017, 977, 269-276.	0.8	7
1389	Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment. , 2017, , 57-87.		3
1390	Iron Pathophysiology in Alzheimer's Diseases. Advances in Experimental Medicine and Biology, 2019, 1173, 67-104.	0.8	40
1391	The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease. Molecular Neurobiology, 2020, 57, 2959-2980.	1.9	180

#	Article	IF	CITATIONS
1392	Discovery and development of ASK1 inhibitors. Progress in Medicinal Chemistry, 2020, 59, 101-179.	4.1	17
1393	Transcriptional Signatures of Tau and Amyloid Neuropathology. Cell Reports, 2020, 30, 2040-2054.e5.	2.9	45
1394	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). Clinical Biochemistry, 2017, 50, 1061-1066.	0.8	16
1395	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. Journal of the American Medical Directors Association, 2020, 21, 1513.e1-1513.e17.	1.2	17
1396	Vascular cognitive impairment and dementia in type 2 diabetes mellitus: An overview. Life Sciences, 2020, 254, 117771.	2.0	46
1397	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurology, The, 2020, 19, 699-710.	4.9	96
1398	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. Brain Communications, 2020, 2, fcaa177.	1.5	10
1415	Mitochondrial TXN2 attenuates amyloidogenesis via selective inhibition of BACE1 expression. Journal of Neurochemistry, 2021, 157, 1351-1365.	2.1	7
1416	Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?. Journal of Investigative Medicine, 2020, 68, 1135-1140.	0.7	17
1417	NLRC3 Delays the Progression of AD in APP/PS1 Mice via Inhibiting PI3K Activation. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-14.	1.9	16
1418	Comprehensive analysis of PM20D1 QTL in Alzheimer's disease. Clinical Epigenetics, 2020, 12, 20.	1.8	16
1419	Combination of plasma amyloid beta $(1-42/1-40)$ and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	3.0	129
1420	Low Levels of Brain-Derived Neurotrophic Factor Trigger Self-aggregated Amyloid β-Induced Neuronal Cell Death in an Alzheimer's Cell Model. Biological and Pharmaceutical Bulletin, 2020, 43, 1073-1080.	0.6	18
1421	Pharmacological Targets and the Biological Mechanisms of Formononetin for Alzheimer's Disease: A Network Analysis. Medical Science Monitor, 2019, 25, 4273-4277.	0.5	31
1422	Haptoglobin Phenotype Among Arab Patients With Mental Disorders. Journal of Clinical Medicine Research, 2018, 10, 196-201.	0.6	1
1423	Lifestyle intervention to prevent Alzheimer's disease. Reviews in the Neurosciences, 2020, 31, 817-824.	1.4	16
1424	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Molecular Systems Biology, 2020, 16, e9356.	3.2	157
1425	The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology. Journal of Endocrinology, 2019, 240, R47-R72.	1.2	16

#	Article	IF	CITATIONS
1426	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. Revista Brasileira De Psiquiatria, 2020, 42, 431-441.	0.9	42
1427	Dietary interventions and cognition of Alzheimer's disease patients: a systematic review of randomized controlled trial. Dementia E Neuropsychologia, 2020, 14, 258-282.	0.3	14
1428	Current Trends in the Development of Drugs for the Treatment of Alzheimer's Disease and their Clinical Trials. Biomedical Chemistry Research and Methods, 2018, 1, e00015.	0.1	7
1429	Alzheimer's Disease, time to turn the tide. Aging, 2018, 10, 2537-2538.	1.4	10
1430	Genomic deletion of TLR2 induces aggravated white matter damage and deteriorated neurobehavioral functions in mouse models of Alzheimer's disease. Aging, 2019, 11, 7257-7273.	1.4	24
1431	Identification of molecular correlations of RBM8A with autophagy in Alzheimer's disease. Aging, 2019, 11, 11673-11685.	1.4	43
1432	The neuroprotective effects of SIRT1 in mice carrying the APP/PS1 double-transgenic mutation and in SH-SY5Y cells over-expressing human APP670/671 may involve elevated levels of $\hat{l}\pm7$ nicotinic acetylcholine receptors. Aging, 2020, 12, 1792-1807.	1.4	15
1433	ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice. Aging, 2020, 12, 14819-14829.	1.4	27
1434	High pulse pressure is a risk factor for prodromal Alzheimer's disease: a longitudinal study. Aging, 2020, 12, 18221-18237.	1.4	5
1435	Detecting potential causal relationship between multiple risk factors and Alzheimer's disease using multivariable Mendelian randomization. Aging, 2020, 12, 21747-21757.	1.4	6
1436	Molecular identification of protein kinase C beta in Alzheimer's disease. Aging, 2020, 12, 21798-21808.	1.4	8
1437	NEAT1 regulates microtubule stabilization via FZD3/GSK3β/P-tau pathway in SH-SY5Y cells and APP/PS1 mice. Aging, 2020, 12, 23233-23250.	1.4	15
1438	The associations between the <i>MAPT</i> polymorphisms and Alzheimer's disease risk: a meta-analysis. Oncotarget, 2017, 8, 43506-43520.	0.8	24
1439	Naoling decoction restores cognitive function by inhibiting the neuroinflammatory network in a rat model of Alzheimer's disease. Oncotarget, 2017, 8, 42648-42663.	0.8	19
1440	Aberrant pattern of regional cerebral blood flow in Alzheimer's disease: a voxel-wise meta-analysis of arterial spin labeling MR imaging studies. Oncotarget, 2017, 8, 93196-93208.	0.8	16
1441	Innate immune activation in Alzheimer's disease. Annals of Translational Medicine, 2018, 6, 177-177.	0.7	64
1442	Microglial priming in Alzheimer's disease. Annals of Translational Medicine, 2018, 6, 176-176.	0.7	75
1443	The role of UNC5C in Alzheimer's disease. Annals of Translational Medicine, 2018, 6, 178-178.	0.7	17

#	Article	IF	CITATIONS
1444	Determining association of rho kinase 1 gene polymorphisms with risk of Alzheimer's disease: a multicenter pilot study. Annals of Translational Medicine, 2018, 6, 434-434.	0.7	2
1445	Probable Novel PSEN1 Gln222Leu Mutation in a Chinese Family with Early-Onset Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 764-769.	0.7	2
1446	Integrated Genomic Analysis Revealed Associated Genes for Alzheimer's Disease in APOE4 Non-Carriers. Current Alzheimer Research, 2019, 16, 753-763.	0.7	9
1447	Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer's Diseases. Current Alzheimer Research, 2019, 16, 836-842.	0.7	11
1448	Biological Evaluation of 8-Hydroxyquinolines as Multi-Target Directed Ligands for Treating Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 801-814.	0.7	5
1449	Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies. Current Alzheimer Research, 2020, 17, 722-734.	0.7	12
1450	Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2020, 20, 1059-1073.	1.0	33
1451	YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease. Current Neuropharmacology, 2017, 15, 906-917.	1.4	58
1452	Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. Current Neuropharmacology, 2018, 16, 758-768.	1.4	12
1453	A Comprehensive Review of Alzheimer's Association with Related Proteins: Pathological Role and Therapeutic Significance. Current Neuropharmacology, 2020, 18, 674-695.	1.4	18
1454	Spirocyclohexadienones as an Uncommon Scaffold for Acetylcholinesterase Inhibitory Activity. Medicinal Chemistry, 2019, 15, 373-382.	0.7	6
1455	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. JMIR Formative Research, 2019, 3, e13417.	0.7	38
1456	Dementia and Traffic Accidents: A Danish Register-Based Cohort Study. JMIR Research Protocols, 2016, 5, e191.	0.5	7
1457	Dementia prevention and reserve against neurodegenerative disease. Dialogues in Clinical Neuroscience, 2019, 21, 53-60.	1.8	17
1458	Honokiol Alleviates Cognitive Deficits of Alzheimer's Disease (PS1V97L) Transgenic Mice by Activating Mitochondrial SIRT3. Journal of Alzheimer's Disease, 2018, 64, 291-302.	1.2	43
1459	Cognitive Reserve, Brain Reserve, APOE É>4, and Cognition in Individuals with Subjective Cognitive Decline in the SILCODE Study. Journal of Alzheimer's Disease, 2020, 76, 249-260.	1.2	9
1460	Therapeutic Angiogenesis with Sound Waves. Annals of Vascular Diseases, 2020, 13, 116-125.	0.2	16
1461	Turmeric Extract Supplementation Reduces Tau Protein Level in Repetitive Traumatic Brain Injury Model. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1953-1958.	0.1	3

#	Article	IF	CITATIONS
1462	miR‑199a decreases Neuritin expression involved inÂtheÂdevelopment of Alzheimer's disease in APP/PS1 mice. International Journal of Molecular Medicine, 2020, 46, 384-396.	1.8	12
1463	Long non-coding RNA ANRIL knockdown suppresses apoptosis and pro-inflammatory cytokines while enhancing neurite outgrowth via binding microRNA-125a in a cellular model of Alzheimer's disease. Molecular Medicine Reports, 2020, 22, 1489-1497.	1.1	39
1464	Association Between Atrial Fibrillation and the Risk of Dementia in the Korean Elderly: A 10-Year Nationwide Cohort Study. Journal of Preventive Medicine and Public Health, 2020, 53, 56-63.	0.7	6
1465	Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets. Neural Regeneration Research, 2017, 12, 914.	1.6	17
1466	Calycosin improves cognitive function in a transgenic mouse model of Alzheimer's disease by activating the protein kinase C pathway. Neural Regeneration Research, 2017, 12, 1870.	1.6	36
1467	Cognitive deficits and Alzheimer-like neuropathological impairments during adolescence in a rat model of type 2 diabetes mellitus. Neural Regeneration Research, 2018, 13, 1995.	1.6	18
1468	Partial improvement in performance of patients with severe Alzheimer's disease at an early stage of fornix deep brain stimulation. Neural Regeneration Research, 2018, 13, 2164.	1.6	20
1469	Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. Neural Regeneration Research, 2019, 14, 1643.	1.6	102
1470	Highlights of ASS234: a novel and promising therapeutic agent for Alzheimer's disease therapy. Neural Regeneration Research, 2020, 15, 30.	1.6	10
1471	Alzheimer's disease, neural stem cells and neurogenesis: cellular phase at single-cell level. Neural Regeneration Research, 2020, 15, 824.	1.6	29
1472	Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors. World Journal of Stem Cells, 2020, 12, 323-338.	1.3	32
1473	Mild TBI in the elderly – risk factor for rapid cognitive impairment in Alzheimer's disease. Romanian Journal of Morphology and Embryology, 2020, 61, 61-72.	0.4	6
1474	Emerging roles of 14-3-3 \hat{I}^3 in the brain disorder. BMB Reports, 2020, 53, 500-511.	1.1	20
1475	The Insomnia Plague in Fictional Macondo. , 2020, 24, .		1
1476	Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 2045-2054.	2.5	5
1477	An AÎ 2 3-10-KLH vaccine decreases AÎ 2 plaques and astrocytes and microglia activation in the brain of APP/PS1 transgenic mice. Acta Neurobiologiae Experimentalis, 2021, 81, 207-217.	0.4	0
1478	Nutraceuticals and Functional Foods in Aging and Aging-Associated Diseases. Healthy Ageing and Longevity, 2021, , 221-238.	0.2	2
1479	Safflower leaf ameliorates cognitive impairment through moderating excessive astrocyte activation in APP/PS1 mice. Food and Function, 2021, 12, 11704-11716.	2.1	5

#	Article	IF	CITATIONS
1480	Diretivas antecipadas de vontade em pacientes com doença de Alzheimer. Revista Bioetica, 2021, 29, 466-474.	0.0	1
1481	Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer's Disease Pathogenesis. Molecular Biology, 2021, 55, 670-682.	0.4	10
1482	Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer's disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis. BMC Complementary Medicine and Therapies, 2021, 21, 259.	1.2	20
1483	Long Non-coding RNAs and Circular RNAs: Insights Into Microglia and Astrocyte Mediated Neurological Diseases. Frontiers in Molecular Neuroscience, 2021, 14, 745066.	1.4	53
1484	Prolonged Volatile Anesthetic Exposure Exacerbates Cognitive Impairment and Neuropathology in the 5xFAD Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, , 1-12.	1.2	2
1485	Altered Volume and Structural Connectivity of the Hippocampus in Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 705030.	1.7	9
1486	Altered intrinsic default mode network functional connectivity in patients with remitted geriatric depression and amnestic mild cognitive impairment. International Psychogeriatrics, 2022, 34, 703-714.	0.6	6
1487	The promise of exosome applications in treating central nervous system diseases. CNS Neuroscience and Therapeutics, 2021, 27, 1437-1445.	1.9	7
1488	Restoration of Calmodulin-Like Skin Protein as Treatment for Alzheimer's Disease. Frontiers in Neurology, 2021, 12, 771856.	1.1	0
1489	Tau Pathology in Neurodegenerative Diseases. Neuromethods, 2022, , 71-97.	0.2	1
1490	Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 738971.	1.7	16
1491	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. Scientific Reports, 2021, 11, 20375.	1.6	9
1492	MicroRNAs as Potential Orchestrators of Alzheimer's Disease-Related Pathologies: Insights on Current Status and Future Possibilities. Frontiers in Aging Neuroscience, 2021, 13, 743573.	1.7	24
1493	Inhibition of Rho Kinase by Fasudil Ameliorates Cognition Impairment in APP/PS1 Transgenic Mice via Modulation of Gut Microbiota and Metabolites. Frontiers in Aging Neuroscience, 2021, 13, 755164.	1.7	19
1494	Preface: Mass spectrometry in Alzheimer disease. Journal of Neurochemistry, 2021, 159, 207-210.	2.1	1
1495	Heterogeneity and Molecular Markers for CNS Glial Cells Revealed by Single-Cell Transcriptomics. Cellular and Molecular Neurobiology, 2022, 42, 2629-2642.	1.7	18
1496	Sex-Stratified Single-Cell RNA-Seq Analysis Identifies Sex-Specific and Cell Type-Specific Transcriptional Responses in Alzheimer's Disease Across Two Brain Regions. Molecular Neurobiology, 2022, 59, 276-293.	1.9	21
1497	Design and synthesis of novel tacrine-dipicolylamine dimers that are multiple-target-directed ligands with potential to treat Alzheimer's disease. Bioorganic Chemistry, 2021, 116, 105387.	2.0	10

#	Article	IF	CITATIONS
1498	Aggregation and structure of amyloid \hat{l}^2 -protein. Neurochemistry International, 2021, 151, 105208.	1.9	19
1499	MicroRNA-455–5p/CPEB1 pathway mediates Aβ-related learning and memory deficits in a mouse model of Alzheimer's disease. Brain Research Bulletin, 2021, 177, 282-294.	1.4	13
1500	Antidementiva., 2016,, 293-299.		0
1501	Neuropsychiatric Symptoms in Cognitive Impairment and Dementia: A Brief Introductory Overview. Neuropsychiatric Symptoms of Neurological Disease, 2017, , 1-7.	0.3	O
1502	Antidementiva., 2017,, 291-297.		0
1504	Editorial. Functional Neurology, 2017, 37, 117.	1.3	О
1505	Alzheimer Disease., 2017,,.		0
1506	Adaptive Behavior Change, Mild Cognitive Impairment and Dementia in Down Syndrome: Case Classification Using the Adaptive Behavior Scale., 2018,, 99-122.		O
1508	Traitement de la maladie d'Alzheimer. , 2018, , 627-635.e1.		0
1509	Biomarqueurs du liquide cérébrospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
1510	Antidementiva. , 2018, , 345-352.		0
1511	Alzheimerio ligos gydymo metodų paieška: klinikinių tyrimų kryptys. Neurologijos Seminarai, 2018, 22, 21-30.	0.0	O
1515	Antidementiva., 2019,, 461-469.		0
1517	Organische (und symptomatische) psychische Störungen. , 2019, , 187-246.e3.		1
1518	Transcriptional Signatures of Progressive Neuropathology in Transgenic Models of Tau and Amyloid Pathology. SSRN Electronic Journal, 0, , .	0.4	0
1519	<i>Cindr</i> , the <i>Drosophila</i> Homolog of the <i>CD2AP</i> Alzheimer's Disease Susceptibility Gene, is Required for Synaptic Transmission and Proteostasis. SSRN Electronic Journal, 0, , .	0.4	1
1520	Results (2): Estimates of Diagnostic Accuracy. , 2019, , 109-148.		0
1521	The Whole Picture: From Isolated to Global MRI Measures of Neurovascular and Neurodegenerative Disease. Advances in Experimental Medicine and Biology, 2019, 1205, 25-53.	0.8	1

#	Article	IF	CITATIONS
1526	Evaluation of Nootropic Activity of Spinacia oleracea in Scopolamine Induced Cognitive Decline Mice. Research Journal of Medicinal Plant, 2019, 13, 155-161.	0.3	0
1530	Effects of Treadmill Running on Oxidative Stress and Heat Shock Protein in Early Stage of 3xTg-AD Mice. Exercise Science, 2019, 28, 381-387.	0.1	0
1531	Emerging Perspectives on DNA Double-strand Breaks in Neurodegenerative Diseases. Current Neuropharmacology, 2019, 17, 1146-1157.	1.4	15
1533	Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer's Disease. , 0, , 123-145.		0
1539	A novel variant c.3706C>T p.(Avg 1236Cys) in the <i>ABCA7</i> gene in a Saudi patient with susceptibility to Alzheimer's disease 9. Intractable and Rare Diseases Research, 2020, 9, 151-155.	0.3	1
1540	The meaning of blood and cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease. Journal of Education, Health and Sport, 2020, 10, 308.	0.0	1
1541	Studying Lipid-Related Pathophysiology Using the Yeast Model. Frontiers in Physiology, 2021, 12, 768411.	1.3	3
1543	Identification of the function and mechanism of m6A reader IGF2BP2 in Alzheimer's disease. Aging, 2021, 13, 24086-24100.	1.4	30
1544	Role of Retinoid X Receptors (RXRs) and dietary vitamin A in Alzheimer's disease: Evidence from clinicopathological and preclinical studies. Neurobiology of Disease, 2021, 161, 105542.	2.1	9
1545	Coenzyme Q and Age-Related Neurodegenerative Disorders: Parkinson and Alzheimer Diseases. , 2020, , 241-268.		0
1546	Beyond the Obvious: Smoking and Respiratory Infection Implications on Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 698-708.	0.8	10
1547	A novel paradigm for assessing olfactory working memory capacity in mice. Translational Psychiatry, 2020, 10, 431.	2.4	4
1548	Estrogen receptor \hat{l}_{\pm} polymorphism is associated with dementia in a Brazilian cohort. Oncotarget, 2020, 11, 4655-4660.	0.8	0
1549	Spicy food consumption is associated with cognition and cerebrospinal fluid biomarkers of Alzheimer disease. Chinese Medical Journal, 2021, 134, 173-177.	0.9	9
1551	Current and Future of Alzheimer's Therapy with the Best Approach. CNS and Neurological Disorders - Drug Targets, 2020, 19, 691-697.	0.8	0
1553	PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes. Environmental Pollution, 2022, 292, 118320.	3.7	52
1554	Humanin and Alzheimer's disease: The beginning of a new field. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130024.	1.1	9
1556	Butyrylcholinesterase as a biomarker in Alzheimer's disease. , 2020, , 263-280.		1

#	Article	IF	CITATIONS
1557	A Complex Containing HNRNPA2B1 and N ⁶ -Methyladenosine Modified Transcripts Mediates Actions of Toxic Tau Oligomers. SSRN Electronic Journal, 0, , .	0.4	0
1558	Antidementiva. , 2020, , 377-382.		0
1559	Alzheimer's disease and other neurocognitive disorders. , 2020, , 161-183.		0
1561	Salivary Biomarkers and Neurodegenerative Conditions. , 2020, , 263-286.		2
1563	Intrinsic antiviral immunity drives neurodegeneration in Alzheimer disease. Journal of Clinical Investigation, 2020, 130, 1622-1624.	3.9	3
1564	Small-Sized Co-Polymers for Targeted Delivery of Multiple Imaging and Therapeutic Agents. Nanomaterials, 2021, 11, 2996.	1.9	5
1565	A functional variant of SHARPIN confers increased risk of late-onset Alzheimer's disease. Journal of Human Genetics, 2022, 67, 203-208.	1.1	8
1566	Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. American Journal of Psychiatry, 2021, 178, 1014-1025.	4.0	11
1567	Burden and correlates of cognitive impairment among hypertensive patients in Tanzania: a cross-sectional study. BMC Neurology, 2021, 21, 433.	0.8	4
1568	Integrated Positron Emission Tomography/Magnetic Resonance Imaging in clinical diagnosis of Alzheimer's disease. European Journal of Radiology, 2021, 145, 110017.	1.2	14
1569	Peptoid Nanosheet-Based Sensing System for the Diagnosis and Surveillance of Amnestic Mild Cognitive Impairment and Alzheimer's Disease. ACS Chemical Neuroscience, 2021, 12, 4257-4264.	1.7	5
1571	Care for patients with dementia. Profese Online, 2020, 13, 1-5.	0.1	0
1574	Brain FDG PET for the Etiological Diagnosis of Clinically Uncertain Cognitive Impairment During Delirium in Remission. Journal of Alzheimer's Disease, 2020, 77, 1609-1622.	1.2	2
1577	The association of clinical phenotypes to known AD/FTD genetic risk loci and their inter-relationship. PLoS ONE, 2020, 15, e0241552.	1.1	7
1578	Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease. American Journal of Translational Research (discontinued), 2017, 9, 184-196.	0.0	14
1579	Accuracy of Quantitative Positron Emission Tomography Assessment for Differentiating Cerebral Age-related from Pathological Amyloid Deposition: A Preliminary Report from a Case-series Study. World Journal of Nuclear Medicine, 2018, 17, 106-111.	0.3	2
1580	SQYZ granules, a traditional Chinese herbal, attenuate cognitive deficits in AD transgenic mice by modulating on multiple pathogenesis processes. American Journal of Translational Research (discontinued), 2018, 10, 3857-3875.	0.0	5
1581	Increased Levels of Protein-methionine Sulfoxide in Plasma Correlate with a Shift from a Mild Cognitive Impairment to an Alzheimer's Disease Stage. Innovations in Clinical Neuroscience, 2019, 16, 29-31.	0.1	4

#	Article	IF	CITATIONS
1582	miR-26b inhibits total neurite outgrowth, promotes cells apoptosis and downregulates neprilysin in Alzheimer's disease. International Journal of Clinical and Experimental Pathology, 2018, 11, 3383-3390.	0.5	6
1583	Long noncoding RNA MALAT1 and its target microRNA-125b are potential biomarkers for Alzheimer's disease management via interactions with FOXQ1, PTGS2 and CDK5. American Journal of Translational Research (discontinued), 2020, 12, 5940-5954.	0.0	9
1584	Detection of presymptomatic Alzheimer's disease through breath biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12088.	1.2	0
1585	Preventive electroacupuncture ameliorates D-galactose-induced Alzheimer's disease-like inflammation and memory deficits, probably via modulating the microbiota-gut-brain axis. Iranian Journal of Basic Medical Sciences, 2021, 24, 341-348.	1.0	1
1586	Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid \hat{l}^2 and Tau Protein. Medical Science Monitor, 2021, 27, e934077.	0.5	1
1587	Antioxidant diets and functional foods attenuate dementia and cognition in elderly subjects. , 2022, , 533-549.		4
1588	Aptamer-nanoconjugates as emerging theranostic systems in neurodegenerative disorders. Colloids and Interface Science Communications, 2022, 46, 100554.	2.0	4
1589	The role of modified Mediterranean neuroprotective diet on emotion, cognition, and depression. , 2022, , 551-579.		0
1590	Inescapable footshocks induce molecular changes in the prefrontal cortex of rats in an amyloid-beta-42 model of Alzheimer's disease. Behavioural Brain Research, 2022, 419, 113679.	1.2	0
1591	Ethanol Alleviates Amyloid-β-Induced Toxicity in an Alzheimer's Disease Model of Caenorhabiditis elegans. Frontiers in Aging Neuroscience, 2021, 13, 762659.	1.7	6
1592	How non-rapid eye movement sleep and Alzheimer pathology are linked. World Journal of Psychiatry, 2021, 11, 1027-1038.	1.3	4
1593	A metabolite panel that differentiates Alzheimer's disease from other dementia types. Alzheimer's and Dementia, 2022, 18, 1345-1356.	0.4	20
1594	A whole-process interpretable and multi-modal deep reinforcement learning for diagnosis and analysis of Alzheimer's disease ^{â^—} . Journal of Neural Engineering, 2021, 18, 066032.	1.8	14
1595	PEG-PEI/siROCK2 inhibits A \hat{l}^2 42-induced microglial inflammation via NLRP3/caspase 1 pathway. NeuroReport, 2022, 33, 26-32.	0.6	8
1596	Alzheimer's Disease and Type 2 Diabetes Mellitus: The Use of MCT Oil and a Ketogenic Diet. International Journal of Molecular Sciences, 2021, 22, 12310.	1.8	16
1597	Proliferation of Tau 304–380 Fragment Aggregates through Autocatalytic Secondary Nucleation. ACS Chemical Neuroscience, 2021, 12, 4406-4415.	1.7	19
1598	Presenilin is involved in larvalâ€pupal metamorphosis development of Bombyx mori. Archives of Insect Biochemistry and Physiology, 2021, , e21855.	0.6	1
1599	Bilberry/red grape juice decreases plasma biomarkers of inflammation and tissue damage in aged men with subjective memory impairment –a randomized clinical trial. BMC Nutrition, 2021, 7, 75.	0.6	6

#	ARTICLE	IF	CITATIONS
1600	The Combination of β-Asarone and Icariin Inhibits Amyloid-β and Reverses Cognitive Deficits by Promoting Mitophagy in Models of Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-20.	1.9	22
1601	Effect of N-methyl-d-aspartate receptor enhancing agents on cognition in dementia: an exploratory systematic review and meta-analysis of randomized controlled trials. Scientific Reports, 2021, 11, 22996.	1.6	2
1602	A mechanistic survey of Alzheimer's disease. Biophysical Chemistry, 2022, 281, 106735.	1.5	34
1603	Dimethyl Fumarate is a Potential Therapeutic Option for Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 443-456.	1.2	15
1604	The Amaryllidaceae alkaloids: an untapped source of acetylcholinesterase inhibitors. Phytochemistry Reviews, 2022, 21, 1415-1443.	3.1	6
1605	Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: mediation by amyloid pathology. Translational Psychiatry, 2021, 11, 577.	2.4	11
1606	Anatomically Standardized Detection of MRI Atrophy Patterns in Early-Stage Alzheimer's Disease. Brain Sciences, 2021, 11, 1491.	1.1	5
1607	Risk factors for subjective cognitive decline: the CABLE study. Translational Psychiatry, 2021, 11, 576.	2.4	15
1608	Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2021, 22, 12470.	1.8	1
1609	Integrative genomic analysis of PPP3R1 in Alzheimer's disease: a potential biomarker for predictive, preventive, and personalized medical approach. EPMA Journal, 2021, 12, 647-658.	3.3	2
1610	Hypothesis: Modulation of microglial phenotype in Alzheimer's disease drives neurodegeneration. Alzheimer's and Dementia, 2021, , .	0.4	2
1611	Association Between Serum Vitamins and the Risk of Alzheimer's Disease in Chinese Population. Journal of Alzheimer's Disease, 2022, 85, 829-836.	1.2	11
1613	Association between Vitamin B1 and Dementia Caused by Different Etiologies in Elderly Adults: A Cross-Sectional Study. SSRN Electronic Journal, 0, , .	0.4	0
1614	Glycosaminoglycans in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 2021, 1325, 189-204.	0.8	7
1615	Neurodegeneration/Demenz., 2021, , 200-208.		0
1616	Antidementiva. , 2021, , 231-239.		1
1617	Presenilin Is Essential for ApoE Secretion, a Novel Role of Presenilin Involved in Alzheimer's Disease Pathogenesis. Journal of Neuroscience, 2022, 42, 1574-1586.	1.7	8
1618	A fragment of cell adhesion molecule L1 reduces amyloid-β plaques in a mouse model of Alzheimer's disease. Cell Death and Disease, 2022, 13, 48.	2.7	16

#	Article	IF	CITATIONS
1619	The role of Alzheimer's disease risk genes in endolysosomal pathways. Neurobiology of Disease, 2022, 162, 105576.	2.1	27
1620	Design, synthesis and biological evaluation of novel pyrazolone derivatives as selective butyrylcholinesterase inhibitors with antioxidant activity against Alzheimer's disease. Journal of Molecular Structure, 2022, 1254, 132319.	1.8	3
1621	Combined Structural MR and Diffusion Tensor Imaging Classify the Presence of Alzheimer's Disease With the Same Performance as MR Combined With Amyloid Positron Emission Tomography: A Data Integration Approach. Frontiers in Neuroscience, 2021, 15, 638175.	1.4	5
1622	Serum neurofilament light chain level as a predictor of cognitive stage transition. Alzheimer's Research and Therapy, 2022, 14, 6.	3.0	19
1623	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	2.7	4
1624	Primary cilia and ciliary signaling pathways in aging and age-related brain disorders. Neurobiology of Disease, 2022, 163, 105607.	2.1	41
1625	Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention. Ageing Research Reviews, 2022, 74, 101544.	5.0	60
1626	Accuracy of quantitative positron emission tomography assessment for differentiating cerebral age-related from pathological amyloid deposition: A preliminary report from a case-series study. World Journal of Nuclear Medicine, 2018, 17, 106.	0.3	4
1627	Current Paradigms to Explore the Gut Microbiota Linkage to Neurological Disorders. European Medical Journal Neurology, 0, , 68-79.	0.0	0
1628	Geniposidic Acid Confers Neuroprotective Effects in a Mouse Model of Alzheimer's Disease through Activation of a PI3K/AKT/GAP43 Regulatory Axis. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-14.	1.5	3
1629	Selenium Neuroprotection in Neurodegenerative Disorders. , 2021, , 1-35.		2
1630	Biomarkers and Precision Medicine in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2021, 1339, 403-408.	0.8	3
1631	The Relationship Between Funcation Connectivity and Amyloid Accumulation in AD Continuum. , 2021, , .		0
1632	Treatment Combining Focused Ultrasound with Gastrodin Alleviates Memory Deficit and Neuropathology in an Alzheimer's Disease-Like Experimental Mouse Model. Neural Plasticity, 2022, 2022, 1-13.	1.0	15
1633	Modeling and Targeting Neuroglial Interactions with Human Pluripotent Stem Cell Models. International Journal of Molecular Sciences, 2022, 23, 1684.	1.8	6
1634	Plasma protein biomarker model for screening Alzheimer disease using multiple reaction monitoring-mass spectrometry. Scientific Reports, 2022, 12, 1282.	1.6	8
1635	Pulsed Arterial Spin Labeling and Segmented Brain Volumetry in the Diagnostic Evaluation of Frontotemporal Dementia, Alzheimer's Disease and Mild Cognitive Impairment. Tomography, 2022, 8, 229-244.	0.8	4
1636	A Comparison of Caregiver Burden for Different Types of Dementia: An 18-Month Retrospective Cohort Study. Frontiers in Psychology, 2021, 12, 798315.	1.1	7

#	Article	IF	CITATIONS
1637	Circ_0003611 acts as a miR-885-5p sponge to aggravate the amyloid-β-induced neuronal injury in Alzheimer's disease. Metabolic Brain Disease, 2022, 37, 961-971.	1.4	5
1638	Memory related molecular signatures: The pivots for memory consolidation and Alzheimer's related memory decline. Ageing Research Reviews, 2022, 76, 101577.	5.0	15
1639	Prevalence and Associated Risk Factors of Cognitive Frailty: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 755926.	1.7	34
1640	Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential. Acta Pharmaceutica Sinica B, 2022, 12, 1019-1040.	5.7	56
1641	Establishing a competing endogenous RNA (ceRNA)-immunoregulatory network associated with the progression of Alzheimer's disease. Annals of Translational Medicine, 2022, 10, 65-65.	0.7	5
1642	Bezafibrate Exerts Neuroprotective Effects in a Rat Model of Sporadic Alzheimer's Disease. Pharmaceuticals, 2022, 15, 109.	1.7	10
1643	Progress in the development of naturally derived active metabolitesâ€based drugs: Potential therapeutics for Alzheimer's disease. Biotechnology and Applied Biochemistry, 2022, 69, 2713-2732.	1.4	4
1644	Necrostatin-1 Relieves Learning and Memory Deficits in a Zebrafish Model of Alzheimer's Disease Induced by Aluminum. Neurotoxicity Research, 2022, 40, 198-214.	1.3	14
1645	Interaction between TRPML1 and p62 in Regulating Autophagosome-Lysosome Fusion and Impeding Neuroaxonal Dystrophy in Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-20.	1.9	1
1646	Inhibitory Mechanism of Baicalein on Acetylcholinesterase: Inhibitory Interaction, Conformational Change, and Computational Simulation. Foods, 2022, 11, 168.	1.9	13
1647	Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2163-2173.	3.3	20
1648	Asparagine endopeptidase-targeted Ultrasound-responsive Nanobubbles Alleviate Tau Cleavage and Amyloid-Î ² Deposition in an Alzheimer's Disease Model. Acta Biomaterialia, 2022, 141, 388-397.	4.1	15
1649	A molecular view of human amyloid-β folds. Science, 2022, 375, 147-148.	6.0	7
1650	Agomelatine Prevents Amyloid Plaque Deposition, Tau Phosphorylation, and Neuroinflammation in APP/PS1 Mice. Frontiers in Aging Neuroscience, 2021, 13, 766410.	1.7	5
1651	Unexpected BrdU inhibition on astrocyte-to-neuron conversion. Neural Regeneration Research, 2022, 17, 1526.	1.6	7
1652	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimerâ∈™s Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	1.2	5
1653	Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease. Frontiers in Molecular Neuroscience, 2021, 14, 821002.	1.4	10
1654	The Protective Role of Scoparia Dulcis Linn. in Alzheimer's Disease. Trends in Sciences, 2022, 19, 2050.	0.2	1

#	Article	IF	CITATIONS
1655	A Growing Link between Circadian Rhythms, Type 2 Diabetes Mellitus and Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 504.	1.8	22
1656	Distance-based \hat{l}^2 -amyloid protein detection on PADs for the scanning and subsequent follow-up of Alzheimer's disease in human urine samples. Analyst, The, 2022, 147, 695-703.	1.7	9
1657	Research on Frequent Itemset Mining of Imaging Genetics GWAS in Alzheimer's Disease. Genes, 2022, 13, 176.	1.0	1
1658	Oligodendrocytes and myelin: Active players in neurodegenerative brains?. Developmental Neurobiology, 2022, 82, 160-174.	1.5	17
1659	Qualitative Assessment of Perfusion Maps Derived from Pulsed Arterial Spin Labeling Magnetic Resonance Imaging (PASL MRI) in Patients with Cognitive Disorders. Iranian Journal of Radiology, 2022, 19, .	0.1	0
1660	A direct interaction between RhoGDIα/Tau alleviates hyperphosphorylation of Tau in Alzheimer's disease and vascular dementia. Journal of NeuroImmune Pharmacology, 2023, 18, 58-71.	2.1	4
1661	Traditional East Asian Herbal Medicine Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2022, 15, 174.	1.7	7
1662	Alzheimer's disease susceptibility locus in CD2AP is associated with increased cerebrospinal fluid tau levels in mild cognitive impairment. Neuroscience Letters, 2022, 771, 136419.	1.0	3
1663	Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2022, 85, 1143-1151.	1.2	7
1664	Integrated Bioinformatics Analysis Identifies Hub Genes Associated with Viral Infection and Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 1053-1061.	1.2	8
1665	High Level Forebrain Expression of Active Tau Kinase p38γ Exacerbates Cognitive Dysfunction in Aged APP-transgenic Alzheimer's Mice. Neuroscience, 2022, 484, 53-65.	1.1	1
1666	Paving the way for reliable Alzheimer's disease blood diagnosis by quadruple electrochemical immunosensing. ChemElectroChem, 0, , .	1.7	2
1667	Potential prevention and treatment of neurodegenerative disorders by olive polyphenols and hidrox. Mechanisms of Ageing and Development, 2022, 203, 111637.	2.2	11
1668	Integrated lipidomics and network pharmacology analysis of the protective effects and mechanism of Yuanzhi San on rats with cognitive impairment. Bioorganic and Medicinal Chemistry, 2022, 58, 116651.	1.4	5
1669	Passion fruit seed extract protects betaâ€amyloidâ€induced neuronal cell death in a differentiated human neuroblastoma SHâ€SY5Y cell model. Food Science and Nutrition, 2022, 10, 1461-1468.	1.5	8
1670	Nitric oxide impairs spatial learning and memory in a rat model of Alzheimer's disease via disturbance of glutamate response in the hippocampal dentate gyrus during spatial learning. Behavioural Brain Research, 2022, 422, 113750.	1.2	9
1671	Amyloid \hat{l}^2 interaction with model cell membranes $\hat{a} \in What$ are the toxicity-defining properties of amyloid \hat{l}^2 ?. International Journal of Biological Macromolecules, 2022, 200, 520-531.	3.6	19
1672	Exploring the dual character of metformin in Alzheimer's disease. Neuropharmacology, 2022, 207, 108966.	2.0	10

#	Article	IF	CITATIONS
1673	Novel magnetic beads with improved performance for Alzheimer's disease biomarker detection. Microchemical Journal, 2022, 175, 107211.	2.3	6
1674	Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease. Nano Today, 2022, 43, 101388.	6.2	15
1675	Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognition. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130097.	1.1	9
1676	Evaluation of Hippeastrum papilio (Ravenna) Van Scheepen potencial as a new industrial source of galanthamine. Industrial Crops and Products, 2022, 178, 114619.	2.5	4
1677	Identification of subjective cognitive decline due to Alzheimer's disease using multimodal MRI combining with machine learning. Cerebral Cortex, 2023, 33, 557-566.	1.6	11
1678	Portable electrochemical micro-workstation platform for simultaneous detection of multiple Alzheimer's disease biomarkers. Mikrochimica Acta, 2022, 189, 91.	2.5	19
1679	The clock modulator Nobiletin mitigates astrogliosisâ€associated neuroinflammation and disease hallmarks in an Alzheimer's disease model. FASEB Journal, 2022, 36, e22186.	0.2	23
1680	Reduced Peripheral Nerve Conduction Velocity is Associated with Alzheimer's Disease: A Cross-Sectional Study from China. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 231-242.	1.0	3
1681	Feasibility and Validity of Cambridge Neuropsychological Test Automated Battery in Mild Cognitive Impairment Screening for Patients with Atrial Fibrillation. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-8.	0.7	1
1682	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics. Frontiers in Neurology, 2022, 13, 826423.	1.1	7
1683	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	2.7	65
1684	Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection. Acta Pharmaceutica Sinica B, 2022, 12, 1987-1999.	5.7	35
1685	Integrative Metabolomic Characterization Reveals the Mediating Effect of Bifidobacterium breve on Amino Acid Metabolism in a Mouse Model of Alzheimer's Disease. Nutrients, 2022, 14, 735.	1.7	18
1686	Association of peripheral immunity with cognition, neuroimaging, and Alzheimer's pathology. Alzheimer's Research and Therapy, 2022, 14, 29.	3.0	17
1687	Recent Advances in the Application Peptide and Peptoid in Diagnosis Biomarkers of Alzheimer's Disease in Blood. Frontiers in Molecular Neuroscience, 2021, 14, 778955.	1.4	4
1688	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	3.0	87
1689	Advances in the discovery of genetic risk factors for complex forms of neurodegenerative disorders: contemporary approaches, success, challenges and prospects. Journal of Genetics, 2018, 97, 625-648.	0.4	1
1690	3-D CNN-Based Multichannel Contrastive Learning for Alzheimer's Disease Automatic Diagnosis. IEEE Transactions on Instrumentation and Measurement, 2022, 71, 1-11.	2.4	6

#	Article	IF	CITATIONS
1691	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12295.	1.2	11
1692	New Perspectives for Treatment in Alzheimer's Disease. , 2022, , 199-225.		0
1693	Beyond Seizure Control: Treating Comorbidities in Epilepsy via Targeting of the P2X7 Receptor. International Journal of Molecular Sciences, 2022, 23, 2380.	1.8	10
1694	Mitochondrial Targeting of Amyloid-β Protein Precursor Intracellular Domain Induces Hippocampal Cell Death via a Mechanism Distinct from Amyloid-β. Journal of Alzheimer's Disease, 2022, 86, 1727-1744.	1.2	5
1695	Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD. Alzheimer's Research and Therapy, 2022, 14, 37.	3.0	12
1696	Ventricular Infusion and Nanoprobes Identify Cerebrospinal Fluid and Glymphatic Circulation in Human Nerves. Plastic and Reconstructive Surgery - Global Open, 2022, 10, e4126.	0.3	3
1697	Genetic, clinical, and biochemical aspects of patients with Alzheimer disease. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022, 58, .	0.4	2
1698	The China Alzheimer Report 2022. Annals of General Psychiatry, 2022, 35, e100751.	1.1	79
1699	Combination of gut microbiota and plasma amyloid- \hat{l}^2 as a potential index for identifying preclinical Alzheimer $\hat{a} \in \mathbb{T}$ s disease: a cross-sectional analysis from the SILCODE study. Alzheimer's Research and Therapy, 2022, 14, 35.	3.0	22
1700	Prevalence of dementia and mild cognitive impairment before incarceration. Journal of the American Geriatrics Society, 2022, 70, 1792-1799.	1.3	4
1701	Genetic and Molecular Evaluation of SQSTM1/p62 on the Neuropathologies of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, 829232.	1.7	7
1702	A human tau seeded neuronal cell model recapitulates molecular responses associated with Alzheimer's disease. Scientific Reports, 2022, 12, 2673.	1.6	4
1703	BG-3DM2F: Bidirectional gated 3D multi-scale feature fusion for Alzheimer's disease diagnosis. Multimedia Tools and Applications, 2022, 81, 10743-10776.	2.6	17
1704	The Humanistic and Economic Burden of Alzheimer's Disease. Neurology and Therapy, 2022, 11, 525-551.	1.4	41
1705	Association Between Common Variants of APOE, ABCA7, A2M, BACE1, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: Data from the PUMCH Dementia Cohort. Journal of Alzheimer's Disease, 2022, 85, 1511-1518.	1.2	3
1706	Administration of miR-195 Inhibitor Enhances Memory Function Through Improving Synaptic Degradation and Mitochondrial Dysfunction of the Hippocampal Neurons in SAMP8 Mice. Journal of Alzheimer's Disease, 2022, 85, 1495-1509.	1.2	3
1707	Agaricus Mushroom-Enriched Diets Modulate the Microbiota-Gut-Brain Axis and Reduce Brain Oxidative Stress in Mice. Antioxidants, 2022, 11, 695.	2.2	6
1708	Alzheimer's Disease: Epidemiology and Clinical Progression. Neurology and Therapy, 2022, 11, 553-569.	1.4	113

#	Article	IF	CITATIONS
1709	Capgras Syndrome as the Core Manifestation of Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-6.	1.2	0
1710	Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer's disease:a systematic review with meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 513-520.	0.9	10
1711	Simultaneous Alteration of the Circadian Variation of Memory, Hippocampal Synaptic Plasticity, and Metabolism in a Triple Transgenic Mouse Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, 835885.	1.7	4
1712	Mechanisms of Acupuncture in Improving Alzheimer's Disease Caused by Mitochondrial Damage. Chinese Journal of Integrative Medicine, 2022, 28, 272-280.	0.7	4
1713	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. , 2022, , 1-24.		2
1714	A prospective multicenter validation study of a machine learning algorithm classifier on quantitative electroencephalogram for differentiating between dementia with Lewy bodies and Alzheimer's dementia. PLoS ONE, 2022, 17, e0265484.	1.1	0
1715	Pharmacotherapeutic combinations for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2022, 23, 727-737.	0.9	6
1716	Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades. Journal of Medicinal Chemistry, 2022, 65, 4727-4751.	2.9	10
1717	Smart-Data-Driven System for Alzheimer Disease Detection through Electroencephalographic Signals. Bioengineering, 2022, 9, 141.	1.6	14
1718	Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimer's Disease Therapy. Nano Letters, 2022, 22, 2450-2460.	4.5	22
1720	Visuoâ€spatial learning and memory impairments in the 5xFAD mouse model of Alzheimer's disease: Effects of age, sex, albinism, and motor impairments. Genes, Brain and Behavior, 2022, 21, e12794.	1.1	21
1721	Metal-Organic Framework Based Drug Delivery for Alzheimer Therapy and Clinical Progress. Mini-Reviews in Organic Chemistry, 2022, 19, .	0.6	0
1722	Amelioration of Experimental Autoimmune Encephalomyelitis in Alzheimer's Disease Mouse Models: A Potential Role for Aβ. Cells, 2022, 11, 1004.	1.8	1
1723	Cerebrospinal fluid biomarkers and genetic factors associated with normal pressure hydrocephalus and Alzheimer's disease: a narrative review. Egyptian Journal of Medical Human Genetics, 2022, 23, .	0.5	0
1724	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age. Frontiers in Aging Neuroscience, 2022, 14, 811146.	1.7	5
1726	Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer's Disease. Molecular Neurobiology, 2022, 59, 3512-3528.	1.9	15
1727	Five Major Psychiatric Disorders and Alzheimer's Disease: A Bidirectional Mendelian Randomization Study. Journal of Alzheimer's Disease, 2022, 87, 675-684.	1.2	6
1728	Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Neurology, 2022, 269, 4270-4280.	1.8	30

#	Article	lF	Citations
1729	Investigating Causal Relations Between Circulating Metabolites and Alzheimer's Disease: A Mendelian Randomization Study. Journal of Alzheimer's Disease, 2022, 87, 463-477.	1.2	10
1730	Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study. Health and Quality of Life Outcomes, 2022, 20, 47.	1.0	4
1731	Molecular Signatures of Mitochondrial Complexes Involved in Alzheimer's Disease via Oxidative Phosphorylation and Retrograde Endocannabinoid Signaling Pathways. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-12.	1.9	5
1732	New Paradigm in Cell Therapy Using Sperm Head to Restore Brain Function and Structure in Animal Model of Alzheimer's Disease: Support for Boosting Constructive Inflammation vs. Anti-Inflammatory Approach. Journal of Immunology Research, 2022, 2022, 1-29.	0.9	3
1733	Role of HSV-1 in Alzheimer's disease pathogenesis: A challenge for novel preventive/therapeutic strategies. Current Opinion in Pharmacology, 2022, 63, 102200.	1.7	28
1734	Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer's Disease. Cellular and Molecular Neurobiology, 2023, 43, 797-811.	1.7	19
1735	MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets. Biomedicine and Pharmacotherapy, 2022, 148, 112681.	2.5	75
1736	Discovery of New 1,3,4-Oxadiazoles with Dual Activity Targeting the Cholinergic Pathway as Effective Anti-Alzheimer Agents. ACS Chemical Neuroscience, 2022, 13, 1187-1205.	1.7	9
1737	Advancing combination treatment with cilostazol and caffeine for Alzheimer's disease in high fat-high fructose-STZ induced model of amnesia. European Journal of Pharmacology, 2022, 921, 174873.	1.7	3
1738	Cellular Reprogramming and Its Potential Application in Alzheimer's Disease. Frontiers in Neuroscience, 2022, 16, 884667.	1.4	3
1739	Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases. Drug Discovery Today, 2022, 27, 1994-2007.	3.2	15
1740	Long-term stability and age-dependence of six regulatory serum proteins. Biomarkers in Medicine, 2022, 16, 511-521.	0.6	3
1741	Rational design, synthesis and activities of hydroxylated chalcones as highly potent dual functional agents against Alzheimer's disease. Bioorganic Chemistry, 2022, 122, 105662.	2.0	6
1742	QSAR modeling, molecular docking, ADMET prediction and molecular dynamics simulations of some 6-arylquinazolin-4-amine derivatives as DYRK1A inhibitors. Journal of Molecular Structure, 2022, 1258, 132659.	1.8	14
1743	Drug delivery of memantine with carbon dots for Alzheimer's disease: blood–brain barrier penetration and inhibition of tau aggregation. Journal of Colloid and Interface Science, 2022, 617, 20-31.	5.0	35
1744	Recent advances in blood and gut microbiota biomarkers for Alzheimer's disease. Scientia Sinica Vitae, 2021, , .	0.1	0
1745	Genome-wide DNA methylation profiling in nonagenarians suggests an effect of <i>PM20D1</i> in late onset Alzheimer's disease. CNS Spectrums, 2023, 28, 174-182.	0.7	2
1746	Global Public Interest and Seasonal Variations in Alzheimer's Disease: Evidence From Google Trends. Frontiers in Medicine, 2021, 8, 778930.	1.2	3

#	ARTICLE	IF	CITATIONS
1747	Therapeutic Mechanism and Key Alkaloids of Uncaria rhynchophylla in Alzheimer's Disease From the Perspective of Pathophysiological Processes. Frontiers in Pharmacology, 2021, 12, 806984.	1.6	14
1748	Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer's Disease. Biomedicines, 2021, 9, 1910.	1.4	35
1749	Alzheimer's Disease Classification Based on Image Transformation and Features Fusion. Computational and Mathematical Methods in Medicine, 2021, 2021, 1-11.	0.7	7
1750	Endogenous \hat{A}^2 induces osteoporosis through an mTOR-dependent inhibition of autophagy in bone marrow mesenchymal stem cells (BMSCs). Annals of Translational Medicine, 2021, 9, 1794-1794.	0.7	4
1751	New Promising Therapeutic Avenues of Curcumin in Brain Diseases. Molecules, 2022, 27, 236.	1.7	37
1752	Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging. Journal of Neurochemistry, 2022, 160, 482-498.	2.1	17
1753	Therapeutic Potential of Ferulic Acid in Alzheimer's Disease. Current Drug Delivery, 2022, 19, 860-873.	0.8	17
1754	China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study. Frontiers in Aging Neuroscience, 2021, 13, 797704.	1.7	2
1755	Deep Learning With 18F-Fluorodeoxyglucose-PET Gives Valid Diagnoses for the Uncertain Cases in Memory Impairment of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 764272.	1.7	2
1756	Effect of APOEϵ4 on Functional Brain Network in Patients with Subjective Cognitive Decline: A Resting State Functional MRI Study. International Journal of General Medicine, 2021, Volume 14, 9761-9771.	0.8	2
1757	Acupuncture and Related Therapies for the Cognitive Function of Alzheimer's Disease: A Network Meta-Analysis. Iranian Journal of Public Health, 0, , .	0.3	4
1758	Rational Design of a Cu Chelator That Mitigates Cuâ€Induced ROS Production by Amyloid Beta. ChemBioChem, 2022, 23, .	1.3	2
1761	Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer's disease: a meta-analysis and systematic review. Neural Regeneration Research, 2022, 17, 2381.	1.6	22
1762	Profiling of circulating chromosome 21â€encoded <scp>microRNAs</scp> , <scp>miR</scp> â€155, and letâ€7c, in down syndrome. Molecular Genetics & Genomic Medicine, 2022, 10, e1938.	0.6	3
1765	Discovery of Novel Drug Candidates for Alzheimer's Disease by Molecular Network Modeling. Frontiers in Aging Neuroscience, 2022, 14, 850217.	1.7	4
1766	Stereotaxic-assisted gene therapy in Alzheimer's and Parkinson's diseases: therapeutic potentials and clinical frontiers. Expert Review of Neurotherapeutics, 2022, 22, 319-335.	1.4	1
1833	Establishing a competing endogenous RNA (ceRNA)-immunoregulatory network associated with the progression of Alzheimer's disease Annals of Translational Medicine, 2022, 10, 65.	0.7	0
1835	Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study. Dementia and Neurocognitive Disorders, 2022, 21, 59.	0.4	3

#	Article	IF	CITATIONS
1838	Combination Therapy in Alzheimer's Disease: Is It Time?. Journal of Alzheimer's Disease, 2022, , 1-17.	1.2	4
1839	Amyloid-beta targeted therapeutic approaches for Alzheimer's disease: long road ahead. Current Drug Targets, 2022, 23, .	1.0	6
1840	Modifying effects of race and ethnicity and <i>APOE</i> on the association of physical activity with risk of Alzheimer's disease and related dementias. Alzheimer's and Dementia, 2023, 19, 507-517.	0.4	7
1841	Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans. Biomolecules, 2022, 12, 667.	1.8	11
1842	Cannabidiol Enhances Microglial Beta-Amyloid Peptide Phagocytosis and Clearance via Vanilloid Family Type 2 Channel Activation. International Journal of Molecular Sciences, 2022, 23, 5367.	1.8	14
1843	Link of BIN1, CLU, and flDE Gene Polymorphisms with the Susceptibility of Alzheimer's Disease: Evidence from a Meta-analysis. Current Alzheimer Research, 2022, 19, 302-316.	0.7	0
1844	Commentary. Clinical Nuclear Medicine, 2022, 47, 707-709.	0.7	6
1845	DWI-based MR thermometry: could it discriminate Alzheimer's disease from mild cognitive impairment and healthy subjects?. Neuroradiology, 2022, , .	1.1	4
1846	Recent Advances Towards Diagnosis and Therapeutic Fingerprinting for Alzheimer's Disease. Journal of Molecular Neuroscience, 2022, , 1.	1.1	6
1847	White Matter and Alzheimer's Disease: A Bidirectional Mendelian Randomization Study. Neurology and Therapy, 2022, 11, 881-892.	1.4	2
1848	Phosphoâ€specific plasma pâ€tau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 734-746.	1.7	11
1849	A Systematic Review of updated mechanistic insights towards Alzheimer's disease CNS and Neurological Disorders - Drug Targets, 2022, 21, .	0.8	3
1850	Systemic inflammation elevates cytosolic prolyl oligopeptidase protein expression but not peptidase activity in the cerebral cortices of familial Alzheimer's disease modeling mice. Brain Disorders, 2022, 6, 100035.	1.1	0
1851	Green tea, epigallocatechin gallate and the prevention of Alzheimer's disease: Clinical evidence. Food Science and Human Wellness, 2022, 11, 765-770.	2.2	15
1852	Neural Stem Cells Secretome Increased Neurogenesis and Behavioral Performance and the Activation of Wnt/β-Catenin Signaling Pathway in Mouse Model of Alzheimer's Disease. NeuroMolecular Medicine, 2022, , .	1.8	4
1853	Italian validation of the DEMQOL-PROXY: Exploratory Factor Analysis, Convergent and Divergent Validity Acta Biomedica, 2022, 93, e2022151.	0.2	0
1854	TGF- \hat{l}^2 as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications. Biomedicines, 2022, 10, 1206.	1.4	25
1855	Novel Cyclopentaquinoline and Acridine Analogs as Multifunctional, Potent Drug Candidates in Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 5876.	1.8	3

#	Article	IF	CITATIONS
1856	Traumatic axonal injury as a key driver of the relationship between traumatic brain injury, cognitive dysfunction, and dementia., 2022,, 475-486.		0
1857	Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	5
1858	β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease. Neurology, 2022, 99, .	1.5	3
1859	Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5
1860	The Systemic Effects of Exercise on the Systemic Effects of Alzheimer's Disease. Antioxidants, 2022, 11, 1028.	2.2	10
1861	Single Cell/Nucleus Transcriptomics Comparison in Zebrafish and Humans Reveals Common and Distinct Molecular Responses to Alzheimer's Disease. Cells, 2022, 11, 1807.	1.8	19
1863	Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. European Journal of Neurology, 2022, 29, 2810-2822.	1.7	20
1864	Aesthetic Preference for Negatively-Valenced Artworks Remains Stable in Pathological Aging: A Comparison Between Cognitively Impaired Patients With Alzheimer's Disease and Healthy Controls. Frontiers in Psychology, 2022, 13, .	1.1	0
1865	The Comparative Efficacy of Multiple Acupuncture for Alzheimer's Disease: A Bayesian Network Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-26.	0.5	3
1866	Brain imaging abnormalities in mixed Alzheimer's and subcortical vascular dementia. Canadian Journal of Neurological Sciences, 0, , 1-36.	0.3	0
1867	Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 0, 14, .	1.7	20
1868	An observation study of urinary biomarker exploratory in Alzheimer's disease using highâ€resolution mass spectrometry. Biomedical Chromatography, 2022, 36, .	0.8	4
1869	Expression relationship and significance of NEAT1 and miR-27a-3p in serum and cerebrospinal fluid of patients with Alzheimer's disease. BMC Neurology, 2022, 22, .	0.8	13
1870	Defective mitophagy and the etiopathogenesis of Alzheimerâ $\!$	3.6	11
1872	Neurocognitive Disorders. , 2022, , .		0
1873	Maackiain Prevents Amyloid-Beta–Induced Cellular Injury via Priming PKC-Nrf2 Pathway. BioMed Research International, 2022, 2022, 1-9.	0.9	2
1874	Primary Microglia Dysfunction or Microgliopathy: A Cause of Dementias and Other Neurological or Psychiatric Disorders. Neuroscience, 2022, 497, 324-339.	1.1	4
1875	Metabolic Reprogramming of Microglia Enhances Proinflammatory Cytokine Release through EphA2/p38 MAPK Pathway in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 88, 771-785.	1.2	8

#	Article	IF	CITATIONS
1877	Total Synthesis and Prediction of Ulodione Natural Products Guided by DFT Calculations. Angewandte Chemie, $0, \dots$	1.6	0
1878	p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia. Molecular Neurobiology, 2022, 59, 5284-5298.	1.9	7
1879	Application of the Amyloid/Tau/Neurodegeneration Framework in Cognitively Intact Adults: The <scp>CABLE</scp> Study. Annals of Neurology, 2022, 92, 439-450.	2.8	10
1880	Classification of early-MCI patients from healthy controls using evolutionary optimization of graph measures of resting-state fMRI, for the Alzheimer's disease neuroimaging initiative. PLoS ONE, 2022, 17, e0267608.	1.1	11
1881	Sirt1 protects against hippocampal atrophy and its induced cognitive impairment in middle-aged mice. BMC Neuroscience, 2022, 23, .	0.8	9
1882	Recent Advances in the Development of Biofluid-Based Prognostic Biomarkers of Diffuse Axonal Injury. , 0, , .		1
1883	Presenilin Deficiency Increases Susceptibility to Oxidative Damage in Fibroblasts. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
1884	A Survey of Mobile Apps for the Care Management of Patients with Dementia. Healthcare (Switzerland), 2022, 10, 1173.	1.0	6
1885	Targeting the alternative oxidase (AOX) for human health and food security, a pharmaceutical and agrochemical target or a rescue mechanism?. Biochemical Journal, 2022, 479, 1337-1359.	1.7	6
1886	The Nuance of Bilingualism as a Reserve Contributor: Conveying Research to the Broader Neuroscience Community. Frontiers in Psychology, 0, 13, .	1.1	5
1887	Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer's disease-like mice. Journal of Neuroinflammation, 2022, 19, .	3.1	10
1888	Total Synthesis and Prediction of Ulodione Natural Products Guided by DFT Calculations. Angewandte Chemie - International Edition, 0, , .	7.2	2
1889	The Correlation Between White Matter Hyperintensity Burden and Regional Brain Volumetry in Patients With Alzheimer's Disease. Frontiers in Human Neuroscience, 0, 16, .	1.0	2
1890	Neuroprotective Effect of Caffeine in Alzheimer's Disease. Molecules, 2022, 27, 3737.	1.7	12
1891	Alzheimer's disease genetic burden is associated with midâ€life depression among persons with normal cognition. Alzheimer's and Dementia, 0, , .	0.4	2
1892	Augmented risk of dementia in hypertrophic cardiomyopathy: A propensity score matching analysis using the nationwide cohort. PLoS ONE, 2022, 17, e0269911.	1.1	O
1893	Multi-Target Effects of ß-Caryophyllene and Carnosic Acid at the Crossroads of Mitochondrial Dysfunction and Neurodegeneration: From Oxidative Stress to Microglia-Mediated Neuroinflammation. Antioxidants, 2022, 11, 1199.	2.2	11
1894	Z-Guggulsterone attenuates cognitive defects and decreases neuroinflammation in APPswe/PS1dE9 mice through inhibiting the TLR4 signaling pathway. Biochemical Pharmacology, 2022, 202, 115149.	2.0	0

#	Article	IF	CITATIONS
1895	Molecular insights into the very early steps of $\hat{Al^2}$ 1-42 pentameric protofibril disassembly by PGC: A molecular dynamics simulation study. Journal of Molecular Liquids, 2022, 361, 119638.	2.3	5
1896	Loss of SST and PV positive interneurons in the ventral hippocampus results in anxiety-like behavior in 5xFAD mice. Neurobiology of Aging, 2022, 117, 165-178.	1.5	8
1897	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. NeuroImage: Clinical, 2022, 35, 103106.	1.4	9
1898	8-Hydroxyquinolines: A Promising Pharmacophore Potentially Developed as Disease-Modifying Agents for Neurodegenerative Diseases: A Review. Heterocycles, 2022, 105, 202.	0.4	1
1899	Impact of Lactate on Mitochondrial Activity in Endothelial Cells Exposed in vitro to the Acute Toxic Effect of beta-Amyloid. Journal of Evolutionary Biochemistry and Physiology, 2022, 58, 875-884.	0.2	0
1900	Astragalus mongholicus Bunge (Fabaceae): Bioactive Compounds and Potential Therapeutic Mechanisms Against Alzheimerâ \in ^{Ms} Disease. Frontiers in Pharmacology, 0, 13, .	1.6	6
1901	The anti-Alzheimer potential of some novel Tacrine-Coumarin Derivatives as a Cholinesterase inhibitor. International Journal of Health Sciences, 0, , 10910-10932.	0.0	0
1902	Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery. Nanomaterials, 2022, 12, 2267.	1.9	5
1903	Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer's Disease. Molecules, 2022, 27, 4175.	1.7	10
1904	Higher susceptibility to 6ÂHz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease. Epilepsia, 2022, 63, 2703-2715.	2.6	11
1905	Horizons in Human Aging Neuroscience: From Normal Neural Aging to Mental (Fr)Agility. Frontiers in Human Neuroscience, 0, 16, .	1.0	4
1906	Traumatic brain injury and postâ€traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. Alzheimer's and Dementia, 2023, 19, 884-895.	0.4	13
1907	Hsp multichaperone complex buffers pathologically modified Tau. Nature Communications, 2022, 13, .	5.8	11
1908	Near-infrared light reduces glia activation and modulates neuroinflammation in the brains of diet-induced obese mice. Scientific Reports, 2022, 12, .	1.6	6
1909	Establishment and Analysis of a Combined Diagnostic Model of Alzheimer's Disease With Random Forest and Artificial Neural Network. Frontiers in Aging Neuroscience, 0, 14, .	1.7	13
1910	The Risk of Developing Alzheimer's Disease and Parkinson's Disease in Patients with Inflammatory Bowel Disease: A Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 3704.	1.0	16
1911	Differentially Aquaporin 5 Expression in Submandibular Glands and Cerebral Cortex in Alzheimer's Disease. Biomedicines, 2022, 10, 1645.	1.4	4
1912	Automated detection of mild cognitive impairment and dementia from voice recordings: A natural language processing approach. Alzheimer's and Dementia, 2023, 19, 946-955.	0.4	16

#	Article	IF	Citations
1913	Regulation of the Human IL-10RB Gene Expression by Sp8 and Sp9. Journal of Alzheimer's Disease, 2022, 88, 1469-1485.	1.2	1
1914	Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers. Brain Communications, 2022, 4, .	1.5	16
1916	Transcranial magnetic stimulation treatment in Alzheimer's disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization. Journal of Neurology, 2022, 269, 5283-5301.	1.8	9
1917	The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review. Molecular Neurobiology, 2022, 59, 5935-5954.	1.9	5
1918	Cerebrospinal Fluid Synaptosomal-Associated Protein 25 Levels in Patients with Alzheimer's Disease: A Meta-Analysis. Journal of Alzheimer's Disease, 2022, , 1-12.	1.2	0
1919	Patient-Derived Fibroblasts With Presenilin-1 Mutations, That Model Aspects of Alzheimer's Disease Pathology, Constitute a Potential Object for Early Diagnosis. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3
1920	Structure-specific amyloid precipitation in biofluids. Nature Chemistry, 2022, 14, 1045-1053.	6.6	11
1921	Blood-based $\hat{Al^2}42$ increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention. Acta Neuropathologica, 2022, 144, 489-508.	3.9	6
1922	Systematic Review on Saliva Biomarkers in Patients Diagnosed with Morbus Alzheimer and Morbus Parkinson. Biomedicines, 2022, 10, 1702.	1.4	10
1923	Loss of body weight in old 5xFAD mice and the alteration of gut microbiota composition. Experimental Gerontology, 2022, 166, 111885.	1.2	3
1924	Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules. European Journal of Medicinal Chemistry, 2022, 240, 114578.	2.6	19
1925	Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status. Biomedicines, 2022, 10, 1760.	1.4	24
1926	Generation of Human Induced Pluripotent Stem Cell Lines SPPHli003-A and SPPHli004-A from Two Patients with Sporadic Alzheimer's Disease in Southwestern China. Stem Cell Research, 2022, , 102876.	0.3	0
1927	Cognition impairment and risk of subclinical cardiovascular disease in older adults: The atherosclerosis risk in communities study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3
1928	Prospective biomarkers of Alzheimer's disease: A systematic review and meta-analysis. Ageing Research Reviews, 2022, 81, 101699.	5.0	17
1929	Role of Mitophagy in neurodegenerative Diseases and potential tagarts for Therapy. Molecular Biology Reports, 2022, 49, 10749-10760.	1.0	11
1930	Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer's Disease. Biomedicines, 2022, 10, 1800.	1.4	10
1931	Novel coumarin derivatives as multifunctional anti-AD agents: Design, synthesis, X-ray crystal structure and biological evaluation. Journal of Molecular Structure, 2022, 1268, 133747.	1.8	6

#	Article	IF	Citations
1932	Systems Genetic Identification of Mitochondrion-Associated Alzheimer's Disease Genes and Implications for Disease Risk Prediction. Biomedicines, 2022, 10, 1782.	1.4	3
1933	Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation. Science Advances, 2022, 8, .	4.7	40
1934	Adenosine receptor signalling in Alzheimer's disease. Purinergic Signalling, 2022, 18, 359-381.	1.1	5
1935	Neuronal cell death mechanisms in Alzheimer $\hat{a} \in \mathbb{N}$ s disease: An insight. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	36
1936	A Novel Pectin-Like Glycopeptide Isolated from the Fruit of <i>Fructus Mori</i> Impedes Aggregation and Production of $A\hat{l}^2$ ₄₂ . Journal of Agricultural and Food Chemistry, 2022, 70, 9908-9918.	2.4	2
1937	Transcranial near-infrared light in treatment of neurodegenerative diseases. Frontiers in Pharmacology, 0, 13, .	1.6	14
1938	Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment. Aging Clinical and Experimental Research, 2022, 34, 2399-2406.	1.4	2
1939	Binding Models of AÎ ² 42 Peptide with Membranes Explored by Molecular Simulations. Journal of Chemical Information and Modeling, 2022, 62, 6482-6493.	2.5	6
1940	Sirtuins promote brain homeostasis, preventing Alzheimer $\hat{a} \in \mathbb{N}$ s disease through targeting neuroinflammation. Frontiers in Physiology, 0, 13, .	1.3	8
1941	Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	3.0	4
1942	SIRT7 Deficiency Protects against AÎ ² 42-Induced Apoptosis through the Regulation of NOX4-Derived Reactive Oxygen Species Production in SH-SY5Y Cells. International Journal of Molecular Sciences, 2022, 23, 9027.	1.8	5
1943	Normalized Theta but Increased Gamma Activity after Acetylcholinesterase Inhibitor Treatment in Alzheimer's Disease: Preliminary qEEG Study. Clinical EEG and Neuroscience, 2023, 54, 305-315.	0.9	3
1945	The causes and consequences of Alzheimer $\hat{a} \in \mathbb{T}^M$ s disease: phenome-wide evidence from Mendelian randomization. Nature Communications, 2022, 13, .	5.8	16
1946	Natural remedies for Alzheimer's disease: A systematic review of randomized controlled trials. Metabolic Brain Disease, 2023, 38, 17-44.	1.4	7
1947	Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer's Disease. Biomedicines, 2022, 10, 1946.	1.4	14
1948	Artificial Intelligence Models in the Diagnosis of Adult-Onset Dementia Disorders: A Review. Bioengineering, 2022, 9, 370.	1.6	15
1949	A circular RNA blood panel that differentiates Alzheimerâ \in ^{m} s disease from other dementia types. Biomarker Research, 2022, 10, .	2.8	4
1950	Insulin Resistance and the Brain–Novel Insights Combining Metabolic Research and Neuroscience. Metabolites, 2022, 12, 780.	1.3	0

#	Article	IF	CITATIONS
1951	Transcriptomic Profile Identifies Hippocampal Sgk1 as the Key Mediator of Ovarian Estrogenic Regulation on Spatial Learning and Memory and ${\rm A\hat{l}}^2$ Accumulation. Neurochemical Research, 2022, 47, 3369-3384.	1.6	2
1952	Quantitative susceptibility mapping as an imaging biomarker for Alzheimerâ \in TM s disease: The expectations and limitations. Frontiers in Neuroscience, 0, 16, .	1.4	12
1953	Anticholinesterase Agents For Alzheimer's Disease Treatment: An Updated Overview. Current Medicinal Chemistry, 2023, 30, 701-724.	1.2	4
1954	Genetic variant rs11136000 upregulates clusterin expression and reduces Alzheimer's disease risk. Frontiers in Neuroscience, 0, 16, .	1.4	3
1955	Lithium Cholesterol Sulfate: A Novel and Potential Drug for Treating Alzheimer's Disease and Autism Spectrum Disorder. CNS and Neurological Disorders - Drug Targets, 2022, 21, .	0.8	2
1956	Cognition and brain health among older adults in Iceland: the AGES-Reykjavik study. GeroScience, 2022, 44, 2785-2800.	2.1	5
1957	Time-restricted feeding rescues circadian disruption-aggravated progression of Alzheimer's disease in diabetic mice. Journal of Nutritional Biochemistry, 2022, 110, 109128.	1.9	2
1958	Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders. Drug Discovery Today, 2022, 27, 103334.	3.2	7
1959	Cornuside Is a Potential Agent against Alzheimer's Disease via Orchestration of Reactive Astrocytes. Nutrients, 2022, 14, 3179.	1.7	8
1960	TRIM family proteins: roles in proteostasis and neurodegenerative diseases. Open Biology, 2022, 12, .	1.5	12
1961	Investigating causal relations between heart failure and Alzheimer's disease: A two-sample Mendelian randomization study. Brain Disorders, 2022, 7, 100047.	1.1	0
1962	Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: Integration of the glutamate/GABA-glutamine cycle. Progress in Neurobiology, 2022, 217, 102331.	2.8	69
1963	Recent advances of small molecule JNK3 inhibitors for Alzheimer's disease. Bioorganic Chemistry, 2022, 128, 106090.	2.0	8
1964	The reactivity of copper complexes with neuronal peptides promoted by catecholamines and its impact on neurodegeneration. Coordination Chemistry Reviews, 2022, 471, 214756.	9.5	8
1965	Lights at night: does photobiomodulation improve sleep?. Neural Regeneration Research, 2023, 18, 474.	1.6	6
1966	Advanced molecular therapies for neurological diseases: focus on stroke, alzheimer's disease, and parkinson's disease. Neurological Sciences, 2023, 44, 19-36.	0.9	2
1967	Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases. Metabolites, 2022, 12, 864.	1.3	1
1968	Importance of Bmal1 in Alzheimer's disease and associated agingâ€related diseases: Mechanisms and interventions. Aging Cell, 2022, 21, .	3.0	15

#	Article	IF	CITATIONS
1969	Associations of fish oil supplementation with incident dementia: Evidence from the UK Biobank cohort study. Frontiers in Neuroscience, $0,16,\ldots$	1.4	4
1970	MicroRNAs, Stem Cells in Bipolar Disorder, and Lithium Therapeutic Approach. International Journal of Molecular Sciences, 2022, 23, 10489.	1.8	4
1972	Carthamus tinctorius L.: A natural neuroprotective source for anti-Alzheimer's disease drugs. Journal of Ethnopharmacology, 2022, 298, 115656.	2.0	5
1973	Influence of genetic and cardiometabolic risk factors in Alzheimer's disease. Ageing Research Reviews, 2022, 81, 101723.	5.0	11
1974	Discovery of potent and selective dual cholinesterases and β-secretase inhibitors in pomegranate as a treatment for Alzheimer's disease. Bioorganic Chemistry, 2022, 129, 106137.	2.0	5
1975	EGCG-Derived Carbonized Polymer Dots: A Multifunctional Scavenger Targeting Alzheimer's Î'-Amyloid Plaques. SSRN Electronic Journal, 0, , .	0.4	O
1976	Investigation of the Protective Effect of Long-Term Exercise on Molecular Pathways and Cognitive Behaviors in Alzheimer Disease Model. SSRN Electronic Journal, 0, , .	0.4	0
1977	Neuroprotection of Triptolide against Amyloid-Beta1-42-induced toxicity via the Akt/mTOR/p70S6K-mediated Autophagy Pathway. Anais Da Academia Brasileira De Ciencias, 2022, 94, .	0.3	7
1978	Natural Therapeutics in Aid of Treating Alzheimer $\hat{a} \in \mathbb{N}$ s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders. Frontiers in Neuroscience, 0, 16, .	1.4	19
1979	Fucoidans inhibited tau interaction and cellular uptake. Carbohydrate Polymers, 2023, 299, 120176.	5.1	3
1980	FTH1- and SAT1-Induced Astrocytic Ferroptosis Is Involved in Alzheimer's Disease: Evidence from Single-Cell Transcriptomic Analysis. Pharmaceuticals, 2022, 15, 1177.	1.7	15
1981	Association between Subclinical Epileptiform Discharge and the Severity of Cognitive Decline in Alzheimer's Disease: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2022, 90, 305-312.	1.2	5
1982	Development of framework by combining CNN with KNN to detect Alzheimer's disease using MRI images. Multimedia Tools and Applications, 2023, 82, 12699-12717.	2.6	14
1983	Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interview. Expert Review of Pharmacoeconomics and Outcomes Research, 0, , 1-8.	0.7	1
1984	Identification of 5 Potential Predictive Biomarkers for Alzheimer's Disease by Integrating the Unified Test for Molecular Signatures and Weighted Gene Coexpression Network Analysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 653-658.	1.7	4
1985	Prediction of Alzheimer's Disease Using Patterns of Methylation Levels in Key Immunologic-Related Genes. Journal of Alzheimer's Disease, 2022, 90, 783-794.	1.2	1
1986	Photobiomodulation for Hypertension and Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 90, 1045-1055.	1.2	10
1987	The Innate and Adaptive Immune Cells in Alzheimer's and Parkinson's Diseases. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-12.	1.9	9

#	Article	IF	CITATIONS
1988	Hypnosis for pain and anxiety management in cognitively impaired older adults undergoing scheduled lumbar punctures: a randomized controlled pilot study. Alzheimer's Research and Therapy, 2022, 14, .	3.0	1
1989	Tau isoform-specific enhancement of L-type calcium current and augmentation of afterhyperpolarization in rat hippocampal neurons. Scientific Reports, 2022, 12, .	1.6	5
1990	Dual-Task-Based Music Therapy to Improve Executive Functioning of Elderly Patients with Early Stage Alzheimer's Disease: A Multiple Case Study. International Journal of Environmental Research and Public Health, 2022, 19, 11940.	1.2	4
1991	Features of the Development and Analysis of Impairments to Social Behavior and Cognitive Functions in Animals with Experimental Alzheimer's Disease. Neuroscience and Behavioral Physiology, 0, , .	0.2	0
1992	Prevalence of Comorbid Dementia in Late-life Depression and Bipolar Disorder: A Retrospective Inpatient Study. Journal of Alzheimer's Disease Reports, 2022, 6, 589-598.	1.2	3
1993	Therapeutic approaches of nutraceuticals in the prevention of Alzheimer's disease. Journal of Food Biochemistry, 2022, 46, .	1.2	9
1994	Research status, hotspots and trends of acupuncture and moxibustion in the treatment of Alzheimer's disease: A bibliometric analysis. Medicine (United States), 2022, 101, e30858.	0.4	6
1995	Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain, 2023, 146, 1592-1601.	3.7	105
1996	Near-Infrared Photothermally Enhanced Photo-Oxygenation for Inhibition of Amyloid-β Aggregation Based on RVG-Conjugated Porphyrinic Metal–Organic Framework and Indocyanine Green Nanoplatform. International Journal of Molecular Sciences, 2022, 23, 10885.	1.8	9
1997	Synthesis and Bioactivity Evaluation of a Novel 1,2,4-Oxadiazole Derivative in vitro and in 3×Tg Mice. Drug Design, Development and Therapy, 0, Volume 16, 3285-3296.	2.0	1
1998	The Involvement of Kynurenine Pathway in Neurodegenerative Diseases. Current Neuropharmacology, 2023, 21, 260-272.	1.4	4
2000	Potential of fluorescent nanoprobe in diagnosis and treatment of Alzheimer's disease. Nanomedicine, 0, , .	1.7	4
2001	HSPA1A, HSPA2, and HSPA8 Are Potential Molecular Biomarkers for Prognosis among HSP70 Family in Alzheimer's Disease. Disease Markers, 2022, 2022, 1-16.	0.6	9
2002	Clinical performance and robustness evaluation of plasma amyloidâ€Î² _{42/40} prescreening. Alzheimer's and Dementia, 2023, 19, 1393-1402.	0.4	22
2003	Amyloid \hat{l}^2 oligomers disrupt piriform cortical output via a serotonergic pathway. Neurobiology of Aging, 2023, 121, 64-77.	1.5	2
2004	Senegenin Rescues PC12 Cells with Oxidative Damage Through Inhibition of Ferroptosis. Molecular Neurobiology, 2022, 59, 6983-6992.	1.9	11
2005	Impaired Dopamine Release and Latent Learning in Alzheimer's Disease Model Zebrafish. ACS Chemical Neuroscience, 2022, 13, 2924-2931.	1.7	3
2006	Excretion of Amyloid- \hat{l}^2 in the Gastrointestinal Tract and Regulation by the Gut Microbiota. Journal of Alzheimer's Disease, 2022, 90, 1153-1162.	1.2	1

#	Article	IF	CITATIONS
2007	The rapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues. Frontiers in Pharmacology, $0,13,.$	1.6	4
2008	Doença de alzheimer. , 2021, , 374-388.		O
2009	Amyloid precursor protein in Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2023, , 261-270.	0.9	4
2010	Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia. Aging Brain, 2022, 2, 100054.	0.7	0
2011	The Role of a Pathological Interaction between β-amyloid and Mitochondria in the Occurrence and Development of Alzheimer's Disease. , 2022, 14, 19-34.		3
2012	The mobile sleep medicine model in neurologic practice: Rationale and application. Frontiers in Neurology, 0, 13, .	1.1	0
2013	Blood plasma protein profiles of neuropsychiatric symptoms and related cognitive decline in older people. Journal of Neurochemistry, 2023, 164, 242-254.	2.1	5
2014	Synaptogenic effect of <i>APP</i> -Swedish mutation in familial Alzheimer's disease. Science Translational Medicine, 2022, 14, .	5.8	29
2015	Treponema denticola Induces Neuronal Apoptosis by Promoting Amyloid- \hat{l}^2 Accumulation in Mice. Pathogens, 2022, 11, 1150.	1.2	5
2016	Differential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers. Diagnostics, 2022, 12, 2425.	1.3	2
2017	An emerging role for stress granules in neurodegenerative disease and hearing loss. Hearing Research, 2022, 426, 108634.	0.9	5
2018	Clinical characteristics and genotype-phenotype correlation analysis of familial Alzheimer's disease patients with pathogenic/likely pathogenic amyloid protein precursor mutations. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
2019	The Link between Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation in the Pathophysiology of Alzheimer's Disease: Therapeutic Implications and Future Perspectives. Antioxidants, 2022, 11, 2167.	2.2	17
2020	Whole-brain mapping of metabolic alterations in a mouse model of Alzheimer's disease by desorption electrospray ionization mass spectrometry imaging. Talanta, 2023, 253, 124046.	2.9	3
2021	A Bibliometric and Visual Analysis of Exercise Intervention Publications for Alzheimer's Disease (1998–2021). Journal of Clinical Medicine, 2022, 11, 5903.	1.0	6
2022	Ovariectomy-induced hormone deprivation aggravates $A\hat{l}^2$ 1-42 deposition in the basolateral amygdala and cholinergic fiber loss in the cortex but not cognitive behavioral symptoms in a triple transgenic mouse model of Alzheimerâ \in ^{TMS} disease. Frontiers in Endocrinology, 0, 13, .	1.5	3
2023	Early Aggregation of Amyloid- $\hat{l}^2(1\hat{a}\in "42)$ Studied by Fluorescence Correlation Spectroscopy. Methods in Molecular Biology, 2023, , 1-14.	0.4	0
2025	(<i>p</i> â€Chlorophenyl)â€3(2 <i>H</i>)pyridazinone Derivatives: Synthesis, <i>in Silico</i> , and AChE/BChE Inhibitory Activity. ChemistrySelect, 2022, 7, .	0.7	3

#	Article	IF	CITATIONS
2026	Glial Glutamine Homeostasis in Health and Disease. Neurochemical Research, 2023, 48, 1100-1128.	1.6	18
2027	A Group of Long Non-coding RNAs in Blood Acts as a Specific Biomarker of Alzheimer's Disease. Molecular Neurobiology, 2023, 60, 566-575.	1.9	3
2028	Next generation of neurological therapeutics: Native and bioengineered extracellular vesicles derived from stem cells. Asian Journal of Pharmaceutical Sciences, 2022, 17, 779-797.	4.3	4
2029	Impaired Visual Inhibition in Amnestic Mild Cognitive Impairment. Clinical EEG and Neuroscience, 0, , 155005942211368.	0.9	0
2030	Increased functional connectivity between nucleus basalis of Meynert and amygdala in cognitively intact elderly along the Alzheimer's continuum. NeuroImage: Clinical, 2022, 36, 103256.	1.4	4
2031	Polymeric nanoparticles as drug delivery systems for dementia. , 2023, , 89-114.		0
2032	The effects and potential of microglial polarization and crosstalk with other cells of the central nervous system in the treatment of Alzheimer's disease. Neural Regeneration Research, 2023, 18, 947.	1.6	6
2033	AChE as a spark in the Alzheimer's blaze – Antagonizing effect of a cyclized variant. Ageing Research Reviews, 2023, 83, 101787.	5.0	4
2034	Preparation and Multitarget Anti-AD Activity Study of Chondroitin Sulfate Lithium in AD Mice Induced by Combination of D-Gal/AlCl3. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-22.	1.9	7
2035	Recent Progress in Research on Mechanisms of Action of Natural Products against Alzheimer's Disease: Dietary Plant Polyphenols. International Journal of Molecular Sciences, 2022, 23, 13886.	1.8	6
2036	Alzheimer's Disease: Treatment Strategies and Their Limitations. International Journal of Molecular Sciences, 2022, 23, 13954.	1.8	66
2037	Speech silence character as a diagnostic biomarker of early cognitive decline and its functional mechanism: a multicenter cross-sectional cohort study. BMC Medicine, 2022, 20, .	2.3	5
2039	Naturally-aged microglia exhibit phagocytic dysfunction accompanied by gene expression changes reflective of underlying neurologic disease. Scientific Reports, 2022, 12, .	1.6	11
2040	Edaravone Attenuates Aβ 1-42-Induced Inflammatory Damage and Ferroptosis in HT22 Cells. Neurochemical Research, 0, , .	1.6	3
2041	Subjective Cognitive Decline Is Associated With Lower Baseline Cognition and Increased Rate of Cognitive Decline. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2023, 78, 573-584.	2.4	6
2042	A Pilot Study of Near-Infrared Light Treatment for Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	1.2	1
2044	Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 2084-2094.	0.4	2
2045	Design, synthesis, and preliminary evaluation of [18F]-aryl flurosulfates PET radiotracers via SuFEx methods for β-amyloid plaques in Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2022, 75, 117087.	1.4	3

#	ARTICLE	IF	CITATIONS
2046	Integrating Neuroimaging Measures in Nursing Research. Biological Research for Nursing, 2023, 25, 341-352.	1.0	1
2047	Identification of core genes in prefrontal cortex and hippocampus of Alzheimer's disease based on mRNAâ€miRNA network. Journal of Cellular and Molecular Medicine, 2022, 26, 5779-5793.	1.6	2
2048	Life satisfaction across the entire trajectory of Alzheimer's disease: A mediation analysis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	1
2049	Anti-inflammatory effects of 9-cis-retinoic acid on \hat{l}^2 -amyloid treated human microglial cells. European Journal of Inflammation, 2022, 20, 1721727X2211436.	0.2	2
2050	Dopamine D2 receptor agonist Bromocriptine ameliorates $\hat{A^2}$ 1-42-induced memory deficits and neuroinflammation in mice. European Journal of Pharmacology, 2023, 938, 175443.	1.7	8
2051	Current mouse models of Alzheimer's disease for investigating therapeutic agents. , 2023, , 31-41.		0
2052	Role of primary aging hallmarks in AlzheimerÂ's disease. Theranostics, 2023, 13, 197-230.	4.6	8
2053	Exploiting task relationships for Alzheimer's disease cognitive score prediction via multi-task learning. Computers in Biology and Medicine, 2023, 152, 106367.	3.9	0
2054	Association of adenosine triphosphate-related genes to major depression and suicidal behavior: Cognition as a potential mediator. Journal of Affective Disorders, 2023, 323, 131-139.	2.0	4
2055	Functional MRI and <i>ApoE4</i> genotype for predicting cognitive decline in amyloid-positive individuals. Therapeutic Advances in Neurological Disorders, 2022, 15, 175628642211381.	1.5	2
2056	Probing protein misfolding and dissociation with an infrared free-electron laser. Methods in Enzymology, 2023, , 65-96.	0.4	1
2057	Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease. Expert Review of Neurotherapeutics, 2022, 22, 863-873.	1.4	1
2058	Necroptosis and Alzheimer's Disease: Pathogenic Mechanisms and Therapeutic Opportunities. Journal of Alzheimer's Disease, 2023, 94, S367-S386.	1.2	7
2059	Blood Biomarkers for the Diagnosis of Neurodegenerative Dementia: A Systematic Review. Journal of Geriatric Psychiatry and Neurology, 2023, 36, 267-281.	1.2	3
2060	A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. Diagnostics, 2022, 12, 2975.	1.3	5
2061	Subjective cognitive decline may mediate the occurrence of postoperative delirium by P-tau undergoing total hip replacement: The PNDABLE study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
2063	Mitochondrial Ca2+ Signaling and Bioenergetics in Alzheimer's Disease. Biomedicines, 2022, 10, 3025.	1.4	6
2064	Role of nonâ€'coding RNAs as biomarkers and the application of omics technologies in Alzheimer's disease (Review). International Journal of Molecular Medicine, 2022, 51, .	1.8	7

#	Article	IF	CITATIONS
2065	BEYİN YAŞLANMASINDA MOLEKÜLER MEKANİZMALAR. Ankara Universitesi Eczacilik Fakultesi Dergisi, 2022 47, 1-1.	'0.2	0
2066	The Role of Ketogenic Diet in the Treatment of Neurological Diseases. Nutrients, 2022, 14, 5003.	1.7	34
2067	Current state of knowledge concerning experimental applications for deep brain stimulation in specific neurologic and psychiatric disorders. Journal of Education, Health and Sport, 2022, 12, 277-285.	0.0	0
2068	PET/MR imaging of inflammation in atherosclerosis. Nature Biomedical Engineering, 2023, 7, 202-220.	11.6	10
2069	Trilateral association of autophagy, mTOR and Alzheimer's disease: Potential pathway in the development for Alzheimer's disease therapy. Frontiers in Pharmacology, 0, 13, .	1.6	17
2070	Persisting neuropsychiatric symptoms, Alzheimer's disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate. Alzheimer's Research and Therapy, 2022, 14, .	3.0	4
2071	Screening of the active Ingredients in Huanglian Jiedu decoction through amide bond-Immobilized magnetic nanoparticle-assisted cell membrane chromatography. Frontiers in Pharmacology, 0, 13, .	1.6	2
2072	Efficacy of pharmacotherapy and non-pharmacotherapy of Alzheimer dementia: A protocol for systematic review and meta-analysis. Medicine (United States), 2022, 101, e32382.	0.4	2
2073	Diagnostic Cut-offs for CSF \hat{l}^2 -amyloid and Tau Proteins in a Danish Dementia Clinic. Clinica Chimica Acta, 2022, , .	0.5	0
2074	Exploring the potential anti-Alzheimer disease mechanisms of Alpiniae Oxyphyliae Fructus by network pharmacology study and molecular docking. Metabolic Brain Disease, 2023, 38, 933-944.	1.4	1
2075	The potential diagnostic accuracy of urine formaldehyde levels in Alzheimer's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
2076	Association of CSF GAP-43 and APOE ε4 with Cognition in Mild Cognitive Impairment and Alzheimer's Disease. Cells, 2023, 12, 13.	1.8	3
2077	TREM2 dependent and independent functions of microglia in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, .	4.4	25
2078	Identification of Two CDK5R1-Related Subtypes and Characterization of Immune Infiltrates in Alzheimer's Disease Based on an Integrated Bioinformatics Analysis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-16.	0.7	2
2079	The effect of the calcium channel blocker nimodipine on hippocampal BDNF/Ach levels in rats with experimental cognitive impairment. Neurological Research, 2023, 45, 544-553.	0.6	2
2080	Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010 – 2020. journal of prevention of Alzheimer's disease, The, 0, , .	1.5	1
2081	Memory-Improving Activity of the Flower Extract from Chrysanthemum boreale (Makino) Maskino in Scopolamine-Treated Rodents. Processes, 2023, 11, 159.	1.3	2
2082	EEG Entropy in REM Sleep as a Physiologic Biomarker in Early Clinical Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 91, 1557-1572.	1.2	5

#	Article	IF	CITATIONS
2083	Denture tracker for edentulous Alzheimer's patients. Journal of Indian Prosthodontic Society, The, 2023, 23, 96.	0.3	2
2084	A blood mRNA panel that differentiates Alzheimer's disease from other dementia types. Journal of Neurology, 0, , .	1.8	1
2085	Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	19
2086	Ganoapplins A and B with an unprecedented 6/6/6/5/6-fused pentacyclic skeleton from Ganoderma inhibit Tau pathology through activating autophagy. Bioorganic Chemistry, 2023, 132, 106375.	2.0	2
2087	Novel Microglia-based Therapeutic Approaches to Neurodegenerative Disorders. Neuroscience Bulletin, 2023, 39, 491-502.	1.5	11
2088	Identification of Artemisia Argyi (AA) Therapy in Alzheimer's Disease (AD) Using Network Pharmacology and Molecular Docking. Advanced Biology, 2023, 7, .	1.4	1
2089	The role of <scp>STING</scp> signaling in central nervous system infection and neuroinflammatory disease. WIREs Mechanisms of Disease, 2023, 15, .	1.5	7
2090	The Binding of Different Substrate Molecules at the Docking Site and the Active Site of γ-Secretase Can Trigger Toxic Events in Sporadic and Familial Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 1835.	1.8	2
2091	Immunity orchestrates a bridge in gut-brain axis of neurodegenerative diseases. Ageing Research Reviews, 2023, 85, 101857.	5.0	6
2092	Compensatory cognition in neurological diseases and aging: A review of animal and human studies. Aging Brain, 2023, 3, 100061.	0.7	3
2093	Fluid dynamics in aging-related dementias. Neurobiology of Disease, 2023, 177, 105986.	2.1	8
2094	Ginsenoside Rk3 ameliorates \hat{A}^2 -induced neurotoxicity in APP/PS1 model mice via AMPK signaling pathway. Biomedicine and Pharmacotherapy, 2023, 158, 114192.	2.5	19
2095	Exercise as a Protective and Therapeutic Intervention in Alzheimer's Disease. Geriatrik Bilimler Dergisi, 2022, 5, 90-96.	1.0	1
2096	Multi-Component Interventions in Older Adults Having Subjective Cognitive Decline (SCD)—A Review Article. Geriatrics (Switzerland), 2023, 8, 4.	0.6	2
2097	Neurodegenerative Erkrankungen. , 2022, , 559-568.		1
2098	The beneficial effect on cognition of noninvasive brain stimulation intervention in patients with dementia: a network meta-analysis of randomized controlled trials. Alzheimer's Research and Therapy, 2023, 15, .	3.0	3
2099	Mitochondrial calcium cycling in neuronal function and neurodegeneration. Frontiers in Cell and Developmental Biology, 0, 11 , .	1.8	10
2100	Clinical efficacy and safety of compound Congrong Yizhi Capsules on Alzheimer's disease in mainland China: A systematic review with trial sequential analysis and GRADE assessment. Journal of Ethnopharmacology, 2023, 309, 116208.	2.0	0

#	Article	IF	CITATIONS
2101	Bloodborne Pancreatic Amylin, a Therapeutic Target for Alzheimer's Disease. Current Alzheimer Research, 2022, 19, 905-908.	0.7	0
2103	Chaperoning of specific tau structure by immunophilin FKBP12 regulates the neuronal resilience to extracellular stress. Science Advances, 2023, 9, .	4.7	5
2105	A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer's disease exacerbated with high fat diet. Cell and Bioscience, 2023, 13, .	2.1	2
2106	Early Detection of Alzheimer's Disease-Related Pathology Using a Multi-Disease Diagnostic Platform Employing Autoantibodies as Blood-Based Biomarkers. Journal of Alzheimer's Disease, 2023, 92, 1077-1091.	1.2	3
2107	A Novel Approach Utilizing Machine Learning for the Early Diagnosis of Alzheimer's Disease. , 2023, 1, 882-898.		4
2108	A new gentiopicroside derivative improves cognitive deficits of AD mice via activation of Wnt signaling pathway and regulation of gut microbiota homeostasis. Phytomedicine, 2023, 113, 154730.	2.3	5
2109	Dual role of nitric oxide in Alzheimer's disease. Nitric Oxide - Biology and Chemistry, 2023, 134-135, 23-37.	1.2	5
2110	Supporting people living with dementia in novel joint activities: Managing tablet computers. Journal of Aging Studies, 2023, 65, 101116.	0.7	1
2111	Independent role of Alzheimer's disease genetics and C-reactive protein on cognitive ability in aging. Neurobiology of Aging, 2023, 126, 103-112.	1.5	1
2112	Gut Microbiota and its Metabolites: Bridge of Dietary Nutrients and Alzheimer's Disease. Advances in Nutrition, 2023, 14, 819-839.	2.9	9
2113	Selenium Neuroprotection in Neurodegenerative Disorders. , 2022, , 2489-2523.		1
2114	Discovery of new, highly potent and selective inhibitors of BuChE - design, synthesis, in vitro and in vivo evaluation and crystallography studies. European Journal of Medicinal Chemistry, 2023, 249, 115135.	2.6	4
2115	Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2023, 80, 117178.	1.4	5
2117	Alzheimer's Disease Prediction using Machine Learning and Transfer Learning Models. , 2022, , .		4
2118	Re: Aducanumab-Related ARIA. Clinical Nuclear Medicine, 2023, 48, 505-506.	0.7	1
2119	Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer's Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia. Cell Death Discovery, 2023, 9, .	2.0	1
2120	Outcome measures for Alzheimer's disease: A global interâ€societal Delphi consensus. Alzheimer's and Dementia, 2023, 19, 2707-2729.	0.4	2
2121	Characteristics of Subjective Cognitive Decline Associated with Alzheimer's Disease Amyloid Pathology: Findings from The CABLE Study. Journal of Alzheimer's Disease, 2023, 92, 581-590.	1.2	1

#	Article	IF	CITATIONS
2123	Application of <i>Caenorhabditis elegans</i> in the evaluation of food nutrition: A review. EFood, 2023, 4, .	1.7	2
2125	Tooth loss and dementia amongst older adults residing in longâ€ŧerm care facilities in Vancouver: A caseâ€control study. Gerodontology, 2023, 40, 491-500.	0.8	0
2126	Correlation of blood–brain barrier leakage with cerebral small vessel disease including cerebral microbleeds in Alzheimer's disease. Frontiers in Neurology, 0, 14, .	1.1	3
2127	Natural Compounds Isolated from African Mistletoes (Loranthaceae) Exert Anti-Inflammatory and Acetylcholinesterase Inhibitory Potentials: In Vitro and In Silico Studies. Applied Sciences (Switzerland), 2023, 13, 2606.	1.3	1
2128	The effects of microglia-associated neuroinflammation on Alzheimer's disease. Frontiers in Immunology, 0, 14, .	2.2	20
2129	Neuroimaging studies of acupuncture on Alzheimer's disease: a systematic review. BMC Complementary Medicine and Therapies, 2023, 23, .	1.2	1
2130	Analysis of gene expression profiles in Alzheimer's disease patients with different lifespan: A bioinformatics study focusing on the disease heterogeneity. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
2131	Soluble and insoluble protein aggregates, endoplasmic reticulum stress, and vascular dysfunction in Alzheimer's disease and cardiovascular diseases. GeroScience, 2023, 45, 1411-1438.	2.1	5
2132	Association of plasma phosphor-tau181 with Al̂² levels may vary by APOE l̂µ4 status and sex among non-demented old adults. Neuroscience Letters, 2023, 802, 137161.	1.0	0
2133	Neurobiological Effects of Chemical Compounds of Species of the Genus <i>Astragalus</i> L. and Prospects for Their Use in Medicine (Review). Drug Development and Registration, 2023, 12, 199-206.	0.2	2
2134	The role of opioid receptors in modulating Alzheimer's Disease. Frontiers in Pharmacology, 0, 14, .	1.6	5
2135	CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer's disease gene expression linked to neuropathology. Science Advances, 2023, 9, .	4.7	4
2136	Effects of Sideritis scardica Extract on Scopolamine-Induced Learning and Memory Impairment in Mice. Journal of Alzheimer's Disease, 2023, 92, 1289-1302.	1.2	5
2137	Natural Corynanthe-Type Cholinesterase Inhibitors from Malaysian Uncaria attenuata Korth.: Isolation, Characterization, In Vitro and In Silico Studies. Metabolites, 2023, 13, 390.	1.3	0
2138	<i>APP^{swe}</i> /i>/ <i>PS1^{î"E9}</i> mice exhibit low oxygen saturation and alterations of erythrocytes preceding the neuropathology and cognitive deficiency during Alzheimer's disease. CNS Neuroscience and Therapeutics, 2023, 29, 1889-1897.	1.9	0
2140	Metal–Organic Frameworks as Sensors for Human Amyloid Diseases. ACS Sensors, 2023, 8, 1033-1053.	4.0	14
2141	The common marmoset as a model of neurodegeneration. Trends in Neurosciences, 2023, 46, 394-409.	4.2	9
2142	The effects of N6-methyladenosine RNA methylation on the nervous system. Molecular and Cellular Biochemistry, 2023, 478, 2657-2669.	1.4	4

#	Article	IF	CITATIONS
2143	The relationship between brain atrophy and brain network connection in Alzheimer's disease., 2022,,.		0
2144	Characterization of brain resilience in Alzheimer's disease using polygenic risk scores and further improvement by integrating mitochondria-associated loci. Journal of Advanced Research, 2024, 56, 113-124.	4.4	0
2145	Changes in CSF sPDGFRβ level and their association with blood–brain barrier breakdown in Alzheimer's disease with or without small cerebrovascular lesions. Alzheimer's Research and Therapy, 2023, 15, .	3.0	7
2146	Reduced Autophagy in Aged Trigeminal Neurons Causes Amyloid \hat{l}^2 Diffusion. Journal of Dental Research, 0, , 002203452311560.	2.5	2
2147	Inhibiting NLRP3 Inflammasome Activation by CY-09 Helps to Restore Cerebral Glucose Metabolism in 3×Tg-AD Mice. Antioxidants, 2023, 12, 722.	2.2	6
2148	Shared peripheral blood biomarkers for Alzheimer's disease, major depressive disorder, and type 2 diabetes and cognitive risk factor analysis. Heliyon, 2023, 9, e14653.	1.4	2
2149	Perceptions of Knowledge, Disease Impact and Predictive Genetic Testing in Family Members at Risk to Develop Early-Onset Alzheimer's Disease (EOAD) and Their Levels of Suicidal Ideation: A Mixed Study. Brain Sciences, 2023, 13, 501.	1.1	0
2150	On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer's disease and Lewy body disease. Frontiers in Aging Neuroscience, 0, 15, .	1.7	3
2151	Endothelial Glycocalyx in Aging and Age-related Diseases. , 2023, 14, 1606.		1
2152	Novel Insight into Functions of Transcription Factor EB (TFEB) in Alzheimer's Disease and Parkinson's Disease. , 2023, 14, 652.		6
2153	Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3 $\hat{1}^2$?. Frontiers in Neuroscience, 0, 17, .	1.4	5
2154	Exploration and Clinical Verification of the Blood Co-Expression Genes of Type 2 Diabetes Mellitus and Mild Cognitive Dysfunction in the Elderly. Biomedicines, 2023, 11, 993.	1.4	2
2155	Baicalein-corrected gut microbiota may underlie the amelioration of memory and cognitive deficits in APP/PS1 mice. Frontiers in Pharmacology, 0, 14, .	1.6	2
2156	Disturbed circadian rhythm and retinal degeneration in a mouse model of Alzheimerâ \in TM s disease. Acta Neuropathologica Communications, 2023, 11, .	2.4	4
2157	Dysfunction of circadian and sleep rhythms in the early stages of Alzheimer's disease. Acta Physiologica, 2023, 238, .	1.8	6
2159	Identification of Bone Metastatic and Prognostic Alternative Splicing Signatures in Prostate Adenocarcinoma. Biochemical Genetics, 2023, 61, 2242-2259.	0.8	0
2160	Plasma β2-microglobulin and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: the CABLE study. Alzheimer's Research and Therapy, 2023, 15, .	3.0	1
2161	NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 92, 1303-1321.	1.2	0

#	Article	IF	CITATIONS
2162	A unique color-coded visualization system with multimodal information fusion and deep learning in a longitudinal study of Alzheimer's disease. Artificial Intelligence in Medicine, 2023, 140, 102543.	3.8	1
2163	The TREM2 H157Y Variant Influences Microglial Phagocytosis, Polarization, and Inflammatory Cytokine Release. Brain Sciences, 2023, 13, 642.	1.1	1
2164	Homocysteineâ€"Potential Novel Diagnostic Indicator of Health and Disease in Horses. Animals, 2023, 13, 1311.	1.0	0
2165	Psychometry in Dementia. , 0, , .		0
2166	Vision transformers for the prediction of mild cognitive impairment to Alzheimer's disease progression using mid-sagittal sMRI. Frontiers in Aging Neuroscience, 0, 15, .	1.7	6
2167	Biomarkers of Alzheimer's disease: Past, present and future clinical use. Biomarkers in Neuropsychiatry, 2023, 8, 100063.	0.7	3
2169	Discoveries and future significance of research into amyloid-beta $\hat{l}\pm7$ -containing nicotinic acetylcholine receptor (nAChR) interactions. Pharmacological Research, 2023, 191, 106743.	3.1	3
2170	Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer's disease: an updated overview of nonpharmacological therapies. Molecular Neurodegeneration, 2023, 18, .	4.4	5
2171	Audiometric Evaluation of the Relationship between Sensorineural Hearing Loss and Chronic Glaucoma. Türk Oftalmoloji Dergisi, 2023, 53, 105-110.	0.4	1
2175	Neurodegenerative diseases. , 2023, , 563-598.		0
2186	Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. , 2023, , 671-712.		0
2191	Alzheimer's Disease Diagnosis Using MRI Images. Cognitive Technologies, 2023, , 195-212.	0.5	0
2195	Don't PANIC: Prototypical Additive Neural Network forÂlnterpretable Classification ofÂAlzheimer's Disease. Lecture Notes in Computer Science, 2023, , 82-94.	1.0	0
2196	Aux-ViT : Classification of Alzheimer's Disease from MRI based on Vision Transformer with Auxiliary Branch. , 2023, , .		0
2199	Neurobiology of the endocannabinoid system and relevance to cannabis use., 2023,, 253-264.		0
2207	Nucleic Acid-Based Strategies to Treat Neurodegenerative Diseases. , 2023, , 105-133.		0
2215	The role of brain noradrenaline in Alzheimer's disease: Implications for a precision medicine-oriented approach., 2024,, 526-539.		0
2247	The CITA GO-ON dialogue system: mid-term achievements. , 2023, , .		0

#	Article	IF	CITATIONS
2249	European Projects for Patients with Dementia and Their Caregivers. Advances in Experimental Medicine and Biology, 2023, , 609-618.	0.8	2
2255	Plant-Derived Drugs for Alzheimer's Disease and Other Neurological Disorders. , 2023, , 1327-1345.		0
2256	Role of Target Fishing in Discovery of Novel Anti-Alzheimer's Agents: In Silico Applications. , 2023, , 245-284.		0
2261	A Logistic Regression and Decision Tree Based Hybrid Approach to Predict Alzheimer's Disease. , 2023, , .		20
2262	Multifaceted roles of mitochondrial dysfunction in diseases: from powerhouses to saboteurs. Archives of Pharmacal Research, 2023, 46, 723-743.	2.7	0
2263	Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development. Cellular and Molecular Neurobiology, 0, , .	1.7	3
2267	Astrocytes in human central nervous system diseases: a frontier for new therapies. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	15
2268	Modeling Life-Span Brain Age fromÂLarge-Scale Dataset Based onÂMulti-level Information Fusion. Lecture Notes in Computer Science, 2024, , 84-93.	1.0	0
2271	Glycogen Synthase Kinase-3β, NLRP3 Inflammasome, and Alzheimer's Disease. Current Medical Science, 2023, 43, 847-854.	0.7	0
2279	Stem Cells Vs Exosomes: Promising Therapeutic Approach and Biomarkers Agent against Neurodegenerative Disorders., 2023,, 169-191.		0
2286	Applications of Induced Pluripotent Stem Cell-Derived Glia in Brain Disease Research and Treatment. Handbook of Experimental Pharmacology, 2023, , .	0.9	0
2287	Classification of Alzheimer's Disease Subjects from MRI Using Deep Convolutional Neural Networks. Lecture Notes in Networks and Systems, 2023, , 277-286.	0.5	2
2292	The effects of different acetylcholinesterase inhibitors on EEG patterns in patients with Alzheimer's disease: A systematic review. Neurological Sciences, 0, , .	0.9	0
2298	Ensemble learning-based multimodal data analysis improving the diagnostic accuracy of Alzheimer's disease., 2023,,.		0
2306	Association between aspirin use and risk of dementia: a systematic review and meta-analysis. European Geriatric Medicine, 2024, 15, 3-18.	1.2	0
2308	Phospholipid Peroxidation in Health and Disease. , 2023, , 405-430.		0
2309	Transcranial direct current stimulation for global cognition in Alzheimer's disease: a systemic review and meta-analysis. Neurological Sciences, 2024, 45, 883-895.	0.9	0
2321	Exploring the Role of Locus Coeruleus in Alzheimer's Disease: a Comprehensive Update on MRI Studies and Implications. Current Neurology and Neuroscience Reports, 0, , .	2.0	О

#	Article	IF	CITATIONS
2324	Advances in $\hat{Al^2}$ imaging probes: a comprehensive study of radiolabelled 1,3-diaryl-2-propen-1-ones for Alzheimer's disease: a review. RSC Advances, 2023, 13, 35877-35903.	1.7	0
2326	Iron Oxide Nanoparticles: A Mighty Pioneering Diagnostic Tool But Is It Really Safe for Carcinoma and Neurodegenerative Diseases?., 0, , .		O
2331	Ensemble Model for Predicting Alzheimer's Disease and Disease Stages with CNN and Transformer Models., 2023,,.		0
2342	Alzheimer Disease Detection using Deep Learning. , 2023, , .		0
2344	Accurate Prediction of Alzheimer's Disease Progression Trajectory via a Novel Encoder-Decoder LSTM Architecture. , 2023, , .		0
2350	Microbial underdogs: exploring the significance of low-abundance commensals in host-microbe interactions. Experimental and Molecular Medicine, 2023, 55, 2498-2507.	3.2	0
2361	Multimodal Contrastive Learning and Tabular Attention for Automated Alzheimer's Disease Prediction. , 2023, , .		0
2365	Silicon-containing nanomedicine and biomaterials: materials chemistry, multi-dimensional design, and biomedical application. Chemical Society Reviews, 2024, 53, 1167-1315.	18.7	1
2369	New biologicals and biomaterials in the therapy of Alzheimer's disease., 2024,, 93-114.		1
2377	Liposomes as carrier for drug delivery in Alzheimer's disease. , 2024, , 153-179.		0
2378	Combinatorial therapy in Alzheimer's disease. , 2024, , 439-461.		0
2380	Psychiatric Cases: Early-Onset Dementia. , 2024, , 489-491.		0
2381	Neuroprotection induced by curcumin. , 2024, , 1441-1463.		0
2382	Enhancing Disease Diagnosis: A CNN-Based Approach for Automated White Blood Cell Classification. , 2023, , .		0
2402	Demenzen. , 2023, , 597-606.		0
2405	Human Stem Cells and Their Future Application in Neurodegenerative Diseases. , 2024, , .		0
2406	Development ofÂaÂMethod forÂtheÂEarly Detection ofÂAlzheimer Using CT Images, Deep Learning Techniques andÂHyper-parameter Tuning. Lecture Notes in Networks and Systems, 2024, , 161-170.	0.5	0
2407	Herbs for Autoimmune Diseases. , 2023, , 361-388.		O

#	Article	IF	CITATIONS
2409	Alzheimer's Disease Prevention and Treatment Based on Population-Based Approaches. Methods in Molecular Biology, 2024, , 15-33.	0.4	0
2426	c. Lessons From the Cardiovascular Risk in Young Finns Study. , 2024, , 87-98.		O